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ABSTRACT  
 
Previous studies from our laboratorory highlighted the neuroprotective 
role of glial cells against neuronal damage especially through protein release 
(Polazzi and Monti, 2010). Given the involvement of glial cells not only in the 
surveillance and homeostasis of the Central Nervous System, but also in 
pathological conditions, in this thesis we focused our study on the glial release 
of three different proteins, Purine Nucleoside Phosphorylase (PNP), 
Superoxide Dismutase 1 (SOD1) and α-synuclein related to different 
neuropathological conditions, i.e. PNP-deficiency, Amyotrophic Lateral 
Sclerosis (ALS) and Parkinson’s disease (PD). 
Purine Nucleoside Phosphorylase (PNP) protein is a ubiquitous 
enzyme, which catalyzes the intracellular cleavage of ribonucleosides to 
generate purine bases. Physiologically, PNP plays a crucial role in the 
metabolism of purines and PNP deficiency causes a rare inherited disease 
determining severe combined immunodeficiency and mental retardation 
(SCID). PNP histochemical localization is restricted to glial cells, whereas its 
expression in neurons is still debated. Similarly to human disease, PNP 
deficiency in mice, due to missense mutations in the gene codifying for this 
enzyme, showed a reduction in number of immature and peripheral T-cells and 
in T-cell proliferation. Neurological symptoms have been described in 50% of 
patients; neurological involvement seems to be related with the severity of 
enzyme deficiency because GTP is necessary for neurotransmission. 
Notwithstanding the relevant role of glial cells in PNP-deficiency, the role of 
PNP in glial cell physiology has never been studied before. 
Superoxide Dismutase 1 (SOD1) catalyzes the dismutation mechanism, 
which is the transformation of superoxide to H2O2, which in turn is converted 
to H2O by catalase, peroxiredoxin (Prx) or glutathione peroxidase. Catalytic 
activity is required to maintain low levels of intra and extracellular ROS, 
superoxide and H2O2, indispensable in signaling or in defense against 
pathogens. If the level of ROS is too high, it may be cause of oxidative stress. 
A previous published study from our laboratory demonstrated constitutive 
SOD1 production and release by microglia and the consequent accumulation in 
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conditioned medium (MCM) with a neuroprotective role of microglia in case 
of neuronal damage; SOD1 was found to be one of the neuroprotective released 
molecules. On the other hand, mutations in SOD1 are a key player in the onset 
of Amyotrophic Lateral Sclerosis (ALS); approximately 20% of familial cases 
(FALS) are due to mutations in the gene coding for SOD1. Neurodegenerative 
diseases, stroke, trauma and hypoxia affect neuronal survival indirectly by 
triggering neuroinflammation. Microglia are then activated (or become 
reactive) in response to insults acquiring a phagocytic phenotype and releasing 
inflammatory mediators, cytokines and chemokines. The acute 
neuroinflammatory response seems to be beneficial to the CNS, since it is an 
attempt to reduce injury and restore damaged tissues. Because of the dual role 
of SOD1 and microglial cells, we decided to study the effect of wild-type and 
mutant SOD1 (G93A and A4V) in glial cell pathophysiology.  
Alpha-synuclein is a ubiquitous protein belonging to a family that also 
includes β- and γ –synucleins. In the brain, α-synuclein represents 0.5-1.0% of 
all cytosolic proteins and is primarily localized at presynaptic terminals. The 
protective or toxic effect of α-synuclein depends on its expression levels in the 
cell: α-synuclein in physiological conditions would have a protective function, 
while its accumulation and its aggregation into oligomers or fibrils would have 
a detrimental effect on cells. Some point mutations (A53T, A30P and E46K) in 
the α-synuclein gene are related to the onset of an autosomal dominant juvenile 
form of Parkinson’s disease. Taking these evidences together and because most 
studies on α-synuclein were performed on neurons, we decided to analyze as a 
first step whether α-synuclein could be secreted by glial cells and then we tried 
to define the conditions of this secretion and its role. 
Therefore, the first aim of this thesis was to analyze the release of PNP, 
SOD1 and α-synuclein by glial cells in physiopathological conditions in in 
vitro models: primary cultures of rat astrocytes and microglia for PNP and 
SOD1, as well as immortalized mouse astrocytes and microglia cell lines for α-
synuclein (respectively IMA2.1 and N9). In particular, for all three proteins the 
effect of different glial activating stimuli (LPS, IFNγ and ATP) on their 
release, as well as their vesicular secretion through exosomes were analysed. 
Considering the role of mutations in the genes codifying for SOD1 and α-
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synuclein in familial forms of neurodegenerative diseases, respectively ALS 
and PD, a second aim was to investigate whether and how overexpression of 
wild-type SOD1 or mutations linked to ALS (G93A and A4V) could alter the 
functioning of microglia and astrocytes, determining activation and thereby 
contribute to inflammation, and whether this condition could affect neuronal 
survival and/or death. In parallel, a preliminary study on α-synuclein release 
was carried on by a preliminary investigation on overexpression of wild-type 
or PD-linked mutant α-synuclein (A53T and A30P) in glial cells. 
By using the above-mentioned in vitro approaches, we observed that all 
brain cells, but mainly microglia and astrocytes, constitutively release PNP. 
Glial stimulation with potent inflammatory agents, like lipopolysaccharide and 
interferon-γ, did not modify PNP release, while ATP and Bz-ATP led to a 
dose-dependent increase of release mediated by P2X7 receptors and occurred 
through the secretion of lysosomal vesicles in the extracellular medium. The 
mechanisms activated by ATP seem to be common in pathological conditions 
such as ischemia, traumatic injury and seizure activity and might suggest a 
pathological role of extracellular PNP in the mechanisms of PNP-deficiency. 
Regarding SOD1, this enzyme is constitutively released by microglial 
cells and astrocytes, even through vesicles and mutant SOD1 (fALS murations) 
appears to be less released than wild-type SOD1. Intracellular accumulation of 
mutant SOD1 in both microglia and astrocytes correlates to dysfunction of 
autophagy mechanisms and promotes the activation of microglial cells. In 
addition, we developed a primary co-culture in vitro model in order to evaluate 
the effect of glial cell SOD1 overexpression on neuronal survival and death. 
We show that microglia exert neuroprotection in cerebellar granule cells 
exposed to the neurotoxic stimulus glutamate, but microglial mutant SOD1 
overexpression appears to be toxic to neurons.  Astrocytes, on the other hand, 
seem to be less susceptible to mutant SOD1overexpression and do not display a 
neuroprotective function against glutamate excitotoxicity, even if 
overexpression of wild-type SOD1 seems to provide neuroprotection. 
Trehalose, a disaccharide known to be able to restore the physiological 
autophagic flux, showed significant ability in restoring the physiological 
pathway of SOD1 expression in glial cells and significantly reduced the death 
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of cerebellar granule neurons due to glutamate excitotoxicity, giving promising 
expectations for future studies. 
Moreover, α-synuclein is constitutively released by microglial cells and 
astrocytes, even through vesicles. The increased release after LPS but not ATP 
treatment underlies the different response of glial cells to different stimuli. 
Since activation of glial cells is strictly related to the progression of 
neurodegenerative diseases, inflammatory pathways might be responsible for 
the impairment of glial cell function. According to this hypothesis, we 
observed that overexpression of α-synuclein mutations linked to Parkinson’s 
disease promoted an increased release of α-synuclein compared to wild-type α-
synuclein. Thus, α-synuclein overexpression, even wild-type α-synuclein, 
promoted the activation of microglia, though not of astrocytes. We could 
speculate that the increased release, together with increased activation, might 
be responsible for reduced neuroprotection and for diffusion of potential toxic 
mutant α-synuclein. 
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1. INTRODUCTION  
 
 
The central nervous system is composed by two different cells type 
with a ratio of 1 to 10-50; neurons and glial cells or neuroglia (Rezaie et al., 
2002). While neurons are specialized in the conduction of electric signals, glial 
cells do not participate directly in signal transmission, though they play an 
important role during neuronal development and are also involved in the 
trophic and protective support of neurons throughout life. 
In the Central Nervous System (CNS) there are four types of glial cells: 
ependymal cells, oligodendrocytes, astrocytes and microglial cells.  
Ependymal cells, whose functions are not clear, are columnar cells 
located close to the brain ventricles and the central canal of the spinal cord. 
Oligodendrocytes are responsible for the formation of the myelin sheet 
in the CNS. The myelin sheet acts as an insulator of axonal segments and is 
indispensable for nerve conduction. 
Astrocytes are the most numerous cells in the CNS; they have a high 
number of ramifications that allow them to contact blood vessels and create the 
blood-brain barrier. 
Microglia are the resident 
macrophages in the central 
nervous system.  They are 
involved in the surveillance of 
the environment; in case of 
injury or neuronal damage, glial 
cells are the most responsive 
cells helping neurons restore 
physiological conditions 
(Hartline 2011). Microglial cells 
represent 5-20% of the glial 
population in the central nervous 
system.  
1.1  THE CENTRAL NERVOUS  SYSTEM 
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The major brain areas rich in microglia are the hippocampus, telencephalic 
region and basal ganglia; the cerebellum and brain stem are much less 
populated (Lawson et al., 1990). 
Since glial cells establish numerous interactions with neurons regulating their 
function, homeostasis and protection from stress and damage, the involvement 
of glial cells in the most known neurodegenerative diseases is well-established, 
though it remains to be characterized. 
 
1.1.1 MICROGLIAL CELLS 
 
Microglia are the resident 
mononuclear phagocytes of the CNS 
(Lawson et al., 1990). Defining the origin 
of microglia has not been easy and there 
have been several schools of thought.  
The concept of neuroglia was 
introduced in 1856 by Rudolf Virchow; 
(Verkhratsk, 2006); he defined 
“nervenkitt” cells with the ability to form a kind of nervous adhesive tissue, 
able to keep connected adjacent cells. At the beginning of the nineteenth 
century, Robertson defined “mesoglia”, phagocytic cells with mesodermal 
origin present in the CNS. Mesoglia mainly correspond to oligodendrocytes, 
renamed by Santiago Ramon y Cajal “third element of the nervous system” to 
further differentiate them from neurons (first element) and neuroglia (second 
element) (Florent et al., 2012). The concept of the third element was clarified 
by Del Rio-Hortega; he called “microglial cells” the non-neuronal, non-
astrocytic third element as distinct from neuroectodermal oligodendroglia or 
oligodendrocytes (Rezaie et al., 2002). 
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1.1.1.1 Origin of microglia  
 
Regarding the origin of microglia, there are two well-known 
hypotheses: the neuroectodermal hypothesis and the myeloid-monocytic 
hypothesis. 
1) The neuroectodermal hypothesis has been supported by studies on the   
identification of microglial markers during the development of the brain, 
germinal matrix, central nervous system or in the neuroectoderm. 
2) The hypothesis that microglia derives from blood monocytes, originating in 
the bone marrow and circulating in the CNS between birth and the 
postnatal period, is the most-approved hypothesis. According to this 
myeloid-monocytic hypothesis, resident microglia and in general resident 
brain macrophages, are derived from circulating blood monocytes during 
embryonic life and in the postnatal period (Polazzi et al., 2010; reviewed by 
Kettenmann H. et al., 2011). However, data related to microglia during 
brain development, before vascularization and the formation of 
macrophages in the neural epithelium from precursors different from the 
ones originating monocytes, together with the phenotypic differences 
between mononuclear phagocytes in the embryonic-fetal stage and 
neonatal-adult period (Takahashi, 2001), suggest that prenatal microglia 
might arise from mesodermal progenitors.  
There is evidence supporting the existence of two different microglial 
populations during fetal and embryonic development; a population with 
myeloid/mesenchymal origin, not necessarily monocytes; and a second 
population, which represents a transient form of fetal macrophages derived 
from blood precursors, probably monocytes, that are related to amoeboid 
microglia observed in the post-natal period in rodents (Rezaie et al., 2005b). 
This second microglial population lays close to blood vessels and can be 
replaced by precursors that originate in the bone marrow and express the 
histocompatibility complex II, indicating their monocytic origin (Eglitis et al., 
1997; Hickey et al., 1998). The phagocytic ability of the two cell populations is 
different, in fact a reduced phagocytic activity is observed in unstimulated cells 
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with branched phenotype, which however is not observed in the amoeboid 
phenotype (Szabo et al., 2013). 
 
1.1.1.2 Microglial phenotypes 
 
Microglial cells are known for their plastic ability and functional 
characteristics depending on their activation state; indeed, it is not difficult to 
observe morphological microglial changes depending on their function (Szabo 
et al., 2013). In physiological conditions, microglial cells are in a state of non-
activation, also call "resting" or “quiescent” state, in which microglial 
morphology is characterized by numerous processes that originate from the 
soma with distal arborization (Streit et al., 1999). In conditions of stress, 
inflammation, injury or particular signals, microglia change their morphology, 
shifting to an “activated” state (Stence  et al., 2001). Cells undergo an 
expansion of the cell body, ramifications become shorter, less arborized and 
located around the soma. This morphological change can induce phagocytic 
functions in microglial cells and an amoeboid ability that allows cells to move 
towards lesions (Thored et al., 2005). 
 
1.1.1.3 Physiological functions of microglia 
 
It is well-known that microglia, even when in a “resting” state, monitor 
the brain microenvironment and synapses. Microglial cells, in fact, are 
essential for the proper functioning of the CNS, since they are a sensor of 
pathological conditions (Polazzi et al., 2010). Their highly-branched 
morphology and plasticity ability, allow microglia to supervise the extracellular 
parenchyma of the CNS and rapidly activate in response to pathological 
conditions, exerting typical macrophage functions such as phagocytosis 
(Neumann et al., 2006, Napoli et al., 2009), secretion of pro-inflammatory 
cytokines (Banati et al., 1993, Gehrmann et al., 1995, Minghetti et al., 1998) 
and the ablity to behave as antigen presenting cells (Beauvillain et al., 2008, 
Aloisi, 2011). 
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The neuroprotective role of microglia is carried out not only as a 
response to neuropathological threats, but also under physiological conditions. 
During brain development, microglia support synaptogenesis through the local 
synthesis of neurotrophic factors, regulating also synaptic transmission and 
remodeling; the interactions between microglia and neurons contribute to the 
development of synapses and neuronal homeostasis, also as a result of injury, 
which arrange for the recovery of neuronal circuits (Polazzi et al., 2013). 
During development, microglia have a role in synaptic maturation, 
while in the adult brain they have a fundamental role in synaptic plasticity. 
Microglial cells are able to exert neurotoxic and neurotrophic effects because 
of their activation state. One of the most peculiar features of microglia is the 
ability to modify their behavior in response to different signals originating 
from other cells located in the brain parenchyma. This function suggests the 
ability to promote neuronal cell survival or death depending on the nature of 
the neural signals that regulate the activation of microglia. Damaged neurons 
may release or express molecules able to modulate the activation of microglia. 
This suggests that different types of neuronal death, apoptosis or necrosis, can 
induce different microglial responses, which can in turn be responsible for 
different neuronal fate (Polazzi et al., 2001).  
Apoptosis or programmed cell death is crucial in CNS development, 
since it allows the removal of neuronal subpopulations. Apoptotic death is a 
common mechanism of neuronal removal during development of the nervous 
system, which occurs only in pathological conditions in the adult brain, such as 
in neurodegenerative diseases. Microglia are involved in this process in 
response to various signals derived from neurons triggering the process of 
programmed cell death through the release of neurotoxic molecules (De la 
Rosa et al., 2000). 
 
1.1.1.4 Pathological functions of microglia 
 
Loss of physiological functions is associated with the onset of 
psychiatric disorders or neurodegenerative diseases. Theoretically, every 
neurological disorder involves inflammation with the consequent activation of 
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resident microglia, accompanied by an increase in cell number and in 
phenotypic change, a phenomenon known as "gliosis". 
Neurodegenerative diseases, stroke, trauma and hypoxia, affect 
neuronal survival indirectly by triggering the state of neuroinflammation. 
Microglia are then activated (or become reactive) in response to insults 
adopting a phagocytic phenotype and releasing inflammatory mediators, 
cytokines and chemokines. The acute neuroinflammatory response seems to be 
beneficial to the CNS, since it is an attempt to reduce injury and restore 
damaged tissues (Wake et al., 2013, Kiefer et al., 1995, Streit  et al., 1999, Imai 
et al., 1997, Lalancette  et al., 2007, Yanagisawa et al., 2008, Madinier et al., 
2009). 
 
Microglia and monocyte-derived macrophage functions –cascade of events. London et al., Front. Cell. 
Neurosci., 2013. 
 
On the other hand, chronic neurodegenerative diseases including 
amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's 
disease (PD), tauopathies and multiple sclerosis (MS), are known to be 
associated with chronic neuroinflammation. Although several differences have 
been found between these chronic diseases, neuroinflammation is a response to 
long-term injury or initial insult. 
A typical feature of neuropathological conditions is the activation of 
microglia and the subsequent release of inflammatory mediators leading to an 
increased oxidative and nitrosative stress. This condition promotes the 
inflammatory cycle; the duration of the inflammatory response and the 
activation of microglia in this case are harmful to the nervous tissue (Frank-
Cannon et al., 2009, Polazzi et al., 2010).  
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Activated microglia have two different phenotypes M1 and M2.  
1) Classically activated microglia, M1 (LPS or IFNγ) have pro-inflammatory, 
neurotoxic properties, inhibiting the proliferation of lymphocytes; M1 
activated macrophages secrete pro-inflammatory cytokines such as 
interleukin IL-1α, IL-1β, tumor necrosis factors (TNF) and nitric oxide 
(NO).  
2) Alternatively activated microglia, M2 (IL-4, IL-13), are able to repair small 
damage and show an anti-inflammatory phenotype, contributing to the 
trophic support of neurons and have the ability to degrade aggregates and 
increase neuroprotective functions due to the production of anti-
inflammatory interleukins (Geissmann et al., 2008, Hu et al., 2014).  
In vitro studies in cell cultures have shown the ambivalent role of 
microglial cells on neurons; neuroprotective but also neurotoxic, while in vivo 
studies mainly support the neuroprotective potential of activated microglia 
(Streit et al., 2008). It has not been clearly defined whether the activation state 
of microglia is beneficial or detrimental to neuronal survival, though the most 
accredited hypothesis today is that microglia may have a dual role depending 
on the nature, duration and extent of injury (Ransohoff et al., 2009). 
In case of acute injury, microglia are able to remove damaged neurons 
through its phagocytic activity. This ability is attenuated by pro-inflammatory 
cytokines, suggesting that microglia involved in the inflammatory response 
could have reduced phagocytic activity (Koenigsknecht-Talboo  et al., 2005). 
In neurodegenerative diseases, microglial activation occurs before 
neuroinflammation. A possible explanation may be that microglial activation 
induces neuroprotection through the elimination of toxic molecules (Polazzi et 
al., 2010). Furthermore, because neurodegenerative diseases cause alterations 
in many other cell besides neurons, not only are neuronal functions altered, but 
also the cross-talk between different cell types (Appel et al., 2010). In 
neurodegenerative diseases, the role of microglia in the early stages, seems to 
be linked to an increase of inflammatory functions resulting in 
neurodegeneration (Polazzi et al., 2010). However this does not exclude the 
hypothesis of microglial dysfunction; the loss of neurotrophic/neuroprotective 
microglial functions induces neurodegeneration (Streit 2014). During aging 
15 
 
and the onset of neurodegenerative diseases, there is a reduction in the 
phagocytic ability of microglia and in the trophic support to neurons. 
Therefore, if on one side the primary activation of microglia reflects a 
physiological mechanism focused on neuroprotection mediated by the secretion 
of cytokines and neurotrophic factors, the removal of damaged cells (Napoli et 
al., 2009) and phagocytosis of polymorphonuclear neutrophils (Neumann et al., 
2006), on the other side the overactivation or the loss of microglial functions 
increases preexisting neuropathology (Streit et al., 2009). Alteration of 
microglial phenotype and as consequence the impairment of physiological 
functions in glial cells, might promote neuronal damage through a “non-cell 
autonomous” mechanism (Kathrin et al., 2014). According to this disease 
mechanism, neurodegeneration is strongly influenced by toxicity or mutant 
protein expression in non-neuronal cells which could be spread to neighbouring 
neurons. 
In the literature, one of the main methods used to activate microglia 
both in vitro and in vivo is treatment with the bacterial endotoxin (LPS) (Hetier 
et al., 1988). In response to LPS microglia release cytokines, chemokines and 
NO. This effect is mediated by TLR4, belonging to the Toll-like receptor 
family (Takeda  et al., 2003).  Microglial activation, however, is reduced by 
treatment with anti-inflammatory compounds, followed by the reduction of 
inducible nitric oxide synthase (iNOS) expression. Microglial activation 
promotes on one hand the decreased production of reactive oxygen species, 
while on the other hand it increases the neuroprotective functions of microglia 
(Nathan et al., 2002). Microglia-mediated neuronal homeostasis has been also 
found altered in serious neuronal damage, which could be mediated by 
glutamate excitotoxicity and is involved in the majority of neurodegenerative 
processes. Glutamate acts via N-Methyl-D-Aspartate (NMDA) receptors and in 
physiological conditions its excess derived from synaptic activity is employed 
by astrocytes. In pathological conditions, glutamate uptake by astrocytes is 
compromised inducing an increase of the intracellular calcium concentration 
and neuronal cell death. LPS-activated microglia express the GLT-1 protein 
involved in glutamate uptake (Hanisch et al., 2007). LPS-treatment of 
hippocampal slices induces the stimulation of microglia and a fast and transient 
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increase in post-synaptic AMPA-mediated currents in the hippocampal neurons 
of the CA1 region. This effect was not observed in animals lacking microglia, 
indicating that LPS stimulation requires microglia and confirming its 
neuroprotective role. Following stimulation, microglia produce adenosine 
triphosphate (ATP), which acts as transmitter and recruits astrocytes that 
release glutamate allowing an increase of excitatory synaptic transmission 
through the glutamate metabotropic receptors (Iadecola et al., 2007). 
 
1.1.2 ASTROCYTES 
 
Astrocytes are the most numerous cells of the CNS (Parpura et al., 
2012). In the human brain, the number of astrocytes was estimated to be more 
than five times the number of neurons (Hartline et al., 2006). During CNS 
development, the generation of astrocytes is subsequent to the initial 
production of neurons.  
Astrocytes exert several important functions during the development of 
gray and white matter. They are also responsible for the formation and function 
of synapses during development, thanks to the release of molecular signals, 
such as thrombospondin. At 
the end of the nineteenth 
century, astrocytes were 
distinguished in protoplasmic 
and fibrous astrocytes based 
on morphological and 
anatomical differences. 
Protoplasmic astrocytes have 
been found in the gray matter 
and wrap around synapses 
through numerous branched 
processes, fibrous astrocytes 
have been found in the white matter and contact the nodes of Ranvier through 
long thin fiber-like processes. Both types of astrocytes establish direct contact 
with blood vessels and form gap junctions between the distal processes of 
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neighbouring astrocytes. At the end of the nineteenth century, Camillo Golgi 
theorized that astrocytes could be connected to blood vessels (Golgi 1871). 
However, only recent studies have highlighted the dynamic processes 
supporting these structural interactions, such as the dialogue between 
astrocytes and other vascular elements. Astrocytes have an ordered 
arrangement and a minimal overlapping, and each one interfaces with blood 
vessels and includes hundreds of synapses (Bushong et al., 2004). The cell 
surface is covered by lamellar extensions and protrusions which make 
astrocytes able to interact with surrounding synapses. Most astrocytes 
possesses the so called "end-feet", contact blood vessels and contribute to the 
formation of the blood-brain barrier (BBB), a diffusion barrier that prevents the 
influx of foreign molecules into the brain parenchyma (Simard et al., 2001).  
 
1.1.2.1 Physiological role of astrocytes 
 
Astrocytes play essential functions in the CNS in physiological 
conditions thanks to the processes able to contact synapses, axons at the nodes 
of Ranvier, neuronal cell bodies and blood vessels at the endothelial cell layer. 
The connections with blood vessels allow astrocytes to collect glucose for 
energy supply, adjust blood flow and the cerebral homeostasis of ions and 
transmitters (Iadecola et al., 2007). Astrocytes play a synaptic role during 
development, but also in the adult brain, especially in remodeling and synaptic 
pruning: they are involved at GABAergic and glutamatergic synapses in 
neurotrasmitter uptake to prevent excitotoxicity by glutamate and play a direct 
role in synaptic transmission by releasing molecules synaptically active such as 
purines (ATP and adenosine), γ-aminobutyric acid (GABA) and D-serine, 
modulating cell excitability and increasing the concentration of the intracellular 
calcium ion (Ca2 +) (Shimizu et al., 2007, Bittner et al., 2010). D-serine binds 
to post-synaptic NMDA receptors (NMDARs), which also bind glutamate 
released from the pre-synaptic terminal. These events facilitate NAMDAR 
activation and induction of synaptic plasticity (Verkhratsky et al., 2010). 
Astrocytes modulate synaptic function through cross talk and exchanging 
gliotransmitters, ions, second messengers and nutrients through gap junctions 
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(Parpura et al., 2009, Ullian et al., 2004). These observations support the 
concept of "tripartite synapses", according to which astrocytes represent the 
third unit element of  signal transmission together with presynaptic and 
postsynaptic terminations (Volterra, 2005). The main role of astrocytes in this 
“model" is to isolate and support the function of individual synapses, ensuring 
spatial specificity in synaptic transmission (Hewett et al., 2009).  
Astrocytes play also a metabolic role, since they are responsible for the 
storage of glycogen granules in the CNS, especially in high-density synaptic 
areas. In conditions of hypoglycemia and high neuronal activity, glycogen is 
able to support cell activity. Glycogen stored in astrocytes may provide lactate, 
which once transferred to adjacent neural elements can be used as aerobical 
fuel by neuronal mitochondria (Bélanger et al., 2011). The involvement of 
astrocyte glycogen stores is required for the formation of long-term memory in 
rats (Pellerin et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Astrocyte functions. (Maragakis et Rothstein, 2006) 
 
Furthermore, although not presenting action potentials along their 
processes, astrocytes express sodium and potassium channels which may be 
involved in evoked currents and show forms of excitability, for example in the 
case of  Ca2+ concentration increases. These increases are necessary for the 
intracellular communication that is established between astrocytes and between 
astrocytes and neurons (Molofsky et al., 2012).  
 
19 
 
1.1.2.2 Pathological role of astrocytes 
 
Astrocytes have role in every aspect of neuronal function, through the 
regulation of blood flow, supply of energy substrates and modulation of 
synaptic function and plasticity, therefore damaged astrocytes are the primary 
cause of serious neural dysfunction (Maragakis et al., 2006). Following 
specific acute injuries, inflammation, chronic neurodegenerative diseases or 
stress, astrocytes respond through the reactive astrogliosis process and the 
expression of glial fibrillary acidic protein (GFAP), a sensitive and reliable 
marker for the immunohistochemical identification of reactive astrocytes. In 
the same way as microglial activation, reactive astrogliosis is not an on-off 
phenomenon, but rather a continuum event modulated by changes in the 
surrounding microenvironment and is regulated by specific inter and 
intracellular signaling (Yamanaka et al., 2008). Depending on the severity of 
the insult, reactive astrogliosis leads to a series of changes in astrocytes at the 
molecular, cellular, and functional (gain or loss of function) level, affecting 
adjacent cells in a beneficial or harmful way. Reactive astroglial cells play 
several essential beneficial functions in response to CNS insults, such as 
repairing the BBB, neuroprotection and limiting the spread of inflammatory 
cells. Loss or alteration of these functions in the astrogliosis process produces 
neuronal dysfunction and could be a primary cause of disease in the CNS such 
as neuropathology, psychiatric disorders, trauma and stroke. Animal models 
have shown that loss of astrocyte function leads to altered CNS function such 
as excitotoxicity-induced neurodegeneration, caused by an altered uptake of 
glutamate or increased inflammation and infection due to the loss of astrocyte 
barrier functions. Following specific inflammation signals, such as LPS 
exposure, a gain of harmful functions may also occur in reactive astrocytes, 
such as the inhibition of axonal regeneration, production of reactive oxygen 
species (ROS), glutamate release and the impairment of the BBB functionality. 
Moreover, the involvement of other cell types, such as microglia, macrophages 
and lymphocytes, stimulates astrocytes to produce cytotoxic levels of 
molecules which are normally non-toxic and contribute to inflammation and 
chronic neuropathic pain (Verkhratsky  et al., 2010, Molofsky et al., 2010, 
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Rappold et al., 2010). Understanding these processes could simplify treatment 
strategies to preserve the beneficial role of astrocytes. Recent studies have 
shown that astrocytes are the main players in many developmental diseases, 
such as autism and schizophrenia, characterised by defects in synaptic 
formation (Parpura et al., 2012, Sofroniew et al., 2009). In fact, in the 
development of white matter, dysfunction or malfunction of astrocyte 
connections or gap junctions leads to demyelination. Given their strong 
involvement in developmental diseases, astroglial cells may be a useful target 
in the development of new therapies. The functionality of astrocytes is altered 
not only in neurodegenerative diseases, such as ALS, Alzheimer's and 
Parkinson's disease, but also in neurodevelopmental diseases such as Rett 
syndrome, X-fragile, Alexander’s disease, epilepsy, autism, psychiatric 
disorders and in brain tumors. 
 
1.1.3 NEURON-GLIA INTERACTIONS 
 
Glial cells represent about 90% of all cells in the human brain. The 
initial role as brain “glue” has been replaced with a more important role of key 
players in brain physiology, metabolism, development, and even neurological 
diseases (Barres, 2008). An essential aspect of normal brain function is the 
bidirectional interaction and communication between neurons and 
neighbouring glial cells; dysregulation of this interaction may contribute to the 
onset of neurodegenerative diseases. Together with astrocytes, microglia can 
release neuromodulatory molecules involved in intracellular signalling and the 
communication with neurons.  
  
 
 
 
 
 
 
Nature Reviews Neuroscience 16, 705–718 (2015). 
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The first evidence of interaction between microglia and neurons is 
given by the complementary expression of the microglial receptor for 
chemokines (CX3CR1) and its neuronal ligand (CX3CL1), thus suggesting the 
ability of microglia to modulate neurotransmission (Béchade et al., 2013). The 
CX3CL1/R1 pathway seems to be involved in synaptic maturation and an 
alteration of this pathway can lead to delayed glutamatergic synaptic 
maturation and alteration of hippocampal development (Paolicelli et al., 2011). 
Another example of neuron-microglia interaction is related to the CD200R   
membrane protein. CD200R is a membrane receptor exclusively expressed by 
microglia while its ligand, CD200 is expressed by neurons, oligodendrocytes 
and astrocytes. CD200-deficient mice display LTP inhibition, further 
underlining the role of microglia in neuronal homeostasis and synaptic 
plasticity (Costello et al., 2011). In fact, microglia is a sensor of neuronal 
activity modulating most contacts between neurons and synaptic elements 
(Tremblay et al., 2011, Wake et al., 2013). The signaling modulating this 
function is not known, though it seems to be mediated by the secretion of 
signaling molecules by microglia, including cytokines (Elkabes et al., 1996, 
Hanisch, 2002) and neurotransmitters (Hanisch, 2002, Flierl et al., 2007), 
which regulate synaptic functions. In vivo studies suggest a role of microglia in 
the regulation of hippocampal  (Battista et al., 2006, Ziv et al., 2006) and sub 
ventricular area neurogenesis (Thored et al., 2009) after stroke. In an in vitro 
co-culture model of neural stem cells with microglia or conditioned medium 
from microglia, the secretion of factors by microglia needed for neurogenesis 
was oberved (Walton et al., 2006). Microglia-neuron interaction and the 
consequent regulation of neuronal homeostasis by microglia were also found in 
severe neuronal damage, such as glutamate excitotoxicity. Glutamate acts via 
N-methyl-D-aspartate (NMDA) receptors inducing an increase of neuronal 
intracellular calcium concentration, and consequent neuronal death. 
Neurotoxicity due to glutamate is involved in numerous neurodegenerative 
processes, such as ischemia and brain injury. In physiological conditions, the 
excess of glutamate resulting from synaptic activity is uptaken by astrocytes, 
while in pathological conditions, glutamate uptake by astrocytes is 
compromised. LPS-activated microglia express the GLT-1 protein implicated 
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in glutamate uptake (Hanisch and Kettenmann,  2007). Microglia stimulation 
with lipopolysaccharide (LPS) treatment of hippocampal slices, induces a rapid 
and transient increase in the spontaneous post-synaptic AMPAergic current in 
hippocampal CA1 neurons. This effect has not been found in animal models 
with microglia depletion, indicating that LPS stimulation requires microglia 
and confirming the neuroprotective role of microglial cells. Following this 
stimulation, microglia recruit astrocytes through the production of ATP. 
Astrocytes release glutamate allowing an increase of excitatory synaptic 
transmission through metabotropic glutamate receptors (Pascual et al., 2012). 
Astrocytes express neurotransmitter receptors, but at the same time, 
thanks to the increase in calcium concentration, they release neurotransmitters 
(ATP, Glutamate, D-serine, and GABA) essential for the modulation of 
neuronal activity (Haydon,  2001, Volterra, 2005) Glutamate release from 
astrocytes seems to be a key modulator of synaptic transmission depending on 
the kinetic of calcium elevations. Slow elevation in astrocytes induces slow 
inward currents in CA1 neurons by acting on post synaptic NMDA receptors 
(Fellin et al., 2004, Angulo et al., 2004).  Faster calcium elevation induces 
presynaptic modulation of synaptic release, by acting on presynaptic mGluR5 
receptors (Shigetomi et al., 2008). Activation of glutamatergic receptors on 
astrocytes, induces the release of D-serine, which acts as a co-agonist of 
NMDA receptors (Mothet et al., 2005). D-serine is synthetized by astrocytes 
from L-serine by serine racemase (SR), mainly expressed in glial cells and 
overexpressed in activated glial cells increasing the production and release of 
D-serine (Wu et al., 2004). Released D-serine promotes the production of 
reactive oxygen species (ROS) and the overactivation of NMDA receptors 
exacerbating glutamate effects and neuronal damage (Mustafa et al., 2010).  
 
1.1.4 GLIAL CELL SECRETION 
 
1.1.4.1 Glial vescicular release mediated by physiopathologycal stimuli 
 
The correlation between neuroinflammation and neurodegeneration has 
not been yet clarified. Many physiological CNS functions involving glia, 
23 
 
including neurodevelopment, memory maintenance, neuroprotection, 
homeostatic and metabolic mechanisms, may be mediated by direct cell-cell 
contact or by the secretion of molecules in a paracrine way both through the 
release of soluble factors and through extracellular vesicles (EVs), able to 
transfer potential toxic, aberrant, non-folded or neuroprotective molecules to 
neighbouring cells.  
In 1909, Hans Held observed granular inclusions in glial processes 
(Held, 1909). A year later, Jean Nageotte observed secretory granules in glial 
cells of the grey matter indicating an active secretion from these cells 
(Nageotte, 1910). Alois Alzheimer called these granules, gliosomes. Glial cell 
secretion includes neuotransmitters, neuromodulators, hormones, peptides, 
metabolic substrates, ROS, growth factors, plastic factors, inflammatory factors 
and neuroprotective molecules. The release of these molecules is mediated by 
several pathways; vesicle-based exocytosis of D-serine (Martineau et al., 2013) 
or glutamate (Montana et al., 2009), diffusion through plasmalemmal 
pores/channels, release of ATP and/or glutamate through anion channels, P2X7 
receptors (Cotrina et a., 1998, Suadicani et al., 2006) and extrusion through 
plasmalemmal transporters (Unichenko et al., 2013). 
Microglia and astrocytes exert their immune function mainly in the 
inflammatory process following acute and chronic neurodegenerative diseases, 
among which psychiatric disorders are included (Shie et al., 2011). In these 
pathological conditions, glial cells become activated (Skaper et al., 2012; 
Collins et al., 2012; Eikelenboom et al., 2012) and exert their function by 
releasing several factors.  
ATP represents one of the most important neuro/glio-transmitters; 
during pathology, ATP is released from damaged cells and acts both as a 
cytotoxic factor and a proinflammatory mediator, being a universal "danger" 
signal (Franke et al., 2012). 
D-serine upregulates glial activation (Panatier et al., 2006). Glutamate 
excitotoxicity is one of the main events responsible of neuronal degeneration 
and motor neuron death in Amyotrophic Lateral Sclerosis (ALS) and the 
impairment in astrocyte uptake of glutamate could be responsible for this event 
(Ilieva et al., 2009). Release from neural cells could be altered by glial cell 
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activation through  neuroinflammatory stimuli; bacterial LPS and interferon- γ 
(IFN-γ), which are able to induce a wide range of inflammatory activities, 
increase phagocytosis, chemotaxis, cytokine secretion, activation of the 
respiratory burst and induction of nitric oxide synthase (Zielasek, Hartung, 
1996), while the neuro/glio-transmitters ATP, which is released by injured and 
dying neural cells, leads to activation of P2X7 receptors in glial cells (Franke et 
al., 2006; Weisman et al., 2012; Skaper et al., 2010).  
Polazzi et al. showed that neuroprotection is due partly to molecules 
with a molecular weight lower than 30kDa, such as TGF-β2, SOD1 and ApoE. 
Transforming growth factor-beta 2 (TGF-β2), as well as SOD1 are 
constitutively released by microglia and neuroprotection could derive partly 
from the interaction between microglial released TGFβ-2 or SOD1 with 
neuronal receptors (Polazzi, 2013).  
 
1.1.4.2 Vescicule-mediated release of proteins 
 
It is known that glial cells signal to neighbouring cells by releasing 
molecules via regulated exocytosis through lysosomes (Verderio et al., 2012; 
Bräuer et al., 2004) and glial cell activation, commonly occurring in most 
neurodegenerative diseases and affecting protein release from these cells by 
influencing their secretory pathways (Bianco et al., 2005; Hanamsagar et al., 
2011). Glia-cell release of molecules may be mediated by extracellular vesicles 
that can be classified according to size, cargo and origin. 
Extracellular vesicles (EVs) comprise shedding microvesicles (MVs), 
exosomes, and apoptotic bodies. Apoptotic bodies are released during 
apoptosis, whereas the other types of vesicles are derived from healthy cells 
(Cocucci et al., 2009, Thery, 2011). Exosomes contain proteins arising from 
the plasma membrane, endocytic pathway and cytosol. They contain limited 
amounts of proteins from other intracellular compartments (nucleus, 
endoplasmic reticulum, Golgi apparatus). RNAs are transported by EVs from 
cell to cell and can modulate gene expression in the recipient cell. In the 
immune system, MHC-peptide complexes are secreted by exosomes from 
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antigen presenting cells (APCs) suggesting a role for exosomes in the adaptive 
immune response. 
Communication within the nervous system could be mediated by EVs; 
exosomes are secreted by neurons, Schwann cells, astrocytes and microglia 
(Potolicchio et al., 2005) and they may be responsible of the transfer of 
pathogenic proteins such as prions, beta-amyloid peptides, superoxide 
dismutase 1, tau and α-synuclein between glial cells and neurons promoting 
neuronal damage. 
Activation of microglia, mediated by ATP (activation of P2X7 
receptors), seems to promote the release of  microvesicles with irregular shape 
and size (0,1-1µm),  carrying pro-inflammatory cytokines to recipient neurons 
increasing inflammation (Verderio et al., 2012).  Similar to microglia, 
astrocyte-derived MVs are increased by activation of P2X7 receptors though 
these vesicles can be up to 8 μm in size and carry intact mitochondria and lipid 
droplets (Falchi, 2013). 
While microglia appear to be mainly involved in the spread of 
inflammatory molecules, astrocytes seem to be mainly implicated in the 
propagation of pathogenic proteins in neurodegenerative disorders. Astrocytes 
expressing mutant SOD1 (copper-zinc superoxide dismutase 1) secrete 
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increased amounts of exosomes, carrying mutant SOD1. These vesicles can 
transfer mutant SOD1 to neurons and induce motor neuron death suggesting a 
role of EVs in the pathogenesis of ALS (Basso et al., 2013). Exposure of 
astrocytes to amyloid peptide triggers the release of pro-apoptotic exosomes 
that contain ceramide and PAR4 (prostate apoptosis response 4). These 
exosomes are taken up by astrocytes and promote their apoptosis suggesting 
that exosome-mediated astrocyte death may contribute to neurodegeneration in 
Alzheimer’s disease (Wang et al., 2012). 
 
 
Purine Nucleoside Phosphorylase (PNP) is a ubiquitous enzyme, which 
catalyzes the intracellular cleavage of ribonucleosides to generate purine bases.  
Physiologically, PNP plays a crucial role in the metabolism of purines 
(Bzowska et al., 2000) and its deficiency causes a rare inherited disease 
determining severe combined immunodeficiency (SCID) (Markert, 1991). 
PNP protein, a trimer of approximately 90,000 daltons, has been found 
in most body tissues, showing the highest levels in lymphoid tissue, thus 
explaining why immune cells are predominantly impaired in PNP deficiency. 
Accordingly, PNP inhibitors have been developed as T-cell selective immune-
suppressants and to treat many forms of leukemia (Balakrishnan et al., 2010; 
Robak et al., 2006; Bantia, Kilpatrick, 2004). PNP knock-out mice recapitulate 
most pathological features of PNP-deficiency (Arpaia, et al., 2000). In this 
animal model, TAT-mediated intracellular delivery of PNP corrects the 
enzyme deficiency (Toro, Grunebaum, 2006). Concerning neurological defects 
in brains from PNP-KO mice, morphological abnormalities and apoptosis were 
detected in the cerebellum, which was smaller than normal with reduced 
Purkinje cell number (Mansouri et al., 2012). 
Despite all data concerning PNP involvement in brain physiopathology, 
little is known regarding its specific brain cell distribution. PNP histochemical 
localization is restricted to glial cells, whereas its expression in neurons is still 
debated (Castellano et al., 1990). Additionally, Dalmau and collaborators 
1.2 PURINE NUCLEOSIDE PHOSPHORYLASE 
(PNP) 
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(1998) suggested that microglial cells could be crucial for the development of 
normal central nervous system (CNS) by controlling purine metabolism. They 
showed different PNP staining depending on microglial morphology and 
observed PNP labeling in blood vessels, some nerve fibers and astrocytes, 
suggesting a complex mechanism of cell interactions in the regulation of 
extracellular purine levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.1 PNP DEFICIENCY 
 
Severe Combined Immunodeficiency (SCID) is a heterogeneous disease 
characterized by a prenatal disorder in the development of T lymphocytes 
leading to profound abnormalities of cell-mediated immunity, antibody 
deficiency, severe viral, bacterial and fungal infections, chronic diarrhoea, 
failure to thrive and skin rashes as typically seen in Omenn syndrome (OS). 
This pathology was first described in a five-year old child with T-cell 
immunodeficiency (Giblett et al., 1975). SCID is caused by mutations in 
different genes mainly involved in the development and function of both T and 
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B cells; natural killer cells are present in 50% of patients with SCID and are 
able to protect against viral, bacterial and fungal infections.  
PNP deficiency is a rare form of SCID (Markert, 1991). As in the 
human disease, PNP deficiency in mice, due to missense mutations in the gene 
codifying for this enzyme, showed a reduction in numbers of immature and 
peripheral T cells and in T cell proliferation (Snyder et al., 1997). Furthermore, 
mutations in PNP caused loss of deoxyguanosine kinase activity. PNP- 
deficiency could be due to block of purine recovery as a consequence of GTP 
depletion or to the accumulation of PNP substrates inosine, guanosine, 
deoxyinosine, and deoxyguanosine.  
The abnormal accumulation of dGTP preferentially in mitochondria, inhibits 
mitochondrial DNA synthesis as a first step of T- lymphocyte apoptosis 
(Young, 1994). 
 
Pathways of purine metabolism, Archives of Disease in Childhood, 1987. 
 
Neurological symptoms have been described in 50% of patients; 
neurological involvement seems to be related with the severity of PNP 
deficiency because GTP is necessary for neurotransmission. These evidences 
support a direct relation between neurological dysfunction and PNP deficiency. 
 
 
Superoxide dismutase (SOD) is an enzyme that exists in three isoforms: 
SOD1 (CuZnSOD); SOD2 (MnSOD); SOD3 (extracellular SOD); each one is 
produced from a different gene with distinct localization, but share the same 
1.3  SUPEROXIDE DISMUTASE 1 (SOD1) 
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function. This distinct localization is important for the compartmentalization of 
redox reactions. 
This enzyme catalyzes the dismutation mechanism, which is the 
transformation of superoxide by SOD to H2O2, in turn converted in H2O by 
catalase, peroxiredoxin (Prx) or glutathione peroxidase (GPx) (Go, Jones D, 
2011). The conversion involves alternative reduction and oxidation of a 
transition metal, such as copper (Cu) and manganese (Mn) that are located in 
the active site of the enzyme (Miao, St Clair, 2009; Zelko  et al., 2002; 
Yamakura, Kawasaki H, 2010;  Ushio-Fukai, 2011). Catalytic activity is 
required to maintain low levels of intra and extracellular ROS, superoxide and 
H2O2,, indispensable in signaling or in defense mechanisms against pathogens. 
If the level of ROS is too high, it may be cause of oxidative stress. 
SOD1 is a 153 amino acid homodimer ubiquitously expressed, mainly 
in the cytoplasm. Each SOD1 subunit binds to a zinc (Zn) and a copper (Cu) 
atom (Pasinelli, Bown R, 2006; Bruijn et al., 2004). The genomic sequence 
coding for SOD1 has high similarity among rat, mouse and human, thus 
indicating a considerable conservation for this gene.  
 
 
                                                                                                                                    Philbert Ip., 2011 
Polazzi et al. demonstrated a constitutive SOD1 production and release 
by microglia and the consequent accumulation in microglia conditioned 
medium (MCM). SOD1 was also found among the low molecular weight 
neuroprotective molecules released by microglia. Treatment of primary 
cerebellar granule neurons with 6-hydroxydopamine (6-OHDA) induced death 
of 50% of cells in 24h, however, co-exposure to MCM was able to restore cell 
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viability. The neuroprotective ability of SOD1 was confirmed by exposing 
primary cerebellar granule neurons to exogenous SOD1 in presence or absence 
of SOD1 inhibitors; neuroprotection was abrogated by SOD1 inhibitors. 
Polazzi et al. also demonstrated an ATP-mediated increase of SOD1 release by 
microglia, confirming the involvement of the lysosomal secretory pathway 
(Polazzi et al., 2013). 
Mutations in SOD1 are a key player in the onset of Amyotrophic 
Lateral Sclerosis (ALS); approximately 20% of familial cases (FALS) are due 
to mutations in the gene coding for SOD1. More than 125 mutations have been 
identified, 114 of them cause the disease, six are silent and five are intronic 
variants that do not lead to ALS. Although most of the 114 mutations are 
missense, twelve mutations are deletions or nonsense mutations that produce 
truncated proteins; all these mutations are specific to FALS and they have been 
found only in 1% of sporadic ALS (SALS). The majority of mutations cause 
reduced dismutation activity while few maintain full catalytic function. There 
is no clear correlation between enzyme activity and clinical disease 
progression, therefore it is still unclear how mutant SOD1 leads to motor 
neuron degeneration (Pasinelli, Bown, 2006). However, it is known that SOD1-
mediated toxicity in ALS is not due to a loss of function rather to gain of one 
or more toxic properties that are independent from SOD1 activity (Lewis et al., 
2014). 
 
1.3.1 AMYOTROPHIC LATERAL SCLEROSIS 
(ALS) 
 
Amyotrophic lateral sclerosis (ALS), also known as motor neuron 
disease, Charcot's disease (from the French neurologist who first described it in 
1860) or Lou Gehrig's disease (Pasinelli and Brown R.H, 2006), is a 
progressive, lethal, neurodegenerative disease, leading to paralysis of the 
voluntary muscles. ALS affects adults of both sexes around 55 years; the 
incidence and prevalence of ALS are respectively 1-2 and 4-6 per 100,000 
cases every year (Pasinelli P, and Brown, 2006). Mutations in superoxide 
dismutase 1 (SOD1), valosin containing protein (VCP), ubiquilin 2 
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(UBQLN2), charged multivesicular body protein 2b (CHMP2B), optineurin 
(OPTN), TAR DNA-binding protein 43 (TDP43), fused in sarcoma (FUS), 
chromosome 9 open reading frame 72 (C9ORF72) have been identified and 
promote the definition of proteinopathy for ALS (Takeuchi et al., 2015). A 
hallmark of neurodegenerative proteinopathies is the formation of misfolded 
protein aggregates that cause cellular toxicity. A key feature of misfolded 
protein diseases is the ability of the pathogenic protein species to propagate in 
a prion-like manner to neighbouring cells and to initiate or promote damage.  
Approximately 90-95% of ALS cases are sporadic (SALS), the 
remaining 5-10% are hereditary, familial ALS (FALS), 20% caused by 
dominant mutations in the gene coding for Cu/Zn superoxide dismutase 1 
(SOD1, chromosome 21q22.11). In ALS patients, more than 150 pathogenic 
mutations in SOD1 have been identified. Despite the involvement of several 
genes in FALS and SALS, there are similarities between all ALS forms: 
progressive degeneration of lower motor neurons (atrophy, cramps, twitching) 
and death of cortical neurons, suggesting a common pathogenic pathway 
(Grada et al., 2014). Motor neuron degeneration leads to impairment of 
neuromuscular function, paralysis of skeletal muscles, paralysis of breathing 
muscles (diaphragm and intercostal muscles) that culminate in respiratory 
failure, which causes death (Pasinelli and Brown, 2006). The main pathological 
hallmark of ALS is the atrophy of motor neurons but accumulation of 
phosphorylated neurofilament inclusions and the deposition of inclusions 
(spheroids) in axons, known as Lewy bodies, as well as activation and 
proliferation of astrocytes and microglia are observed (Hall et al., 1998; Wilms 
et al., 2001). Unfortunately, there is currently no therapy available for this 
neuropathology; the only approved drug, riluzole,  only prolongs the life of 
patients by a few months (Pasinelli and Brown, 2006; Lewis et al., 2014). 
Therefore, the characterization of the cellular and molecular processes involved 
in the onset and progression of the disease is necessary to identify new 
potential targets useful for therapeutic strategies, as well as for the 
identification of biomarkers for early diagnosis and therapeutic follow-up. 
When the disease affects upper motor neurons, it is defined as primary lateral 
sclerosis (PLS). The majority of patients affected by PLS develop consequent 
32 
 
problems in lower motor neurons (MND), satisfying the criteria for the 
diagnosis of ALS. Impairment in lower motor neurons (MND) classified the 
pathology as progressive muscular atrophy (PMA), though disease progression 
is not different from ALS. Frontotemporal lobar degeneration (FTLD) affects 3 
or 4 persons/100,000 per year and is characterized by abnormal behaviour and 
language. The main hallmark of FTLD are inclusions containing TAR DNA-
binding protein 43 (TDP-43), similar to the ones found in the motor neurons of 
ALS patients.  
In physiological conditions, TDP-43 is located in the nucleus while in the 
pathology the phosphorylated protein and C-fragment aggregates are located in 
the cytoplasm. The presence of both TDP-43 and mutant SOD1 aggregates in 
FALS is controversial; there are groups supporting the absence of TDP-43 
aggregation (Al-Chalabi and Leigh, 2005; Chio et al., 2009) and groups 
supporting the presence of these aggregates (Wills et al., 2009).  These 
evidences may classify ALS and FTLD as a different manifestation of the same 
disease spectrum.  
 
                     
Interaction between ALS and FTD. Robberecht & Philips. Nature Reviews Neuroscience 14, 248-264. 
 
The mechanism involved in the onset of ALS is not clearly defined; 
cellular degeneration, protein misfolding, presence of aggregates in the 
cytoplasm, ROS, excitotoxicity, impairment of axonal transport and abnormal 
calcium metabolism could be due to the loss of physiological function or gain 
of toxic function in the proteins responsible of the disease. 
Recent studies suggest a correlation between exposure to solvents, pesticides, 
metals, chemical compounds and the onset of ALS regarding the neurotoxic 
properties of these substances. (Bonvicini et al., 2010). 
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ALS Neurodegeneration mechanisms. Robberecht & Philips, Nature Reviews Neuroscience 14, 
248-264. 
 
1.3.2 MUTANT SOD1 IN ALS 
 
As previously described, microglia may show a direct neuroprotective 
effect against neuronal damage, as well as through the involvement of small 
neuroprotective molecules released such as SOD1.  
The function of SOD1 is controversial; neuroprotective in physiological 
conditions, but responsible for the onset of ALS, if mutated. 
Many hypotheses have been considered about the role of SOD1 
mutations in ALS. SOD1 mutations could i) alter the enzymatic activity of 
SOD1 through the copper aberrant catalysis or the binding of a wrong metal 
due to an alteration in the configuration of the active channel, or ii) cause a 
rapid reduction in the bond between SOD1 and copper resulting in the 
formation of superoxide anion (Bruijn et al., 2004), or iii) give SOD1 an 
unstable conformation promoting the aggregation of the protein. Protein 
aggregates increase with disease progression (Johnston et al., 2000; Wang et 
al., 2002). 
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The G93A mutation is the most common SOD1 mutation in Europe and 
is also the most studied one, especially in mouse models. Substitution of G93 is 
predicted to destabilize the β -barrel (Hart et al., 1998). 
Transgenic mice overexpressing human SOD1 G93A mutation show 
the first symptoms at 3 months of age but the severity of the disease depends 
on the expression levels of the mutant protein. The progressive weakness 
characteristic of these mice coincides with microglial activation, astrogliosis, 
loss of motor neurons in the spinal cord and intracellular aggregates both in 
motor neurons and glia, thus well-representing the human disease.  The 
inhibition of the proteasome ability to remove aberrant proteins seems a 
sufficient condition to induce the formation of aggregates in glial cells 
expressing mutant SOD1 (Bruijn et al., 2004). 
These evidences led to a "non-cell autonomous" hypothesis for 
neurodegeneration in ALS, in which non-neuronal cells of the brain play a 
central role in inducing neuronal death (Wang et al., 2009). 
Mutant SOD1 causes  astrogliosis, activation, infiltration and the 
inflammatory response of microglia, (increased production of nitric oxide and 
toxic cytokines), leading to further damage to motor neurons and accelerated 
disease progression (Polazzi and Monti, 2010). 
 
1.3.3 GLIAL CELL INVOLVEMENT IN ALS 
 
Involvement of microglia in ALS was postulated in the early 90s in in 
vivo models of the disease, by studying microglial activation in the brain and 
spinal cord of patients. Activation of microglia correlates with disease 
progression, leading to the idea that immuno-inflammatory mechanisms may 
contribute to ALS. Neuro-inflammation in ALS is also indicated by the fact 
that anti-inflammatory drugs could exert protective effects in mouse models of 
ALS. However, the role of microglia in neuro-inflammation and whether 
microglial activation is a cause or a consequence of the degeneration of motor 
neurons has not been fully clarified. Metabolism of nitric oxide (NO) may 
provide a link between microglial activation and oxidative damage to motor 
neurons. Mutant SOD1 is able to catalyze the production of reactive oxygen 
species such as peroxynitrite, which promote the expression of inducible nitric 
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oxide synthase (iNOS) (Li et al., 2005). iNOS converts arginine into citrulline 
and produces NO. Production of NO may play an important role in the 
transition from M2 to M1 phenotype and consequently in neuronal toxicity 
(Lewis et al., 2014). 
Astrocytes are the most abundant cells in the adult nervous system. In 
mouse models of ALS, astrocyte degeneration is due to the interaction of 
glutamate with one of its receptors, GluR2, which is less expressed than in 
control conditions. The GluR2 subunit is impermeable to Ca2+ and thus 
protects motor neurons from excitotoxicity. Mutant SOD1 expressed in 
astrocytes alters the impermeable property of the receptor, making motor 
neurons vulnerable to excitotoxicity (Ilieva et al., 2009). Pharmacological 
blockade of the glutamate receptor slows the degeneration of astrocytes, delays 
the onset of symptoms and improves life expectancy. Thus the GluR2 
glutamate receptor may be investigated as a therapeutic target. Although the 
expression of mutant SOD1 confined to astrocytes is not sufficient for disease 
development, selective reduction of mutant SOD1 in astrocytes slows down 
disease progression and the consequent activation of microglia, demonstrating 
the functional cross-talk between astrocytes and microglia. (Nagai et al., 2007). 
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Co-cultures between glia and neurons underline the role of glia in the 
onset and progression of ALS confirming the "non-cell autonomous" 
hypothesis for  neurodegeneration in ALS (Wang et al., 2009). 
 
 
  
SNCA is the gene encoding for α-synuclein. It is also called PARK1 
and PARK4 and was mapped in 1997 on the long arm of chromosome 4 by US 
researchers who studied a famous Italian family, "Contursi family”.  
(Polymeropoulos et al., 1997). It is composed by 7 exons of which 5 are 
encoding (Norris et al., 2004). α-synuclein is a ubiquitous protein belonging to 
a family that also includes β- and γ –synucleins. It is mainly expressed in the 
brain but also in the 
myocardium, connective tissue, 
spleen, prostate, thyroid,  
pancreas and in platelets. In the 
brain, alpha-synculein represents 
0.5-1.0% of all cytosolic 
proteins and it shows both 
cytosolic and nuclear 
localization in neuronal cells 
and is primarily located at the 
presynaptic end (Iwai et al., 
1995). α-synuclein is composed 
of 140 amino acids and three distinct regions: an N-terminal amphipathic 
region, with a short conserved sequence and α-helix structures (1-60), a 
hydrophobic intermediate region (NAC) containing the non-amyloid β 
component (61-95) and a C-terminal region, characterized by long and variable 
sequences of serine and tyrosine residues involved in the interaction with other 
proteins (96-140) (Venda et al., 2010). Binding with phospholipids induces 
changes in the N-terminal region. The protein modifies its secondary structure 
from about 3% to over 70% of α-helices. The NAC domain promotes the 
formation of β sheets (Serpell et al., 2000; El-Agnaf and Irvine, 2000). The N-
1.4 ALPHA-SYNUCLEIN (α-syn) 
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terminus region and the NAC domain contain a binding domain responsible for 
the association between α-synuclein and the cell membrane (Eliezer et al., 
2001). Alpha-synuclein protein produced by recombination or through 
purification does not show an orderly secondary or tertiary structure, however, 
its N-terminal region assumes an α-helix conformation upon binding with 
phospholipidic vesicles (Vekrellis et al., 2004). 
 Although the physiological function of α-synuclein has not yet been 
clarified, its interaction with synaptic vesicles has been shown through electron 
microscopy. It is generally associated to the pre-synaptic membrane, where it 
stabilizes the curvature of the bilayer and is involved in the maintenance of 
membrane integrity during the release of neurotransmitters (Eliezer et al., 
2001) and in vesicle traffic and fusion during signal transmission at the 
synaptic level (Auluck et al., 2010; Iwai et al., 1995). Studies on α-synuclein 
knockout mices how that despite not being essential for the normal 
development of the nervous system, α-synuclein is involved in long-term 
regulation and in the maintenance of presynaptic function (Chandra et al., 
2004) and it is necessary for the genesis, location and  maintenance of the 
presynaptic reserve pool (Cabin D.E. et al., 2002).  α-synuclein is transmitted 
from neuron to neuron and to astrocytes through endocytosis and inclusion 
bodies (Lee et al., 2010; Rappold and Tieu, 2010), but whether it can also be 
released by glial cells has not been yet clarified. α−synuclein has a 
predominantly cytosolic distribution but its ability to adhere to cell membranes 
allow it to display other cellular locations (Nakamura et al., 2011; Kamp et al., 
2010). The presence of α-synuclein in mitochondria has been reported: some 
studies detected α-synuclein presence at the level of the outer mitochondrial 
membrane (Nakamura et al., 2011; Zhang et al., 2008) and the inner 
mitochondrial membrane in PD patients (Devi et al., 2008; Martin et al., 2006). 
Overexpression of α-synuclein interferes with complex I (Nakamura et al., 
2011; Chinta et al., 2010; Loeb et al. 2010; Liu et al., 2009) and complex IV 
(Martin  et al., 2006) activity of the mitochondrial respiratory chain and this 
leads to an increased production of reactive oxygen species and nitric oxide, 
resulting in oxidative stress and the release of cytochrome c (Parihar et al., 
2009). 
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1.4.1 PARKINSON’S DISEASE 
 
Parkinson's disease (PD) is the second most common neurodegenerative 
disease after Alzheimer's disease. PD affects more than 1% of the population 
aged 55 years and more than 3% of the population aged 75 years (Pankratz et 
al., 2009). There are also early-onset cases, which are found in 5-10% of 
patients, whose initial symptoms appear between ages 20 and 50. Much more 
rarely, juvenile-onset forms (EOPD) can be identified, whose symptoms appear 
before age 20 (Wood-Kaczmar et al., 2006). Only 5% of cases are inherited; 
the remaining 95% of cases are sporadic idiopathic and the causes are still not 
clear, although the main risk factor appears to be aging. PD was described for 
the first time in 1817. The English physician James Parkinson described the 
clinical history of 6 patients affected by a neurological disease, which he 
named "shaking palsy".  
Characteristic hallmarks of PD are the death of nigral dopaminergic 
neurons projecting from the substantia nigra pars compacta and the presence in 
these neurons of cytoplasmic inclusions called "Lewy bodies", whose main 
component is represented by α-synuclein (Steiner et al., 2011; Kahle, 2008). 
The first gene related to the onset of PD was SNCA, encoding for α-synuclein 
(Polymeropoulos et al, 1997).  
The monogenic forms of PD can be divided in autosomal dominant and 
autosomal recessive forms.  Regarding the autosomal recessive forms, 
mutations in the parkin (PINK1) and protein deglycase (DJ1) genes are the 
most relevant clinical aspect (Houlden and Singleton, 2012; Zimprich et al., 
2011). Regarding the autosomal dominant forms of PD, three are the genes 
involved; LRRK2, VPS35 and α-synuclein. Some point mutations (A53T, 
A30P and E46K) in α-synuclein gene are related to the onset of an autosomal 
dominant juvenile form of PD (Singleton et al., 2013; Zarranz et al., 2004; 
Polymeropoulos et al., 1997), while multiplication of the entire locus seems to 
lead to a more severe early onset of the disease depending on the number gene 
copies (Fuchs et al., 2007; Singleton et al., 2003).  
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While the causes responsible for neuronal death remain largely 
unknown, the most likely hypotheses are pathogenic factors common to many 
neurodegenerative diseases, such as oxidative stress, apoptosis, mitochondrial 
dysfunction, neuroinflammation and dysfunction of protein degradation 
mechanisms (Bové and Perier, 2012). In this complex scenario, it is plausible 
that both genetic and environmental factors may contribute to PD development. 
Clinical description of PD is based on motor symptoms: bradykinesia, rigidity, 
resting tremor and postural instability (Schrag and Quinn, 2000). Recently, 
non-motor symptoms related to the disease have been discovered (Martinez-
Martin et al., 2011; O'Sullivan et al., 2008), anxiety, depression, psychosis and 
impulse control disorder, sleep disturbances, cognitive and sensory disorders, 
cardiovascular, gastrointestinal and genitourinary disorders (Dissanayaka et al., 
2010; Weintraub et al., 2010). Moreover, dementia occurs in 20% of cases 
(Pankratz et al., 2009). Currently there are no treatments available to counteract 
the disease, only therapies that slow down progression. The most common 
pharmacological approach is the treatment of PD patients with levodopa, a 
dopamine precursor, able to cross the blood-brain barrier where it is converted 
in dopamine. Therapy with levodopa improves the life of patients, but after few 
years of treatment, they show side effects characterized by alternative periods 
of preserved motor capability and periods of akinesia or tremor. Because PD 
causes loss of at least 70% of neurons in the nervous system, the aim of new 
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pharmacological therapeutic trends is to find neuroprotective and neurotrophic 
drugs.  
 
1.4.2 MUTANT α-syn IN PARKINSON’S DISEASE 
 
Interest in α-synuclein has increased due to its direct involvement in 
many neurodegenerative diseases. Its pathogenicity, in fact, is related to its 
propensity to aggregate and to be the main component of amyloid plaques in 
Alzheimer's patients (Campion et al. 1995). 
 
  
α-syn toxicity model (Irwin et al., 2013). 
 
In 1997 a mutation on chromosome 4 was identified in PD patients and 
one year later it was shown to be the missense mutation A53T in the α-
synuclein gene (Polymeropoulos et al. 1997). α-synuclein fibrils are  the main 
component of Lewy bodies in PD patients, but they are also found in other 
types of aggregates, Lewy neurites or oligodendroglial inclusions, that 
characterize diseases indicated as "synucleinopathies" (Steiner et al., 2011; 
Kahle, 2008;). In this group of pathologies, we find dementia with Lewy 
bodies (DLB), a variant of Alzheimer's disease (LBVAD), Huntington's 
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disease, fronto-temporal dementia, progressive supranuclear palsy, Down 
syndrome, multiple system atrophy (MSA) and neurodegeneration with iron 
accumulation type 1 (NBIA-1) (Jellinger, 2003). The molecular mechanisms 
linking α-synuclein to the pathogenesis of these diseases are not yet fully 
understood. In the past years, it was believed that the presence of mutant α-
synuclein or its overexpression could promote the formation of toxic protein 
aggregates. Recently, it has been demonstrated that in case of special types of 
injuries, α-synuclein has a protective role. According to the current state of the 
art, the protective or toxic effect of α-synuclein depends on its level of 
expression in the cell: α-synuclein in physiological conditions would have a 
protective function, while its accumulation and aggregation into oligomers or 
fibrils would have a detrimental effect for cells (Irwin et al., 2013; Vekrellis et 
al., 2004).  
Missense mutations in the gene (A53T, A30P), duplication or 
triplication of the wild-type form of α-synuclein are neurotoxic and responsible 
for familial forms of PD (Mosharov et al., 2006). In solution, A53T and A30P 
mutations increase the rate of oligomerization of α-synuclein and the formation 
of β sheets (Uversky and Fink, 2002); the mutation rate of the fibrils is 
increased by the A53T mutation and reduced by the A30P mutation (Conway 
et al., 2000) and α-synuclein overexpression causes the formation of aggregates 
in many cell lines, while in mouse models, the formation of non fibrillar 
inclusions in the same brain regions as Lewy bodies. Mice also display damage 
in the nigrostriatal dopaminergic system and movement deficits (Stefanova et 
al., 2001). In an α-synuclepin transgenic model of Drosophila melanogaster, 
neuronal loss and formation of inclusions similar to Lewy bodies from patients 
were observed (Feany and Bender, 2000). Accumulation of α-synuclein causes 
the blockade of vesicular trafficking from the endoplasmic reticulum to the 
Golgi apparatus (Cooper et al., 2006). Moreover, α-synuclein has been shown 
to be involved in the modulation of mitocondrial functions (Stichel et al., 2007; 
Martin et al., 2006). 
Lastly, α-synuclein activity is related to the presence of dopamine (DA). 
Catecholamines, in particular dopamine, react with α-synuclein in order to 
stabilize the protofibrils and promote their aggregation (Conway et al., 2001). 
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Also other conditions seem to facilitate α-synuclein aggregation: contact with 
toxic substances, such as paraquat and rotenone, which act through the 
inactivation of mitochondrial activity, oxidative stress and even aging. In fact, 
aged cells are no longer able to remove α-synuclein, therefore its levels 
increase in the cytoplasm and accumulate pathologically (Li et al., 2004). 
According to its conformational and functional state, α-synuclein can be 
degraded by the ubiquitin-proteasome system or through autophagy. In the 
past, it was believed that soluble forms were degraded by the ubiquitin-
proteasome system, while aggregates through autophagy. Subsequent studies 
have shown that even the soluble forms of α-synuclein can reach the lysosomal 
compartment to be degraded (Jackson-Lewis et al., 2000). The ubiquitin-
proteasome system seems unable to remove α-synuclein mutant forms and 
fibrils that accumulate in aggregates (Singleton et al., 2003). 
 
1.4.3 GLIAL CELL INVOLVEMENT IN 
PARKINSON’S DISEASE 
 
Microglia seems to play an important role in PD given that the 
substantia nigra pars compacta is the brain region with the highest density of 
microglia and in PD patients, the presence of reactive microglia which 
stimulates the production of free radicals, resulting in neuronal oxidative 
damage has been reported. In vitro, overexpression of wild-type or mutant 
human α-synuclein (A53T and A30P) in the BV2 microglial cell line, drives 
microglial cells towards the reactive phenotype characterized by the increase of 
arachidonic acid metabolism, cytokine and interleukin secretion, reactive 
oxygen species, tumor necrosis factor α (TNF-α) and nitric oxide (NO) 
production (Rojanathammanee et al. 2011). 
In addition to microglia, astrocytes also confer neuroprotection, both 
through the removal of toxic molecules from the extracellular space and 
through the release of trophic factors and antioxidant molecules. However, in 
pathological conditions, astrocytes release proinflammatory cytokines and 
other toxic molecules that are harmful to dopaminergic neurons. Astrocytes 
density is low in the substantia nigra pars compacta, which is the most affected 
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region, while it is high in other less affected areas in the disease, as in the 
ventral tegmental area. Therefore Damier and colleagues hypothesized that 
neurons in the substantia nigra pars compacta might be more vulnerable to 
illness because of the lack of neuroprotective glial cells (Hirsch and Hunot S, 
2009; Damier et al., 1993). Astrocytes confer neuroprotection to dopaminergic 
neurons via lysosomes eliminating the toxic extracellular excess of α-
synuclein. Lee and colleagues reported that α-synuclein is transmitted from 
neuron to neuron and from neuron to astrocyte through endocytosis and 
inclusion bodies (Lee et al., 2010) and this property led them to suggest that α-
synuclein may have prion-like properties (Rappold et al., 2010). 
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2. AIMS 
 
Previous results from our laboratory clearly demonstrated that 
microglial cells exert a neuroprotective role through the release of soluble 
factors (Polazzi et al., 2001, 2009, 2013, 2015; Polazzi & Monti, 2010). In 
order to clarify this neuroprotective effect both in physiological and 
pathological conditions, a firm aim of this thesis was to check whether i) 
proteins related to neurological diseases were released by glial cells, ii) their 
release could also be mediated by vesicles, iii) they could be involved in glial 
activation and therefore neuroinflammation. 
To perform these experiments we used in vitro models of glial cells: 
primary cultures of rat astrocytes and microglia, as well as immortalized mouse 
astrocytes and microglia cell lines (respectively IMA2.1 and N9). 
We focused our attention on three proteins: PNP, SOD1 and alpha-
synuclein. 
The interest on these proteins derived from the fact that they are all 
involved in brain neuropathology, since mutations in the gene codifying for 
PNP induce PNP deficiency, a neurodevelopmental disorder characterized by 
immunodeficiency, while SOD1 and alpha-synuclein are both involved in 
neurodegenerative diseases, amyotrophic lateral sclerosis and Parkison’s 
disease respectively, both characterized by the presence of protein aggregates, 
neurodegeneration and neuroinflammation.  
Because in all these neurological diseases there is a strong involvement of 
immune cells, we focused on the role of glial cell secretion, since most studies 
focused on neurons only.  
Neurodegenerative diseases, stroke, trauma and hypoxia affect neuronal 
survival indirectly by triggering neuroinflammation. Microglia are then 
activated in response to insults acquiring a phagocytic phenotype and releasing 
inflammatory mediators, cytokines and chemokines. The acute 
neuroinflammatory response seems to be beneficial to the CNS, since it is an 
attempt to reduce injury and restore damaged tissues. 
Because glial cells play a crucial role in brain pathophysiology, mainly 
following their activation, we assessed whether the release of these proteins 
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could be influenced by typical inflammatory stimuli, such as 
lipopolysaccharide (LPS), interferon-γ (IFN-γ) and ATP.  
Since it is known that protein release in glial cells could occur through the 
lysosomal secretory pathway (Dubyak, 2012; Takenouchi, 2009) and since 
glial secretion through extracellular vesicles (EVs) has acquired increased 
importance in physiological glial-neuron communication, we also assessed 
whether PNP, SOD1 and alpha-synculein could be released by glial cells 
through this pathway.  
Considering previous studies from our laboratory on the 
neuroprotective role of microglial cells against neuronal damage (Polazzi et al., 
2013), the second aim of this project was to study the role that proteins 
secreted by glial cells may have on pathological conditions. 
Polazzi et al., demonstrated a neuroprotective role of microglia exerted 
by low molecular weight secreted proteins. SOD1 was identified as one of 
these molecules, constitutively produced, released and accumulated in 
conditioned medium (MCM). However, mutations in SOD1 are some of the 
main hallmarks observed in patients affected by familial Amyotrophic Latera 
Sclerosis (ALS) and glial cells appeared to be crucial for the initiation and 
progression of disease, since a non-cell autonomous mechanism for ALS 
neurodegeneration has been postulated (Ilieva et al, 2009). 
Mutant SOD1 has been shown to cause a reduction in glial cell 
physiological function, activation of microglial cells characterized by an 
elevated production of cytotoxic molecules such as ROS, inflammatory 
molecules including iNOS, pro-inflammatory cytokines and failure of astrocyte 
glutamate uptake, thus suggesting that motor neuron degeneration could be 
triggered by glial cell dysfunction (Weydt et al., 2004; Hensley et al., 2006; 
Liao et al., 2012; Frakes et al., 2014). 
In agreement with these evidences, we overexpressed in rat primary cultures of 
microglia and astrocytes wild-type SOD1 and fALS-linked SOD1 mutants 
(G93A and A4V), to compare the effect of different mutations on glial cell 
activation and microglial phenotype. 
Glutamate excitotoxicity is considered one of the main causes of neuronal 
death in ALS; in order to clarify the role of glial cells in ALS 
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neurodegeneration, we developed an in vitro model of primary neuron-
microglia and neuron-astrocyte contact co-cultures to evaluate the effect of 
wild-type and mutant SOD1 overexpression in glial cells on neuronal survival 
and death after exposure to glutamate.  
Furthermore, we carried on a parallel study on α-synuclein expression 
and by from glial cells as well as on the effect of wild-type or familial PD-
linked mutant α-synuclein over-expression. So far, most studies have mainly 
investigated the role of α-synuclein in neurons, excluding non-neuronal cells, 
such as glial cells. Parkinson’s disease (PD), however, involves the alteration 
of many other cell types besides neurons, modifying not only neuronal 
function, but also the cross-talk between different neurons and neighbouring 
cells (Appel et al., 2010). According to the “non-cell autonomous” hypothesis, 
we started a preliminary study on the expression and release of α-synuclein in 
physiopathologycal conditions. First, we assessed whether glial cells released 
α-synuclein and whether the release could be influenced by typical 
inflammatory stimuli, such as lipopolysaccharide (LPS) and ATP. α-synuclein 
is transmitted from neuron to neuron and from neuron to astrocyte through 
endocytosis and inclusion bodies (Rappold et al., 2010; Lee et al., 2010), 
however whether it could be released even by microglial cells is still unclear. 
We also performed experiments to verify the involvement of the lysosomal 
secretory pathway and vesicles in α-synuclein release.  
The role of D-serine in the modulation of N-methyl-D-aspartate receptors 
(NMDAR) is known; D-serine is synthetized by astrocytes from L-serine. Glial 
cell activation stimulates the release of cell death mediators, such as glutamate, 
cytokines and reactive oxygen species (ROS). The increase in extracellular 
glutamate levels is considered one of the main causes of neuronal death (Van 
Damme et al., 2005; Bruijn et al., 2004). We assessed whether L-serine could 
mediate α-synuclein release. 
α-synuclein is also involved in neurodegenerative diseases; its pathogenicity is 
related to its propensity to aggregate, as shown to be the main component of 
amyloid plaques in Alzheimer's patients (Campion et al. 1995). 
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Missense mutations in the α-synuclein gene (A53T, A30P), or duplication or 
triplication of the wild-type form are neurotoxic and responsible for familial 
forms of PD (Mosharov et al., 2006). 
To this aim, we overexpressed in immortalized cell lines of microglia 
and astrocytes wild-type or familial PD-linked mutant α-synuclein (A53T and 
A30P), to compare the effect of different mutations on glial cell viability. 
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3. MATERIAL AND METHODS 
 
 
Animals sacrificed for primary cell cultures were Wistar rats, bred with 
free access to food and water and kept in a light-dark 12/12 hour cycle (Levi et 
al., 1993). Experiments were conducted in accordance to European Community 
and Italian laws, and approved by the Ethical Committee for Animal 
Experimentation of the University of Bologna (Protocol No. 17-72-1212). In 
addition, University veterinarians periodically checked animal health. 
In order to allow the cell adhesion, flasks were treated with poly-L-
lysine (Sigma-Aldrich, St. Louis, MO, USA), a synthetic compound that 
enhances cell adhesion favoring growth and differentiation. The 1 mg/ml stock 
solution of poly-L-lysine (Sigma, 30,000 <MW <70,000) was resuspended in 
sterile distilled water and used at a concentration of 10 µg/ml. The entire 
surface of the flasks was covered with poly-L-lysine, which was removed after 
30 minutes and flasks were left to dry. We obtained mixed cultures of glial 
cells from cerebral cortices of newborn rats. After 6/7 days in culture, we were 
able to obtain pure secondary cultures of microglia through mechanical 
detachment, while pure astrocyte cultures were obtained by trypsinization. 
The complete medium used to maintain cultured glial cells consisted of Basal 
Medium Eagle (BME, Life Technologies Ltd, Paisley, UK) supplemented with 
10% heat-inactivated Fetal Bovine Serum (FBS, Life Technologies), 50 mg/ml 
gentamicin and 2-mM L-glutamine (Sigma-Aldrich).  
The 5 solutions used for the mixed culture preparation were composed 
as follows: 
 
 
 
 
 
3.1 PRIMARY RAT CULTURE OF MICROGLIA 
AND ASTROCYTES  
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SOLUTIONS   
Solution 1 KREBS 10X 15 ml 
 MgSO4 3,82% 1,2 ml 
 BSA 0,45 g 
 H2O 135 ml 
Solution 2 Trypsin 9,38 mg 
 Solution 1 37,5 ml 
Solution 3 Solution 1 22,5 ml 
 DNAse 5,4 mg 
 Trypsin inhibitor 11,7 mg 
 MgSO4 3,82% 225 µl 
Solution 4 Solution 1 31,5 ml 
 Solution 3 6 ml 
Solution 5 CaCl2 1,2 % 22,5 µl 
 MgSO4 3,82% 150 µl 
 Solution 1 18,75 ml 
 
KREBS STOCK SOLUTION 10X pH 7.4 
NaCl (1.32 M) 38,6 g 
KCl (0.05M) 1.85 g 
Na2HPO4 + 12 H2O 
(0.085M) 
15,2g 
NaHPO4+H2O 
(0.21M) 
1,45g 
Glucose (0.1M) 9,9 g 
Phenol red 50 mg 
H2O 500 ml 
 
All reagents were from Sigma-Aldrich. 
To prepare mixed primary cultures of glial cells, newborn Wistar rats (1 
day) were sacrificed and cortices were immediately removed. From each 
animal we obtained of 5/6 mixed culture 75 cm2 flasks on average. Meninges 
were removed by mechanical dissociation in solution 1, using sterile tweezers. 
20 ml of solution 2 containing trypsin were added to the hemispheres in 
solution. In order to allow enzymatic dissociation, tissues were incubated in a 
water bath at 37 ° C for 15 minutes. At this point, solution 4 containing the 
trypsin inhibitor trypsin and DNAse were added to block the reaction. After a 
quick centrifuge (1000 rpm, 4 minutes) the supernatant was removed and the 
pellet was resuspended in 5 ml of solution 3 with a glass Pasteur pipette in 
order to mechanically obtain complete tissue dissociaion. After a last wash in 
solution 5, the pellet was resuspended in BME (Life Technologies) 
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supplemented with 10% FBS (Life Technologies), 50 mg/ml gentamicin 
(Sigma-Aldrich) and 2 mM L-glutamine (Sigma-Aldrich), previously heated at 
37 ° C and  cells were plated in poly-L-lysine coated flasks (Sigma-Aldrich). 
Flasks were kept in a humidified incubator at 37 ° C with 5% CO2. After 2 
days, the medium was  replaced with fresh medium to remove debris and non-
adherent cells. After 7-8 days in culture, astrocytes were confluent and 
microglia grew on the astrocyte monolayer. 
To obtain a pure secondary culture of microglia, microglia were 
detached by mechanically shaking the flasks, the cell culture medium was 
collected and centrifuged. The obtained pellet was resuspended in 10 ml of 
serum-free BME (Life Technologies), cells were counted with Neubauer 
counting chamber and plated at the density of 1.5x106 or 2x106 /35mm Ø dish 
in 2ml of serum-free BME (Life Technologies), depending on the experiment. 
Flasks were replaced with fresh complete BME (Life Technologies) and after 
3-4 more days microglia was ready to be detached again.  
To purify astrocyte cultures, 10-day-old primary mixed glial cultures 
were vigorously shaken to detach microglia and oligodendrocytes growing on 
top of the astrocyte monolayer. The remaining adherent cells were detached 
with 0.25% trypsin/EDTA (Life technologies), centrifuged and  resuspended in 
fresh BME (Life Technologies) medium without serum and plated on poly-L-
lysine-coated (Sigma-Aldrich) 35 mm Ø Petri dishes at a density of 0.5 x 106 
cells/1 ml medium/well.  
 
 
Cerebellar granule neurons (CGNs) obtained from 7-day old rats reach 
full differentiation after 7 days further in culture (7 DIV) (Gallo et al., 1987). 
Primary CGNs are the most-widely used model to study cellular and molecular 
mechanisms of survival and neuronal death, since it is an almost pure culture, 
with no contamination with glia or other types of neurons (Contestabile A. 
2002). The culture medium used to maintain neurons was composed by BME 
(Life Technologies) supplemented with 10% heat-inactivated FBS (Life 
3.2 PRIMARY RAT CULTURE OF CEREBELLAR 
GRANULE NEURONS (CGNs) 
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Technologies), 50 mg/ml gentamicin (Sigma-Aldrich), 2 mM L-glutamine 
(Sigma-Aldrich) and 25mM KCl (Sigma-Aldrich).  
In order to prepare this neuronal culture, the following 5 solutions were 
used:  
  
SOLUTIONS   
Solution 1 KREBS 10X 25 ml 
 MgSO4 3,82% 2 ml 
 BSA 0,75 g 
 H2O up to 250 ml 
Solution 2 Trypsin 12.5 mg 
 Solution 1 up to ml 
Solution 3 Solution 1 Up to 25 ml 
 DNAse 3.12 mg 
 Trypsin inhibitor 13 mg 
 MgSO4 3,82% 250 µl 
Solution 4 Solution 1 8 ml 
 Solution 3 42 ml 
Solution 5 CaCl2 1,2 % 320 µl 
 MgSO4 3,82% 320 µl 
 Solution 1 Up to 40 ml 
 
All reagents were from Sigma-Aldrich. 
To obtain a primary culture of cerebellar granule neurons, we collected 
cerebella from 7-day old rats. After meninges were removed, the cerebellar 
tissue was collected in a 50 ml falcon tube with solution 2 containing trypsin 
and incubated in a water bath at 37 ° C for 15 minutes in order to enhance the 
enzymatic dissociation of the tissue. At this point, trypsin activity was blocked 
by adding solution 4 containing trypsin inhibitor and DNAse (Sigma-Aldrich), 
to degrade DNA that may accumulate after cell disruption. After a quick 
centrifuge, 4 minutes at 1000 rpm,the pellet was mechanically dissociated in 
solution 3. Then, after a wash in solution 5 and the last centrifuge, 7 minutea at 
1000 rpm, the cell pellet was resuspended in complete BME (Life 
Technologies), cells were counted and plated at the density of 2.4x106 cells in 
2 ml of medium in 35 mm Ø Petri dishes previously coated with poly-L-lysine 
(Sigma-Aldrich) as previously described. After 16h in a humidified incubator 
at 37 ° C, 5% CO2, 10 mM cytosine arabinoside (Sigma-Aldrich) was added to 
cell cultures to reduce the proliferation of non-neuronal cells and obtain pure 
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neuronal cultures. After 7 days in vitro (7-DIV), cerebellar granule neurons 
were fully differentiated and ready to be used. 
 
 
In order to use immortalized cell line cultures, sterile instruments and 
solutions were used under a laminar flow hood. To increase cell adhesion, Petri 
dishes were pre-coated with poly-L-lysine (Sigma-Aldrich), as previously 
described. 
 IMA 2.1 cells are an immortalized murine astrocyte cell line, while N9 cells 
are an immortalized murine microglia cell line. 
IMA 2.1 and N9 cell lines were kept in culture in 10 cm Ø Petri dishes 
with 9 ml of Dulbecco's Modified Eagle Medium (DMEM, Life Technologies) 
supplemented with 10% FBS, 1% Penicillin/Streptomycin solution and 2 mM 
L-glutamine. For subsequent experiments, cells were trypsinized and plated at 
an initial density of 5 × 105 cells/60 mm diameter Petri dish and 2x105 cells /35 
mm diameter dish for 24 hours in complete DMEM medium. 60 mm diameter 
Petri dishes were used for Western blot analysis and nitrite detection, while 35 
mm diameter Petri dishes were used for immunocytochemistry and Hoechst 
staining. 
 
3.4.1 TREATMENT WITH LPS 
 
In order to activate microglial cells, one of the first methods described 
in the literature was treatment with the bacterial endotoxin lipopolysaccharide 
(LPS) (Hetier et al., 1988). In vitro activation of microglia with LPS mimics 
the glial activation that occurs in vivo, as a result of an acute inflammatory 
stimuli, but also chronic microglial activation due to neurodegenerative 
diseases (Petrova et al., 1999; Pahan et al., 1997; Nishiya et al. 1995). LPS 
3.3 IMA 2.1 AND N9 IMMORTALIZED CELLS 
LINES  
3.4 CULTURE TREATMENTS 
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treatment is known to increase the production and release of pro-inflammatory 
cytokines and chemokines (Qin et al., 2004; Kong et al., 1997;  Lieberman et 
al., 1989), as well as to induce the up-regulation of nitric oxide synthase 
(iNOS) and the consequent increase of nitric oxide (NO) secretion (Pahan et 
al., 1997; Boje and Arora, 1992) mediated by the TLR4 receptor (Takeda et al., 
2003). Primary microglia and astrocytes, as well as immortalized N9 and IMA 
2.1 cell lines were plated in BME (microglia and astrocytes) or  DMEM (N9 
and IMA2.1) medium supplemented with 2 mM glutamine and 1% 
penicillin/streptomycin, without serum at previously described denisities and 
stimulated for 24 hours with increasing concentrations of LPS [1; 10; 100; 
1000 ng/ml].   
 
3.4.2 TREATMENT WITH INTERFERON- γ (IFN- γ) 
 
In parallel to LPS stimulation, primary microglia and astrocytes were 
also treated with interferon-γ (IFN-γ). IFN-γ is produced by activated T 
lymphocytes and natural killer cells; it modulates immunological responses and 
stimulates the production of reactive nitrogen and oxygen species and 
cytokines/chemokines in microglia (Schroder et al., 2017). Primary microglia, 
astrocytes and neurons were plated in BME medium without serum, as 
previously described, and stimulated for 24 hours with increasing 
concentrations of IFN-γ [1; 10; 100 ng/ml].  
 
3.4.3 TREATMENT WITH ADENOSINE 
TRIPHOSPHATE (ATP) AND 2'-3'-O-(4-
BENZOYLBENZOYL)-ATP (BZ-ATP) 
 
Adenosine triphosphate (ATP) and its stable form 2'-3'-O-(4-
benzoylbenzoyl)- ATP (Bz-ATP) are stimuli both able to activate P2X7 
receptors expressed by macrophages and microglia. Activation of microglia by 
ATP induces the formation of membrane permeable pores, stimulates 
monocyte and macrophage lysosomal secretion, induces the activation of 
intracellular signals including the influx of calcium which in turn stimulates the 
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activation of the MAP kinase pathway and eventually the activated state of 
microglia. ATP-mediated activation through the activation of P2X7 receptors 
appears to be not chronic, less aggressive than the activation mediated by LPS, 
and mainly leading to an apoptotic condition (Takato et al., 2009). 
Primary cultures of glial cells were stimulated for 1 hour with 
increasing concentrations of ATP [0.5, 1 mM] or Bz-ATP [125, 250 µM].  
Oxidized ATP (ox ATP) is an inhibitor of P2X7 receptors, known to 
inhibit T- cell proliferation and interfere with the innate immune response 
(Lang et al., 2010). Suramin is a non-selective antagonist of P2 receptors and, 
in a similar way to ox ATP, it could inhibit the immune response, though it 
also has anti-inflammatory proprieties. Microglia and astrocytes were pre-
treated with 300µM ox ATP or 50 µM suramin for 1 hour and then treated with 
ATP or Bz-ATP. 
N9 and IMA2.1 cells were stimulated for 4 hours with increased 
concentrations of ATP [100, 500 µM]. Cells were collected in lysis buffer (1% 
SDS, 50 mM Tris HCl pH 7.4, 1 mM EDTA, protease inhibitor cocktail 10 µl/ 
ml) and stored at -80°C for western blot analysis. An equal volume of 
conditioned medium (500µl) was collected and concentrated by using 
Microcon-YM-3 (EMD Millipore Corporation, Billerica, MA, USA), 
resuspended in 15 µl of Loading buffer 4 X (1M Tris HCl pH 7.0 1 ml; 20% 
SDS 2 ml; Glycerol 2 ml; 20 mg of Bromophenol Blue,  1 M DTT 1:5) and 
stored at -20 ° C for western blot analysis. In parallel, primary cultures of 
microglia and astrocytes were treated with 500 µM ATP and fixed with 4% 
paraformaldehyde (PFA) for immunocytochemistry assays.  
 
3.4.5 L-SERINE TREATMENT 
 
D-serine is a neuromodulator of N-methyl-D-aspartate receptors 
(NMDAR), able to allow the opening of these receptors by glutamate. The 
NMDA receptor has a binding site for glycine, but D-serine is an endogenous 
agonist stronger than glycine (Panatier et al., 2006). D-serine is synthesized in 
astrocytes from L-serine thanks to the enzyme serine racemase (SR), expressed 
mainly in glial cells (Wolosker et al., 1999) and upregulated by glial activation 
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(Wu and Barger, 2004). The SR enzyme catalyzes the elimination of water 
from both  L-serine and D-serine to form pyruvate (Foltyn V.N. et al., 2004).  
We treated IMA 2.1 and N9 cell lines with different concentrations of 
L-Serine (Sigma-Aldrich). IMA 2.1 and N9 cells were plated as previously 
described and treated for 24 hours with increasing concentrations of L-serine in 
DMEM without serum [0,10,50,100 µM]. 
 
3.4.6 TREATMENT WITH THREALOSE 
 
We treated primary cultures of microglia and astrocytes overexpressing  
wild-type and mutant SOD1 with 5mM trehalose (Sigma-Aldrich), which is 
able to induce autophagy, for 48 hours in serum-free BME. 2x106 microglial 
cells and 5 x105 astrocytes were plated in 35 mm diameter Petri dishes in 
serum free BME, transfected with SOD1 plasmids as described in the 
following paragraphs and treated with thehalose.  
 
3.5.1 PURIFICATION OF PLASMID DNA 
 
In order to amplify the plasmids used for cell transfection (pcDNA3.1 
(+)), competent bacteria were used (E. coli, DH-5α strain). Bacteria were first 
subject to thermal shock, which allows an increase in the permeability of the 
plasma membrane and the consequent entry of the plasmids within the bacteria. 
Starting from a "pre-inoculum" of transformed bacteria selected by the 
presence of plasmids with antibiotic resistance, 1 ml of pre-inoculum was 
added to 50 ml Lurina-Bertani  broth (LB) with ampicillin at a final 
concentration of 100 µg/ml and incubated at 37 ° C on an orbital shaker at 250 
rpm overnight. 
The next day, the bacterial suspension was centrifuged at 4000 rpm 
(USA LE G DEL PROTOCOLLO) for 15 minutes at 4 ° C. To purify plasmid 
DNA, the NucleoBond XTra kit Midi / Maxi (Macherey-Nagel) was used. The 
kit consists of resuspension buffer RES (50 mM  Tris-HCl, 10 mM EDTA, 100 
3.5 GLIAL CELL TRANSFECTION 
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mg/ ml RNase A, pH 8.0), bacterial Lysis Buffer (200 mM NaOH, 1% SDS) 
added to the cell pellet and gently mixed by inversion, allowing the lysis of the 
bacterial cells for 5 minutes. At this point, equilibration EQU Buffer (100 mM 
Tris, 15% ethanol, 900 mM KCl, Triton X-100 0.15% adjusted to pH 6.3 with 
H3PO4) was used to balance the purification columns and inserted paper filters. 
Neutralization Buffer NEU (KAC 2.8 M, pH 5.1) was added to the cell lysate, 
mixed by inversion, and loaded onto the previously equilibrated columns with 
paper filters. The paper filters were again washed with buffer EQU before 
being removed and the columns were washed with washing Buffer WASH 
(100 mM Tris, 15% ethanol, 900 mM KCl, Triton X-100 0.15%  adjusted to 
pH 6.3 with H3PO4). Plasmid DNA was bound by the column resin and eluted 
by adding elution Buffer ELU (100 mM Tris, 15% ethanol, 1 M KCl, adjusted 
to pH 8.5 with H3PO4) and 2-isopropanol was added to the eluate at room 
temperature. Plasmid DNA was centrifuged at 15000 g for 30 minutes at 4 ° C 
and the DNA pellet was washed again with 70% ethanol. The pellet was left to 
dry at room temperature, before being resuspended in sterile deionized H2O. 
Plasmid concentration and purity were then determined by using a UV 
Nanodrop spectrophotometer (Thermo scientific, NanoDrop Products, 
Wilmington, DE, USA). 
pcDNA3.1 plasmids encoding for human WT SOD1, G93A SOD1 and A4V 
SOD1, were kindly provided by Prof. Angelo Poletti, University of Milan, Italy 
(Sau et al., 2007). pcDNA3.1(+) plasmids encoding for WT α-synuclein, A30P 
α-synuclein A30P and A53T α-synuclein, were kindly provided by Dr. Nelson 
Cole (Department of Health & Human Services. National Institute of Health, 
Maryland, USA). 
 
3.5.2 TRANSFECTION OF GLIAL PRIMARY 
CULTURES  
 
To transfect primary microglia and astrocytes with SOD1 plasmids, we 
used Lipofectamine® 2000 (Life Technologies). Lipofectamine is a cationic 
lipid forming liposomes (lipid vesicles containing exogenous DNA) which 
57 
 
allows the formation of a complex containing negatively charged nucleic acids 
able to fuse with the cell membrane. 
Microglial cells were plated at a density of 2×106 cells/2ml serum-free 
BME (Life Technologies) /35-mm Ø Petri dishes coated with poly-L-lysine 
(Sigma-Aldrich). Astrocytes were plated at a density of 5×105 cells/1ml serum-
free BME/35-mm Ø Petri dishes coated with poly-L-lysine (Sigma-Aldrich). 
Cells were transiently transfected with a pEGFP empty vector, as transfection 
control, and pEGFP encoding for wild-type or mutant (G93A and A4V) human 
SOD1. According to the manufacturer’s protocol, we used 1,25 µg of pDNA 
and 2,5 µl of Lipofectamine (Life Technologies) 2000 for 1x106 cells in Opti-
MEM/serum-free BME (Life Technologies) without antibiotics for 2 hours; the 
medium was then replaced with serum-free BME and cells were incubated for 
24 hours. Conditioned media were collected and stored at -20°C for western 
blot analysis and nitric oxide detection assay. 
 
3.5.3 TRANSFECTION OF GLIAL CELL LINES 
 
Transient transfection with empty vector, WT α-synuclein, or mutant 
α-synuclein (A30P and A53T) of glial cells lines was performed with 
polyethyleneimine (PEI) (Boussif O. et al. 1995), a polymer that at neutral pH 
has a high cationic charge and it is able to bind DNA, entering into the cell by 
endocytosis. 
IMA 2.1 and N9 cells were plated in 6 cm Ø Petri dishes for western 
blot analysis and in 35 mm Ø Petri dishes for immunocytochemistry. The final 
transfection volume was 1 ml per 6 cm Ø Petri dish using 7 micrograms of 
pDNA and 500µl for 35 mm Ø   Petri dishes using 4 micrograms of each 
pDNA. Each pDNA and PEI were equilibrated in 150 mM NaCl in order to 
have 1/20 of the final transfection volume for each mix. Once equilibrated, the 
PEI mix was added to the pDNA mix and after 15 minutes, the PEI-pDNA mix 
was added to cells plated in serum free DMEM.   
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Glial cells or immortalized cell lines plated at the previous described 
densities, and conditioned media, were collected 2, 4, 24 or 48 hours after the 
respective treatments. Cells were collected in lysis buffer (1% SDS, 50 mM 
Tris HCl pH 7.4, 1 mM EDTA, protease inhibitor cocktail 10 µl/ ml) and 
stored at -80°C for western blot analysis. 500µl of conditioned medium were 
collected and concentrated by using Microcon-YM-3 filters (EMD Millipore 
Corporation, Billerica, MA, USA), resuspended in 15 µl of 4 X Loading buffer 
(1M Tris HCl pH 7.0 1 ml; 20% SDS 2 ml; Glycerol 2 ml; 20 mg of 
Bromophenol Blue,  DTT 1:5 of the total volume)  and  stored at -20 ° C for 
western blot analysis. 
 
 
2h serum-free medium was collected from cultures of primary 
microglia (1.8x106  cells/ 35 mm Ø dish), primary astrocytes (6x105  cells/ 35 
mm Ø dish) or from IMA2.1 and N9 cell lines (5×105 cells/well in 60 mm Ø 
dishes)  treated or not with 500 µM ATP, centrifuged for 10 minutes at 1500 
rpm at room temperature, filtered through 0.22 µm filters and immediately 
ultracentrifuged for 2 h at 100,000 g, 4°C. Aliquots of conditioned medium and 
of the supernatant (500 μl) obtained after ultra-centrifugation were 
concentrated by using Microcon-YM-3 (Millipore, Billerica, Mass., USA) and 
then resuspended in 20 μl Loading buffer 4 X (1M Tris HCl pH 7.0 1 ml; 20% 
SDS 2 ml; Glycerol 2 ml; 20 mg of Bromophenol Blue,  DTT 1:5 of the total 
volume) as well as pellets obtained after ultracentrifugation  and stored at -20 ° 
C for western blot analysis. 
 
3.6 CELLS AND CONDITIONED MEDIA 
3.7 PURIFICATION OF EXTRACELLULAR 
VESICLES FROM CONDITIONED MEDIUM 
59 
 
Co-cultures are one of the best in vitro systems to study cell 
interactions. There are different co-cultures systems; neuronal exposure to 
conditioned medium, trans-well systems or direct contact co-cultures. In the 
experiments reported in this thesis, direct contact co-cultures between 
cerebellar granule neurons and glial cells (microglia or astrocytes) were used. 
Co-cultures were set up by plating microglia or astrocytes (in serum 
free BME KCl 25mM), previously transfected in suspension with wt or 
mutSOD1 plasmids on top of fully differentiated neurons (7-DIV). 
2x106 microglial cells or 5x105 astrocytes overexpressing SOD1 were plated on 
top of 2.4x106 differentiated cerebellar granule neurons. Both types of co-
cultures were subjected to treatment with 100 mM glutamate for 24h, which 
mimics excitotoxicity, or with trehalose or with both trehalose and glutamate. 
After 24h, co-cultures were fixed with 4% paraformaldehyde in PBS and nuclei 
were stained with Hoechst 33258 (2µg/ml; Sigma-Aldrich) to quantify 
neuronal damage as described in the immunocytochemiststy paragraph. 
 
 
 
Immunocytochemistry is a highly specific method to define the 
intracellular localization of proteins. The technique is based on the principle of 
antigen-antibody conjugation and a detection system that makes visible the 
conjugated antibodies with a fluorescent microscope. There are direct or 
indirect methods, the latter involving the use of a primary antibody specifically 
raised against the molecule of interest and a secondary antibody conjugated to 
a fluorescent substance.  
2x106 microglial cells or 5x105 astrocytes plated on 35 mm Ø Petri 
dishes in serum free BME, with or without ATP stimulation were used to assay 
PNP localization; 2x106 microglial cells or 5x105 astrocytes plated on 35 mm 
3.8 CO- CULTURE OF CEREBELLAR GRANULE 
NEURONS (CGNs) with PRIMARY 
MICROGLIA OR ASTROCYTES 
OVEREXPRESSING wt/ mutSOD1 
3.9 IMMUNOCYTOCHEMISTRY 
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Petri dishes Ø in serum free BME overexpressing wt and mutSOD1 were used 
to assay SOD1 localization and autophagy in physio-pathological conditions; 
2.5x105 IMA2.1 or N9 cells plated in 35 mm Ø Petri dishes in serum free 
DMEM were used to assay α-synuclein localization. All cell cultures were 
fixed in 4% paraformaldehyde in. After a quick wash in PBS, 4% PFA in PBS 
was added for 20 minutes. Following another wash in PBS, fixed cells were 
stored at 4°C. Fixed cells were permeabilized with PBS-0.1% Triton at room 
temperature by washing 3 x 10 minutes. Non-specific sites were saturated with 
PBS-0.1% Triton + 3% BSA + 1% Normal Goat Serum for  90 minutes at 
room temperature; cell line non-specific sites were saturated with  PBS-0.1% 
Triton + 1% BSA + 5% Normal Goat Serum for 90 minutes at room 
temperature. Cells were then incubated overnight at 4 ° C with primary 
antibodies diluted in PBS-Triton + 1% BSA. Cells were washed 3 x 5 minutes 
in PBS before the incubation with fluorescent secondary antibodies diluted in 
PBS-Triton + 1% BSA for 90 minutes at room temperature. To remove non-
specific signals, 3 x 5 minutes additional washes in PBS were performed. 
Nuclei were stained by incubating cells with Hoechst solution (2µg/ml), a dye 
that binds to chromatin. After a quick wash in PBS, Pro Long Gold Antifade 
Reagents (Life Technologies) was used to mount fixed and stained cells. 
Stained cells were photographed with a fluorescence microscope (Eclipse 
Hoechst staining TE 2000-S microscope; Nikon, Tokyo, Japan) equipped with 
an AxioCam MRm (Zeiss, Oberkochen, Germany) digital camera. 
 
Primary antibody Dilution Secondary antibody Dilution 
PNP (Santa Cruz) 1:2000 Anti-rabbit FITC 
(Sigma-Aldrich) 
1:500 
α-synuclein 
(Santa Cruz) 
1:500 Anti-rabbit-fitc 
(Sigma-Aldrich) 
1:500 
LAMP1 (Santa Cruz) 1:300 Anti-mouse-tritc 
(Sigma-Aldrich) 
1:500 
MAP LC3 β2 (Santa Cruz) 1:500 Anti-mouse-tritc 
(Sigma-Aldrich) 
1:500 
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Greiss assay (Ricart-Jané et al. 2002) allows the identification of 
chemical products from nitric oxide in the conditioned medium. 
Pathological conditions such as treatment with different concentrations 
of pro-inflammatory agents and overexpression of wild type or mutant SOD1 
and wild type or mutant α-synuclein in glial cells induce activation of glial 
cells and consequently an increase in the activity of inducible nitric oxide 
synthase (iNOS). Greiss assay was used to quantify the release of nitric oxide 
in the culture medium. 
A nitrate standard curve was performed with NaNO2 at known 
concentrations from 50 μM to 0.39 μM in order to quantify nitrite 
concentration in the medium. 5 mM sulfanilamide (Sigma-Aldrich) was added 
to culture media and the standard curve. Sulfanilamide reacts with nitrite under 
acid conditions to form a diazonium cation, which subsequently couples with 
N-1-naphthyl-ethylenediamine dihydrochloride (NEDA 40mM; Sigma-
Aldrich) to produce a colored azo dye. After 15 minutes of incubation at room 
temperature in the dark, absorbance was read at 540 nm in a Multiplate 
Spectophotometric Reader (Bio-Rad Laboratories). 
 
 
Hoechst 33258 (2'-[4-ethoxyphenyl]-5-[4-methyl-1-piperazinyl]-2,5'-bi-
1H-benzimidazole trihydrochloride trihydrate) is a cell-permeable DNA stain 
that is excited by ultraviolet light and emits blue fluorescence at 460-490 nm. 
Hoechst preferentially binds to adenine-thymine (A-T) DNA regions, into the 
minor groove, and exhibits distinct fluorescence emission spectra that are 
dependent on dye:base pair ratios. 
To determine the effect of glutamate on CGNs in presence or absence 
of microglia or astrocytes overexpressing wild-type or mutant SOD-1, co-
culture nuclei were stained with Hoechst 33258 (2µg/ml; Sigma-Aldrich) for 5 
3.10 NITRIC OXIDE DETECTION ASSAY 
3.11 HOECHST STAINING AND NUCLEI 
COUNTING 
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minutes at room temperature. Hoechst stain was also used to determine the 
viability of N9 and IMA2.1 cells overexpressing wild-type and mutant α-
synuclein.  
Stained cultures were photographed with a fluorescence microscope 
(Eclipse Hoechst staining TE 2000-S microscope; Nikon, Tokyo, Japan) 
equipped with an AxioCam MRm (Zeiss, Oberkochen, Germany) digital 
camera and nuclei counting was performed on 5 random fields from each Petri 
dish by using ImageJ NIH software. Cell survival was evaluated by counting 
normal and condensed nuclei (size between 4.2 and 4.8 µm).  A 5-minute 
incubation is enough to stain CGNs nuclei. At this condition, Hoechst hardly 
stains microglia and astrocyte nuclei, which usually require at least 20 minutes 
of incubation (Polazzi et al., 2015). Microglial nuclei that occasionally stain 
can be excluded because they are oval (not round as CGN nuclei) and 
considerably larger. Condensed nuclei were easily distinguished from normal 
nuclei by their size, their fragmented morphology, and also by their brightness, 
being more intense in condensed nuclei than in normal ones. 
 
 
 
Western blot is a biochemical technique used to identify a protein of 
interest, thanks to the electrophoretic separation of proteins in a 
polyacrylamide gel, the subsequent protein transfer onto a nitrocellulose 
membrane, and the use of a specific primary antibody to recognize the protein 
of interest bound to the nitrocellulose membrane. 
Western Blot allowed us to verify the release of proteins in the 
conditioned medium and to evaluate the expression of proteins in cell lysates. 
500 µl of conditioned medium were collected and concentrated using 
Microcon-YM-3 filters (EMD Millipore Corporation, Billerica, MA, USA) and 
resuspended in 15 µl of Loading buffer 4 X (1M Tris HCl pH 7.0 1 ml; 20% 
SDS 2 ml; Glycerol 2 ml; 20 mg of Bromophenol Blue,  DTT 1:5 of the total 
volume), while parallel cell samples were collected in Lysis Buffer (1 % SDS, 
50 mM Tris pH 7.4, 1 mM EDTA, 10 µl/ml protease inhibitor cocktail and 10 
µl/ml phosphatase inhibitor cocktail), sonicated and protein content quantified 
3.12 WESTERN BLOT 
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by the Lowry assay (Lowry et al. 1951). A BSA (Sigma-Aldrich 1,5mg/ml) 
standard curve was performed at known protein concentrations in order to 
quantify the total amount of protein in each sample. Solution 1 consisting of 
98% of solution A (2% Na2CO3 in NaOH 0.1M), 1% of solution B (CuSO4 ∙ 
5H2O 0.5%) and 1% of solution C (1% Na-K tartrate) was added to each 
sample and the standard curve. Subsequently solution 2 (50% Folin and 
Ciocalteu’s phenol reagent and 50% distilled water Bi) was added and after 30 
minutes absorbance was read in a spectrophotometer at 700 nm in order to 
determine total protein concentration. 
Concentrated conditioned media and cell samples resuspended in 
Loading Buffer 4X (1M Tris HCl pH 7.0 1 ml; 20% SDS 2 ml; Glycerol 2 ml; 
Bromophenol Blue of 20 mg) plus DTT 1:5 of the total volume) were boiled 
and  loaded into a 10% or 12 % sodium dodecyl sulfate-polyacrylamide gel 
(SDS-PAGE; Bio-Rad). Acrylamide and protein markers were supplied by 
Bio-Rad, while the other reagents were from Sigma-Aldrich. Gel 
electrophoresis was run at constant 120 V in an electrophoretic Mini-Protean II 
cell (Bio-Rad) filled with 1X running buffer (H2O bd; 25 mM Tris base; 192 
mM Glycine; 0.1% SDS ). After electrophoresis, proteins were transferred onto 
a nitrocellulose membrane (GE Healthcare). Transfer from the cathode to the 
anode was carried out at constant 400 mA for 2 hours in the Mini Trans-Blot 
Cell system (Bio-Rad), with 1X transfer buffer (50 mM Tris, 200mm  glycine, 
plus 20% methanol. 
Membranes were blocked for 1h with a blocking solution made of 4% nonfat 
dried milk (Bio-Rad)/0.1% Tween-20 in PBS (Sigma-Aldrich), pH 7.4 and 
incubated over night at 4 °C with primary antibodies in PBS-0.1% Tween 20. 
Membranes were washed 3 x 10 minutes with blocking solution and incubated 
with specific secondary antibodies conjugated to horseradish peroxidase for 90 
minutes at room temperature in PBS-0.1% Tween 20, pH 7.4. Membranes were 
then washed 3 x 10 minutes with PBS-0.1% Tween 20, pH 7.4 and 5 minutes 
with PBS. Labeled proteins were visualized by using the ClarityTM Western 
ECL Substrate (Bio-Rad) and detected using a ChemiDoc™ MP imaging 
system and Image Lab software (Bio-Rad). 
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Primary antibody Dilution Secondary antibody Dilution 
SOD1 (Santa Cruz) 1:1000 Anti-rabbit (Santa Cruz) 1:2000 
LAMP1 (Santa Cruz) 1:500 Anti-mouse (Santa Cruz) 1:2000 
MRC1 (Santa Cruz) 1:1000 Anti-goat (Santa Cruz) 1:4000 
TREM2 (Santa Cruz) 1:1000 Anti-rabbit (Santa Cruz) 1:2000 
iNOS (Santa Cruz) 1:1000 Anti-rabbit (Santa Cruz) 1:2000 
MAP LC3 β2 (Santa Cruz) 1:1000 Anti-mouse (Santa Cruz) 1:2000 
GAPDH (Santa Cruz) 1:5000 Anti-mouse (Santa Cruz) 1:2000 
Β-Actin (Sigma-Aldrich) 1:1000 Anti-rabbit (Santa Cruz) 1:2000 
PNP (Santa Cruz) 1:2000 Anti-rabbit (Santa Cruz) 1:2000 
α-synuclein 
(Santa Cruz) 
1:1000 Anti-rabbit (Santa Cruz) 1:1000 
Phospho-mTOR 1:1000 Anti-rabbit (Santa Cruz) 1:2000 
mTOR 1:1000 Anti-mouse (Santa Cruz) 1:2000 
 
 
High Performance Liquid Chromatography (HPLC) is a technique that 
allows the separation of two or more compounds (analytes) in solution. The 
separation process is based on analyte affinity to the stationary phase located 
within the chromatographic column, and the mobile phase that flows through 
the column. Because the stationary phases packaged in columns consist of fine 
particle (3-5 µm), it is necessary to flow the mobile phase at an elevated 
pressure (50-150 atm) that allows flows of a few ml/min. Solutes are separated 
in the column and then analyzed by a detector able to send signals to a 
computer that quantifies data with a chromatogram. The signal related to each 
analyte is identified by a peak and quantified by its height or by the area under 
the peak. In order to associate each peak to any component of the sample and 
quantify it, a standard solution of known composition and title was provided. 
HPLC was used to quantify the release of glutamate and serine in conditioned 
media from transfected microglia and astrocytes exploiting the liquid-liquid 
partition chromatography in reverse phase. A Beckman Coulter Ultrasphere 
ODS column packed with the stationary phase formed by 5 μm diameter 
particles was used. 20 µl of each medium were introduced into the flow. The 
detector (Varian 9070) can reveal glutamate and serine coming out (eluate) 
3.13 HIGH PERFORMANCE LIQUID 
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from the column. To measure the amount of glutamate and serine, standard 
solutions of serine and glutamate at concentrations between 0.625 µM and 20 
µM were used. 
 
 
 
Real Time PCR (qRT-PCR) is a technique that allows DNA 
amplification and quantification by measuring DNA amplification during the 
exponential phase of the polymerase chain reaction. 
In order to detect PNP and α-synuclein mRNA expression in microglia, 
astrocytes and cerebellar granule neurons, real-time PCR was performed on 
extracted total RNA. For total RNA extraction, 2 × 106 microglial cells, 0.5 × 
106 astrocytes and 2.4 × 106  CGNs  were lysed in 1 ml of Tri-reagent (Sigma-
Aldrich), according to the manufacturer’s protocol.  The first step consisted in 
treatment with chloroform and centrifugation to separate 3 phases: the aqueous 
phase containing RNA, the interphase with DNA and the bottom organic phase 
containing proteins. Isopropanol was added to the aqueous phase which was 
subsequently centrifuged and the RNA pellet was washed in 75% ethanol and 
allowed to dryRNA pellets were resuspended in DEPC diethyl pyrocarbonate)-
treated deionized water (Sigma-Aldrich). RNA levels were quantified using a 
NanoDrop UV spectrophotometer (Thermo scientific, NanoDrop Products, 
Wilmington, DE, USA) and stored at −80°C until used for cDNA synthesis. . 
In order to remove any DNA contamination, treatment with DNase I (DNase I, 
RNase-free, Thermo-Fisher Scientific) was used. For each sample, 1 μg of 
DNase-treated RNA was retro-transcribed using the Superscript III First-Strand 
Synthesis SuperMix for qRT-PCR kit (Life Technologies) following the 
manufacturer’s protocol. cDNAs were stored at −20°C until used for qRT-
PCR. 
Rat PNP, α-synuclein and β-actin qRT-PCR primers were designed as 
follows: 
Rat PNP   
Forward: 5' ATCCGTGACCACATCAACCT 3'  
Reverse: 5' TTGAAAGCCTTCTGCCTCAT 3' 
3.14 QUANTITATIVE REAL TIME PCR 
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Rat α-synuclein  
Forward: AGACCAAAGAACAAGTGACAA  
Reverse: TCTTCACCCTTGCCCATCTG  
Rat β-Actin 
Forward: 5′ AGCAGATGTGGATCAGCAAG 3′ Tm  
Reverse: 5′ AACAGTCCGCCTAGAAGCAT 3′ Tm  
cDNA samples were diluted to a final concentration of 20 ng/μl. A 2X 
master mix of iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories, 
Segrate, Italy) was mixed with the adequate primers (final concentration 0.2 
μmol/l), cDNA (40 ng per replicate) and deionized water. qRT-pCR was 
performed using an iCycler IQ (Bio-Rad) thermal cycler and real-time PCR 
measurements were carried out in duplicate with three biological replicates. 
mRNA relative expression levels were normalized using β-actin as the internal 
control.  
Relative gene expression was calculated using the ΔΔCt method, where 
Ct represents the cycle threshold. ΔCt values were calculated as difference 
between the target genes and the expression of the endogenous gene β-Actin. 
ΔΔCt values were calculated as differences to control sample; ΔΔCt values were 
expressed as percentage of values measured for controls. 
 
 
 
All quantitative data are expressed as means ± SE from independent 
experiments. Statistical significance between different treatments was 
calculated with GRAPHPAD PRISM 6 (La Jolla, California, USA) by using 
one-way analysis of variance (ANOVA) followed by post-hoc comparison 
through Bonferroni’s test. A value of p < 0.05 was considered statistically 
significant. 
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4. RESULTS 
 
4.1.1 PNP EXPRESSION AND RELEASE BY RAT 
PRIMARY CULTURES OF MICROGLIA, ASTROCYTES 
AND DIFFERENTIATED CGNS 
 
Purine Nucleoside Phosphorylase (PNP) localization in the brain seems 
to be restricted to glial cells, while its expression in neurons is still debated 
(Castellano et al., 1990). Because of the crucial role of microglia in the 
development of the central nervous system by controlling purine metabolism, 
we decided, as a first step, to check the level of PNP expression in primary 
cultures of glial cells and cerebellar granule neurons. The expression of PNP 
was evaluated by different methods. By using immunofluoresce, we observed 
that microglia and astrocytes expressed high levels of PNP, with marked 
staining in all examined cells, mainly located in the nucleus and cytoplasm, 
while differentiated CGNs showed a robust nuclear labeling, with almost no 
staining on neurites (Fig. 1A). The difference in PNP expression between glial 
cells and neurons was confirmed by real-time PCR, showing the highest levels 
of PNP mRNA in microglial cells and the lowest in differentiated CGNs 
(Figure 1B). Western blot analysis (Fig. 1C) confirmed the presence of PNP 
protein in all neural cells, even though it was more significantly expressed in 
glial cells than in CGNs. In order to study whether PNP was released by the 
different types of brain cells in culture, we performed western blot analysis to 
evaluate the amount of PNP protein in media conditioned for different times by 
primary microglia, astrocytes or neurons. As shown in figure 1D, western blot 
analysis revealed that PNP was constitutively released and accumulated in the 
culture medium (conditioned medium, CM) by microglia (MCM) or astrocytes 
(ACM) and, to a lesser extent, in medium conditioned by  CGNs (CGN-CM) 
for 6 and 24 hours.  
 
4.1 PNP RELEASE BY GLIAL CELLS 
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Fig. 1. PNP expression in rat primary microglia, astrocyte and cerebellar granule 
neuron (CGNs) cultures.  
Immunofluorescence analysis (1A) of PNP expression (green) in rat 
primary cultures with nuclear Hoechst chromatin staining (blue) (Scale bar: 15 
μm). PNP mRNA expression in rat primary microglia, astrocyte and 
differentiated cerebellar granule neuron cultures was analyzed by qRT-PCR 
(1B). Relative gene expression was calculated using the ΔΔCt method, where Ct 
represents the cycle threshold. ΔCt values were calculated as the difference 
between the target gene and the expression of the endogenous gene β actin.  
ΔΔCt values are the mean ± S.E. of 3 different samples and are expressed as 
percentage versus differentiated CGN values. Western Blotting analysis of  
PNP expression (1C) and PNP release (1D) from rat primary microglia, 
astrocyte and differentiated cerebellar granule neuron cultures. Cells were 
plated in serum free medium at a density of 1.5 × 106 cells/1ml for microglia, 
0.5 × 106cells/1ml for astrocytes 2.4× 10 6cells/2ml for  differentiated 
cerebellar granule neuron cultures per 35mm Ø Petri dish. To assay protein 
release, 500µl of serum free conditioned medium collected at 6 or 24 hours 
after culture were concentrated.  
 
4.1.2 INFLAMMATORY STIMULI DO NOT 
MODIFY CONSTITUTIVE PNP SECRETION FROM 
CULTURED MICROGLIA, ASTROCYTES AND 
DIFFERENTIATED CGNS   
 
One of the first stimuli described in literature able to activate microglia 
was the  bacterial endotoxin lipopolysaccharide (LPS) (Hetier et al., 1988). In 
vitro activation of microglia induced by LPS mimics the glial activation that 
occurs in vivo due to inflammatory stimuli, but also the chronic microglial 
activation due to neurodegenerative diseases (Hetier et al., 1988). Activation 
increases the production and release of pro-inflammatory cytokines, as well as 
chemokines (Kong et al., 1997; Lieberman et al., 1989), and up-regulates nitric 
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oxide synthase (NOS) (Pahan et al., 1997; Boje and Arora, 1992) mediated by 
the TLR4 receptor (Takeda et al., 2003).  
In several neuropathological situations, interferon-γ (IFN-γ) is produced 
by activated T-lymphocytes and natural killer cells, modulates immunological 
responses and stimulates the production of reactive nitrogen and oxygen 
species and cytokines/chemokines in microglia (Schroder et al., 2004).  
Because glial cells play a crucial role in brain pathophysiology, mainly 
as consequence to their activation, we assessed whether PNP release could be 
influenced by typical inflammatory stimuli, such as lipopolysaccharide (LPS) 
and interferon-γ (IFN-γ). Primary microglia, astrocyte and differentiated CGNs 
cultures were exposed for 24 hours to increasing concentrations of LPS and 
IFN-γ; CMs were then collected and analyzed by western blot analysis, in 
parallel with corresponding cell lysates. None of the two stimuli affected the 
amount of PNP neither in cells nor in the medium conditioned by microglia 
(Fig. 2A-B), astrocytes (Fig. 2C-D) or CGNs (Fig. 2E-F). 
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Fig 2. Effect of activation through lypopolysaccharide (LPS) and interferon-γ (IFN-
γ) on PNP release by microglia, astrocytes and cerebellar neurons.  
Representative western blot analysis of PNP protein released in 
conditioned media (upper lanes), PNP protein expression (middle lanes) and β-
actin expression as loading control (lower lanes) in whole cell lysates from rat 
primary microglial (2A- 2B), astrocyte (2C- 2D) and cerebellar neuron (2E-2F) 
cell cultures stimulated for 24 hours with increasing LPS concentrations of 
LPS [1; 10; 100 ng/ml] (2A- 2C-2E) or IFN-γ [1; 10; 100 ng/ml] (2B- 2D- 2F). 
Equal volumes (500 µl) of 24h-conditioned medium from microglia (MCM), 
astrocytes (ACM) and differentiated cerebellar granule neurons (NCM) were 
concentrated and loaded in parallel with 20µg of total protein lysate from the 
same cell cultures. Equal loading was confirmed by staining with Red 
Ponceaus S performed on membranes before immunodetection.  
 
4.1.3 ATP ENHANCES CONSTITUTIVE PNP 
SECRETION FROM CULTURED MICROGLIA AND 
ASTROCYTES 
 
It is known that ATP is abundantly released by all neuronal cells and 
represents one of the most important neuro/glio-transmitters. In 
neuropathology, ATP is released by damaged cells and acts both as a cytotoxic 
factor and a pro-inflammatory mediator, being a universal "danger" signal 
(Franke, et al., 2012).ATP-mediated activation through the activation of P2X7 
receptors appears not to be chronic, but less aggressive than the activation 
mediated by LPS and mainly leading to an autophagic apoptotic condition 
(Takato et al., 2009). Thus we wondered whether it could affect/modulate PNP 
secretion in the examined cells. Exposure of microglial cells (Fig.3A) and 
astrocytes (Fig.3B) to ATP enhanced PNP release in the extracellular medium 
after 1h.  
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Fig.3. Effect of ATP on PNP extracellular release in primary cultures of rat 
microglia and astrocytes.  
Western Blot analysis (3A-3B) and relative densitometries (3C-3D) of 
PNP release in media conditioned for 1 hour by primary rat microglia and 
astrocyte cells treated with increasing ATP concentrations [0, 0,5  or 1 mM]. 
500 µl of conditioned medium were concentrated and loaded to assay PNP 
release. Data are expressed as percentage of controls and are the mean ± s.e. 
from three independent experiments. *p < 0.05; **p < 0.01 compared to 
controls. Equal loading was confirmed by staining with Red Ponceaus S 
performed on transfered membranes. 
 
4.1.4 PNP RELEASE IS MEDIATED VIA THE 
LYSOSOMAL SECRETORY PATHWAY 
 
Since ATP is known to induce protein release through the lysosomal 
secretory pathway (Dubyak, 2012; Takenouchi, 2009), we verified whether this 
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pathway could be involved also in PNP release. By immunofluorescence, we 
observed in astrocyte (Fig. 4A) and microglia (Fig. 4B) cultures that PNP 
staining co-localized with LAMP-1, a well-known lysosomal protein. 
Interestingly, the exposure of brain cell cultures to ATP determined a scattered 
distribution of both PNP and LAMP-1 signals, possibly in agreement with 
activation of lysosomal release. 
Since glial secretion through extracellular vesicles (EVs) has acquired  
increased importance in physiological glial-neuron communication, we 
assessed whether PNP protein could be released by glial cells this way. EVs 
were isolated from MCM and ACM collected after 2 hours of 500 µM ATP 
treatment or control exposure of cultured cells. Western blot analysis revealed 
the presence of PNP in both the soluble (SF) and the pellet fraction (PF, 
containing EV) from both MCM and ACM, mainly in conditioned media from 
ATP-stimulated cells (Fig. 4C-D), being the pellet fraction also positive for 
LAMP-1. These data demonstrate that microglia and astrocytes release PNP 
through both a classical and an EVs-mediated release, the latter occurring 
through the lysosomal secretory pathway upon exposure to ATP. 
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Fig. 4. Co-localization of PNP with the lysosomal protein LAMP-1 in astrocytes and 
microglia and consequent PNP release via extracellular vesicles (EVs).  
Immunofluorescence analysis of PNP (green) and LAMP-1 (red, 
lysosomal marker) expression in microglia (4A) and astrocyte (4B) cell 
cultures in basal conditions (control) and after stimulation with 500 µM ATP 
for 1 hour (lower lane) (Scale bar: 15 μm). PNP and LAMP-1 protein 
expression evaluated by Western blot analysis and relative densitometry 
analysis (D, F) performed on aliquots of 2 hour-conditioned media (500µl) 
collected from rat microglial  (4C) and astrocyte (4D) cultures and on samples 
from the soluble (SF) or   pellet fractions (PF) isolated from the same MCM 
and ACM treated or not with ATP (500 µM). Images are representative of 
three independent experiments. Each bar represents the mean ± S.E. PNP 
protein expression as percentage versus control conditioned medium *** p < 
0.001; PNP protein expression as percentage versus ATP conditioned medium 
### p < 0.001. One way ANOVA followed by Bonferroni’s multiple 
comparison test. 
 
4.1.5 INVOLVEMENT OF P2X7 RECEPTORS IN 
PNP RELEASE 
 
Since ATP was effective on PNP release in both types of glial cells, we 
compared the effect of ATP with 3'-O-benzoyl-benzoyl-ATP (Bz-ATP), a 
stable form of ATP, used in a range of selective concentrations able activate 
P2X7 receptors [125, 250 µM] (Young et al., 2007). At the same time, two 
non-selective P2 receptor antagonists were used: oxidized ATP (ox-ATP) and 
suramin. Oxidized ATP (ox-ATP) is a selective inhibitor of the P2X7 receptors 
(Lang et al., 2010). Suramin is a non-selective antagonist of P2 receptors and, 
similarly to ox ATP, it could inhibit immune response but, at the same time, it 
also has anti-inflammatory proprieties. By analyzing medium conditioned by 
microglia (Fig. 5B-D-F-H) or astrocytes (Fig. 5A-C-E-G), we observed that 
Bz-ATP treatment in microglia (Fig. 5D-H) and astrocytes (Fig. 5C-G) 
stimulated PNP release by both cell types in a dose-dependent way. This effect 
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was even greater than the one caused by cell exposure to 0.5 or 1.0 mM ATP. 
As expected, cell pre-treatment for 1h with Ox-ATP, a non-competitive 
antagonist of P2X7 receptor (Michel et al., 2000; Hibell et al., 2001; Bartlett et 
al., 2014), completely blocked the effect of Bz-ATP on PNP release (Fig. 5C-
D) and significantly reduced the effect of ATP (Fig. 5A-B). Cell pre-treatment 
for 1 hour with suramin, a non-selective antagonist of P2 receptor, did not 
inhibit  PNP release mediated by Bz-ATP (Fig. 5G-H);  however, suramin pre-
treatment seemed to promote a non-statistically significant increase in ATP-
mediated PNP release (Fig.5E-F). Together these findings support the specific 
involvement of P2X7 receptors in the ATP-mediated induction of PNP release. 
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Fig 5. P2X7 receptor involvement in PNP release by primary microglia and 
astrocytes.  
Western Blot analysis and relative densitometry of PNP protein 
expression in conditioned media (500 µl) for 1 hour by primary rat microglia 
(B-D-F-H) and astrocyte (A-C-E-G) cells treated with increasing ATP 
concentrations [0, 0.5 or 1.0 mM] (A-B-E-F) or Bz-ATP [0, 125,250 µM] (C-
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D-G-H) and pre-treated with ox-ATP (A-B-C-D) or suramin (E-F-G-H). Equal 
loading was confirmed by membrane staining with Red Ponceaus S. Data are 
expressed as percentage versus controls and are the mean ± S.E. from three 
independent experiments. * p < 0.05; ** p < 0.01 * p <0.001 compared to 
controls # p < 0.05; ## p < 0.01; ### p< 0.001 compared to pre-treated 
controls. One way ANOVA followed by Bonferroni’s multiple comparison 
test. 
 
 
4.2.1 MICROGLIAL SOD1 RELEASE THROUGH 
LYSOSOMES 
 
Previous studies from our lab have shown in rat primary cultures a 
neuroprotective role of microglial cells against different types of neuronal 
damage through the release of soluble factors, being SOD1 one of the 
molecules identified in microglial conditioned medium showing a 
neuroprotective function (Polazzi et al., 2013). In addition, astrocytes also 
release SOD1 through exosomes in mouse primary cultures (Basso et al., 
2013). Therefore, we decided to check whether also microglial cells release 
SOD1 through exosomes. Thus, first we performed western blot analysis on 
media conditioned for 2, 24, and 48 hours by primary cultures of rat microglia 
(MCM) and astrocytes (ACM). As shown in figure 6, SOD1 is constitutively 
released by both microglia (Fig. 6A) and astrocytes (Fig. 6B) and accumulates 
significantly over time in the medium. We then isolated vesicles from 2h-
MCM and 2h-ACM in control conditions or after treatment with ATP 500 µM 
for 2 hours. This stimulation is known to promote vesicular secretion in many 
immune cells, including macrophages and monocytes, through P2X7 receptors 
(Dubyak, 2012). Western blot analysis of conditioned media, as well as of the 
4.2 SOD1 RELEASE FROM RAT PRIMARY 
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soluble and pellet fractions, with the latter positive to Lysosome Associated 
Membrane 1 (LAMP-1), indicates that both microglia (Fig.6C) and astrocytes 
(Fig. 6D) release SOD1 through a vesicular secretion; this also confirms 
previously published data of SOD1 secretion through the lysosomal secretory 
pathway (Polazzi et al., 2013). The presence of vesicular structures with a 
diameter compatible with exosomes has been confirmed in parallel samples of 
microglial conditioned medium through atomic force microscopy (Fig. 6E and 
F). 
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Fig.6. SOD1 release from rat primary cultures of microglia and astrocytes.  
Western blot analysis of SOD1 in conditioned medium for 2, 24 or 48h 
by microglia (A) or astrocytes (B), with relative densitometries and PNP 
protein as loading control, shows that not only microglia, but also astrocytes 
release SOD1, which accumulates in conditioned medium. Western blot 
analysis of media conditioned for 2h by rat primary culture of microglia (C) 
and astrocytes (D), in control conditions or in presence of ATP 500 μM, 
indicates that glial cells release SOD1 also through vesicles, since SOD1 is 
present in the ultracentrifuged pellet, which is also positive for the lysosome-
associated membrane protein-1 (LAMP-1).  In situ Peak-Force atomic force 
microscopy images of purified exosomes obtained in buffer at room 
temperature (E-F). The heights of the features on the substrate are coded 
according to the attached color table. Exosomes display a relatively narrow size 
distribution (evident in the large scale image). 
 
4.2.2 INTRACELLULAR MUTANT SOD1 
ACCUMMULATION IN PRIMARY CULTURES OF 
MICROGLIA AND ASTROCYTES 
 
Taking into account both the role of released SOD1 and the non-cell-
autonomous hypothesis for ALS neurodegeneration, we decided to study 
whether the presence of SOD1 expressing mutations linked to familial ALS 
(G93A and A4V) could alter SOD1 glial release and whether this could be 
correlated to an alteration of glial phenotype. Therefore, we decided to 
transiently over-express in rat primary cultures of microglia and astrocytes  
human wild-type and fALS-linked SOD1 mutants (G93A and A4V) fused with 
the GFP reporter gene (kind gift from Prof. Poletti, University of Milan, Italy). 
Western blot analysis performed on the media conditioned for 24 h after 
transfection with SOD1-WT-EGFP, SOD1-G93A-EGFP, SOD1-A4V-EGFP 
plasmids shows that both wild-type and mutant SOD1 were expressed and 
released by microglia (Fig.2A) and astrocytes (Fig.2B). However, the amount 
of intracellular mutant SOD1 was significantly lower than the amount of wild-
type SOD1 and we also observed a significant difference in SOD1 release 
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between cells that overexpressed the two mutations, being A4V SOD1 released 
even less than G93A SOD1, accordingly to the severity of disease caused by 
the mutations. 
Interestingly, Western blot analysis performed on the same cells, from 
which we collected the previously shown conditioned media, showed strong 
intracellular accumulation of mutant SOD1, with an even more evident 
accumulation of A4V SOD1, compared to wild-type SOD1 both in microglial 
cells (Fig.2C) and astrocytes (Fig.2D). The intracellular accumulation of 
mutant SOD1 was confirmed by immunofluorescence analysis of EGFP SOD1 
in parallel cultures of primary rat glial cells. Microglial cells (Fig.2E) and 
astrocytes (Fig.2F) overexpressing SOD1-G93A-EGFP and specially SOD1-
A4V-EGFP demonstrated stronger intracellular accumulation of SOD1, as well 
as co-localization of SOD1 with the marker of lysosomal vesicles (LAMP-1), 
than microglial cells overexpressing SOD1-WT-EGFP which was more 
widespread. Taken together, these data demonstrated for the first time an 
intracellular accumulation of mutant SOD1 not only in neurons, but also in 
glial cells.  
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Fig.7. Altered SOD1 release in microglia and astrocytes overexpressing mutant 
SOD1.  
Western blot analysis and relative densitometry of SOD1 released (A, 
B) and overexpressed (C,D) in 24h conditioned medium by microglia (A) and 
astrocytes (B) and lysed microglial cells (C) and astrocytes (D) over-expressing 
wild-type SOD1-EGFP or with mutations linked to familial ALS (G93A and 
A4V), with the protein PNP as loading control for conditioned media and β-
actin for cell lysates. Each bar represents the percentage versus SOD1-WT of 
exogenous/endogenous SOD1 ratio for conditioned media and of SOD1/β-actin 
ratio in cell lysates. Each bar represents the mean ± S.E. of four samples from 
different experiments.  * p < 0.05, ** p < 0.01, *** p < 0.001 compared to WT 
SOD1; # p < 0.05, ## p < 0.01 compared to G93A SOD1. Bonferroni’s post-
hoc test following one-way ANOVA. The intracellular accumulation of mutant 
SOD1 is confirmed by immunofluorescece analysis of SOD1 (green), LAMP-1 
(red) and Hoechst (blue) in microglial cells (E) and astrocytes (F). Scale bar = 
10 µm. 
 
4.2.3 AUTOPHAGIC PATHWAY ALTERATION IN 
MICROGLIAL CELLS OVEREXPRESSING MUTANT 
SOD1 
 
Intracellular accumulation of mutant SOD1 could be due to alteration of 
intracellular degradation pathways and/or intracellular trafficking, suggesting a 
dysfunction in the glial autophagic pathway. This hypothesis is also supported 
by the fact that impairment of the autophagy process seems to contribute to 
motor neuron death and disease progression in ALS, though it has never been 
studied in glial cells expressing mutant SOD1 (Lee et al., 2015; Castillo et al., 
2013). Here, we studied the expression of LC3 II (microtubule-associated 
protein 1A/1B-Light Chain 3), which is considered a reliable autophagic 
marker. During the formation of autophagosomes, the cytosolic protein LC3 I 
is lipidated to LC3 II and recruited to the autophagosomal membrane (Tanida 
et al., 2008). Western blot analysis and relative densitometries (Fig. 8A) 
showed a slight increase in LC3II expression in microglial cells overexpressing 
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SOD1-G93A-EGFP, but a statistically significant reduction in microglial cells 
overexpressing SOD1-A4V-EGFP compared to microglial cells overexpressing 
wild-type-SOD1-EGFP. In parallel conditions, astrocytes seem not to express 
LC3II. Interestingly, immunofluorescence analysis confirmed the LC3 II 
reduction and revealed a change in subcellular localization in microglial cells 
overexpressing SOD1-A4V-EGFP, being LC3II present in the center of 
microglial cells and not in a vesicular organization, as in control cells (Fig. 
8C). In addition, we evaluated another autophagy marker, mTOR (mammalian 
target of rapamycin), which is a negative regulator of autophagy when 
phosphorylated on Ser 2448. Through western blot analysis, we observed that 
the p-mTOR Ser 2448/total m-TOR ratio (Fig.8B) decreases in microglial cells 
overexpressing SOD1-G93A-EGFP and in a statistically significant way in 
microglial cells overexpressing the SOD1-A4V-EGFP. 
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Fig.8. Autophagy markers in microglial cells overexpressing wild-type or mutant 
SOD1.  
Western blot analysis and relative densitometry for the expression of 
the autophagy marker Light Chain 3 microtubule-associated protein (LC3) (A) 
and for mTOR phosphorylation on serine 2448 (B). Each bar is the mean ± 
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S.E. from three experiments of the LC3/GAPDH ratio and of the 
P(Ser2448)mTOR/total-mTOR ratio expressed as the percentage versus WT 
SOD1. * p < 0.05 relative to WT SOD1; # p < 0.05, ## p < 0.01 relative to 
G93A SOD1. Bonferroni’s post-hoc test following one-way ANOVA. 
Impairment in the autophagy patway in microglial cells (C) is confirmed by 
immunofluorescence analysis of SOD1 (green), LC3 (red) and Hoechst (blue) 
in microglial cells (E) and astrocytes (F). Scale bar=10 µm. 
 
4.2.4 EFFECT OF WILD-TYPE AND MUTANT SOD1 
OVEREXPRESSION ON MICROGLIA AND ASTROCYTE 
ACTIVATION AS WELL AS ON MICROGLIAL 
PHENOTYPES 
 
Protein intracellular accumulation, observed in many proteinopathies, 
seems to be responsible for glial cell activation (Ferretti et al., 2012), which is 
also a typical hallmark of ALS. Given that the increase in intracellular iNOS 
expression and the consequent release of NO is considered a marker of glial 
activation (Yuste et al., 2015), we evaluated whether the overexpression of 
wild-type or mutant SOD1 in glial cells could influence iNOS expression and 
nitrite production. In microglial cells, mutant SOD1 overexpression slightly 
increased iNOS expression, as shown by Western Blot analysis (Fig.9A), while 
in parallel samples nitrite levels in the medium (Fig.9C) were significantly 
elevated, clearly indicating the activation of microglial cells overexpressing 
mutant SOD1 compared to wild-type SOD1.  On the other hand, 
overexpression of mutant and wild-type SOD1 in astrocytes did not cause any 
difference neither in iNOS expression (Fig.9B) nor in nitrite levels (Fig.9D), 
further underling the different response of the two glial cell types to SOD1 
overexpression. Furthermore, considering that microglia activation is often 
associated with their shift from the M2 neuroprotective to the M1 neurotoxic 
phenotype even in ALS (Zhao et al., 2013), we evaluated the expression of two 
cellular markers linked to microglia alternate activation, the Triggering 
Receptor Expressed on Myeloid Cell 2 (TREM2) and the Mannose Receptor C 
Type 1 (MRC1), also associated to the microglial phagocytic activity (Lue et 
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al., 2015; Colton et al., 2006). As shown in figure 9E and 9F, there was no 
difference in TREM2 and MRC1 expression, suggesting that microglial 
activation due to mutant SOD1 overexpression leads to the M1 phenotype 
without losing M2 features and that no differences are evident between the two 
SOD1 mutations. 
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Fig.9. Effect of wild-type and mutant SOD1 overexpression on microglia and 
astrocyte activation, as well as on microglial M1/M2 phenotypes.  
Mutant SOD1 compared to wild-type overexpression, induces partial 
microglial, but not astrocyte activation, as indicated by Western Blot analysis 
and the relative densitometry of iNOS expression, as well as by nitrite 
production in microglia (A, C) and astrocytes (B, D), respectively. Each bar is 
the mean ± S.E. of three experiments as ratio to GAPDH. Data are expressed as 
percentage versus controls.  For nitrite production (C, D), each bar is the mean 
± S.E. of three experiments expressed in micromolar concentration. ** p < 
0.01, *** p < 0.001 relative to WT SOD1, ### p < 0.001 relative to G93A 
SOD1. Bonferroni’s post-hoc test following one-way ANOVA 
 
4.2.5 EFFECT OF GLIAL CELLS 
OVEREXPRESSING WILD-TYPE OR MUTANT SOD-1 
ON NEURONAL SURVIVAL/DEATH IN CONTACT CO-
CULTURES 
 
In order to clarify the role of glial cells in ALS neurodegeneration, we 
used an in vitro model of primary neuron-microglia and neuron-astrocyte 
contact co-cultures to evaluate the effect of wild-type and mutant SOD1 
overexpression confined to glial cells, on neuronal survival and death. To this 
aim, we used primary differentiated cerebellar granule neurons (7DIV CGNs), 
since they grow as basically pure cultures without any glial cell contamination, 
and we then plated primary microglia or astrocytes previously transfected with 
SOD1-WT-EGFP, SOD1-G93A-EGFP or SOD1-A4V-EGFP on top of CGNs. 
We maintained co-cultures in physiological conditions or exposed them to 
glutamate excitotoxicity, through a chronic treatment with 100 µM glutamate 
for 24 h. Neuronal survival/death was evaluated by counting condensed nuclei, 
considered an index of apoptosis, and total nuclei, after Hoechst staining. As 
shown in figure 10A and 10B, differentiated CGNs co-cultured with microglia 
confirmed the previously demonstrated neuroprotective role of microglia 
against glutamate excitotoxicity (Eleuteri et al., 2008), while there was no 
significant difference in neuroprotection between control microglial cells and 
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microglial cells expressing wild-type or mutant SOD1. However, in 
physiological conditions, overexpression of wild-type SOD1 did not alter 
neuronal survival, however microglial overexpression of SOD1-G93A-EGPF 
and SOD1-A4V-EGFP rendered microglial cells toxic by themselves, 
promoting neuronal death in co-culture. On the contrary, co-culture between 
CGNs and astrocytes (Fig. 10C, D) evidenced a different role of astrocytes 
compared to microglia. Astrocytes do not seem to be neuroprotective by 
themselves, however overexpression of wtSOD1-EGFP in astrocytes seemed to 
promote neuronal survival compared to control CGNs and CGNs co-cultured 
with astrocytes overexpressing mutant SOD1.  
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Fig.10. Effect of glial cells overexpressing wild-type or mutant SOD1 on neuronal 
survival/death in contact co-cultures.  
Hoechst staining (A, C) and nuclei counting (B, D) of condensed/total 
nuclei of differentiated CGNs co-cultured with microglia (A, B) or astrocytes 
(C, D) overexpressing wild-type or mutant SOD1. Scale bar = 20 µm. Each bar 
is the mean ± S.E. of three independent experiments performed in duplicate 
and is expressed as the percentage of apoptosis, i.e. the ratio between 
condensed, apoptotic and total nuclei. ** p < 0.01, *** p < 0.001 relative to 
control CGNs; # p < 0.01 relative to CGNs + microglia or CGNs + astrocytes 
overexpressing WT SOD1; § < 0.01 relative to control  CGNs + microglia or 
CGNS + astrocytes. Bonferroni’s post-hoc test following one-way ANOVA. 
 
4.2.6 GLUTAMATE AND SERINE RELEASE BY 
MICROGLIA AND ASTROCYTES OVEREXPRESSING 
WT AND MUTANT SOD1 
 
Considering the role of glutamate and serine in glutamate excitotoxicity 
leading to ALS neuronal death (Paul and De Belleroche, 2012; 2014) and given 
that activated glial cells increase glutamate release (Brown and Vilalta, 2015; 
Milanese et al., 2009), we decided to measure the levels of glutamate and 
serine through HPLC in 24 h conditioned media from microglia and astrocytes 
overexpressing SOD1-WT-EGFP, SOD1-G93A-EGFP and SOD1-A4V-EGFP. 
As shown in table 1, 24h MCM contained both aminoacids at comparable 
levels, being glutamate ~30 µM and serine~60 µM concentrations. On the 
contrary, in 24 h ACM glutamate levels were lower than in 24 h ACM, though 
both media contained a greater amount of serine, reaching a ~ 250µM 
concentration. However, in media conditioned by both glial cells, no 
significant differences were observed following SOD1-WT-EGFP, SOD1-
G93A-EGFP or SOD1-A4V-EGFP over-expression, thus indicating that the 
presence of mutant SOD1 alters the release of SOD1 by itself, as well as of 
other proteins (Basso et al., 2013), but not the release of these two important 
aminoacids, at least in our experimental conditions. 
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Table 1. HPLC measurement of glutamate and serine in 24 h conditioned media. 
HPLC measurement of glutamate and serine concentrations in 24h 
conditioned media from primary rat microglia and astrocytes overexpressing 
EGFP-SOD1-WT or EGFP-SOD1-G93A or EGFP-SOD1-A4V. The table 
shows the µM  concentration of each amino acid. Each value is the average of 
three / four experiments ± SE. One-way analysis of variance (ANOVA) 
followed by post-hoc Bonferroni test. 
 
4.2.7 TREHALOSE REDUCES THE 
INTRACELLULAR ACCUMMULATION OF SOD1 
 
Trehalose (a-D-glucopyranosyl a-D-glucopyranoside) is a disaccharide 
naturally occurring in insects, plants, fungi and bacteria, though not in 
vertebrates (Richards et al., 2002). Trehalose protects against environmental 
stress, desiccation, dehydration, heat, cold and oxidation (Richards et al., 2002; 
Chen and Haddad, 2004). It was reported that trehalose can promote the 
clearance of autophagy substrates, such as mutant huntingtin protein or the 
A30P and A53T mutants of alpha-synuclein (Sarkar et al., 2007). Oral 
administration of trehalose in a transgenic mouse model of HD decreased 
polyglutamine aggregates in the brain and liver, improved motor function and 
extended lifespan (Tanaka et al., 2004). It has also been reported that trehalose 
treatment can ameliorate behavioral and pathological symptoms in a mouse 
model of tauopathy (Rodriguez-Navarro et al., 2010). Considering the data 
previously obtained on intracellular mutant SOD1 accumulation and the 
 
Concentration 
(µM) 
Control SOD1-WT SOD1-G93A SOD1-A4V 
microglia 
glutamate 39,53 ±13,81 32,88±10,70 33,85±10,27 47,43±9,62 
serine 79,73±17,54 61,95±18,54 59,55±15,96 68,63±21,83 
astrocytes 
glutamate 11,63±6,21 12,43±2,11 12,03±1,99 10,60±1,66 
serine 189,97±36,16 272,73±72,15 249,97±64,90 312,93±21,53 
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preliminary data on autophagy impairment in primary microglial cells, we 
decided to study whether this treatment could promote the clearance of mutant 
SOD1. As previously described, we transiently overexpressed in rat primary 
cultures of microglia and astrocytes wild-type SOD1, G93A SOD1and A4V 
SOD1 fused with the GFP reporter gene. Two hours after transfection, cells 
were treated with 5 mM trehalose for 48 hour in serum free BME to improve 
the autophagic flux. Western blot analysis performed on media conditioned for 
48 h after transfection (Fig.11A) showed that both wild-type and mutant SOD1 
were released by microglia with a significant difference in SOD1 release 
between cells that overexpressed the two SOD1 mutants and wild-type SOD1 
without any difference between control cells and treated cells. Interestingly, 
Western blot analysis performed on the same cells from which we collected the 
previously shown conditioned media (Fig.11C) showed that mutant SOD1 
levels were significantly decreased by trehalose treatment suggesting that 
trehalose enhances autophagy activity and accelerates the degradation of 
mutant SOD1. 
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Fig.11. Trehalose restores mutant SOD1 expression in microglia similar to control 
levels.  
Western blot analysis and relative densitometry of SOD1 released (A) 
and expressed (C) in 48h conditioned medium and in lysed  microglial cells 
overexpressing wild-type SOD1, G93A SOD1 and A4V SOD1 with or without 
trehalose treatment. Each bar represents the percentage versus SOD1-WT of 
exogenous/endogenous SOD1 ratio for conditioned media and of SOD1/β-actin 
ratio in cell lysates. Each bar represents the mean ± S.E. of four samples from 
different experiments. *** p < 0.001 compared to WT SOD1; # p < 0.05, ###p 
< 0.001 compared to G93A SOD1. Bonferroni’s post-hoc test following one-
way ANOVA.  
 
4.2.8 TREHALOSE REDUCES THE ACTIVATION 
STATE OF MICROGLIAL CELLS OVEREXPRESSING 
MUTANT SOD1 
 
Protein intracellular accumulation, observed in many proteinopathies, 
seems to be responsible for glial cell activation (Ferretti et al., 2012), defined 
by the increase in the intracellular expression of iNOS and the consequent 
release of NO (Yuste et al., 2015). As previously showed (Fig.9 A,C), mutant 
SOD1 overexpression promoted an activation state in microglial cells without 
any change in the expression of  two markers related to the alternative 
microglial activation, TREM2 and MRC1, thus suggesting that in our 
experimental conditions  microglial cells did not lose the M2 features. Data 
recently published, showed an interesting reduction in CD11b levels in the 
spinal cord of trehalose-treated G93A SOD1 mice compared to controls, as 
well as a reduction of IBA1 and GFAP levels in the lumbar spinal cord of the 
same animals at both 90 days of age and during end-stage disease (Li, 2015), 
indicating these conditions as evidence of a reduced gliosis that occurs in ALS 
mouse models and patients. Trehalose treatment of primary microglia 
overexpressing wild-type SOD1, G93A SOD1 and  A4V SOD1, reduced the 
intracellular expression of iNOS (Fig. 12B) without interfering with microglial 
phenotype (Fig.12C). 
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Fig.12. Effect of trehalose treatment on microglial activation.  
Western blot analysis and relative densitometry of iNOS and TREM2 in 
microglial cells overexpressing wild-type SOD1, G93A SOD1 and A4V SOD1 
for 48h with or without 5 mM trehalose treatment. Each bar represents 
SOD1/β-actin ratio. Each bar represents the mean ± S.E. of four samples from 
different experiments. * p < 0.05 compared to WT SOD1; ## p < 0.01 
compared to G93A SOD1. Bonferroni’s post-hoc test following one-way 
ANOVA.  
 
4.2.9 NEUROPROTECTIVE FUNCTION OF 
TREHALOSE IN GLIA-NEURON CO-CULTURE MODEL 
 
Co-culture is an easy in vitro model to mimic the crosstalk between 
glial cells and neurons. As previously described, microglia exerted a 
neuroprotective effect in cerebellar granule cells exposed to glutamate, but 
microglial overexpression of mutant SOD1 appears to be toxic to neurons. 
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Astrocytes, on the other hand, did not show any neuroprotective effect by 
themselves, though they seemed to display a neuroprotective role when wild-
type SOD1 was overexpressed. According to the “non-cell-autonomous 
mechanisms” and considering the ability of toxic molecules to spread to 
neighbouring cells promoting injury as well as the previous promising results 
on the efficacy of trehalose in removing accumulated SOD1 in microglia, we 
performed a co-culture model between microglia or astrocytes overexpressing 
SOD1-WT-EGFP, SOD1-G93A-EGFP or SOD1-A4V-EGFP and 
differentiated primary cerebellar granule neurons. Both types of co-cultures 
were exposed to treatment with 100 mM glutamate for 24h, which mimics 
excitotoxicity or with 5 mM trehalose or with both trehalose plus glutamate. As 
previously reported, glutamate is toxic for neurons, since CGNs showed a 
significant increase in apoptosis percentage compared to control cells. 
Microglia, known to be neuroprotective in case of neuronal damage, in control 
conditions or overexpressing wild-type SOD1, partially reduced glutamate 
toxicity, but the simultaneous treatment with trehalose surprisingly restored 
and even decreased neuronal death under control conditions. Microglial 
overexpression of SOD1-G93A-EGPF and SOD1-A4V-EGFP rendered 
microglial cells toxic by themselves, promoting neuronal death in co-cultures. 
The promising ability of trehalose is not only reducing neuronal death but, 
even more significantly to our research, it seems to decrease microglia toxicity 
due to mutant SOD1 overexpression. 
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Fig.13. Effect of trehalose on microglial neuroprotective/neurotoxic effects due to 
overexpression of wild-type or mutant SOD1 in co-cultures with CGNs  
Hoechst staining (A) and nuclei counting (B) of condensed/total nuclei 
of differentiated CGNs co-cultured with microglia overexpressing wild-type or 
mutated SOD1 in presence or absence of threalose. Scale bar = 20 µm. Each 
bar is the mean ± S.E. of three independent experiments performed in duplicate 
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and expressed as the percentage of apoptosis, i.e. the ratio between condensed, 
apoptotic and total nuclei. ** p < 0.01, *** p < 0.001 relative to control CGNs; 
#p < 0.01 relative to CGNs + micro overexpressing WT SOD1; § < 0.01 
relative to control  CGNs + microglia; ° p < 0.05; °° p < 0.01; °°° p < 0.001 
relative to the respective Glutamate + Trehalose treatment; 
çç 
p < 0.01; 
ççç 
p < 
0.001. Bonferroni’s post-hoc test following one-way ANOVA. 
 
 
4.3.1 α-SYNUCLEIN EXPRESSION AND RELEASE 
FROM RAT PRIMARY CULTURES OF MICROGLIA, 
ASTROCYTES AND DIFFERENTIATED CGNS 
 
We have previously shown results on the release of two proteins, PNP 
and SOD1, respectively involved in neuropathological conditions such as PNP-
deficiency and ALS, in primary rat cultures of microglia and astrocytes. 
Considering the role of many proteins in the onset of neurodegenerative 
diseases and the well-known proteinophaties, we tried to define the release of 
α-synuclein by glial cells both in physiological and pathological conditions, i.e. 
Parkinson’s disease.  
α-synuclein (α-syn) is involved in many neurodegenerative diseases, 
including Parkinson's disease (PD) where the protein is the main component of 
toxic aggregates called "Lewy bodies" (Steiner et al., 2011; Kahle, 2008). 
Although α-synuclein function in cells is not yet clarified, according to the 
well-known hypothesis, the protective or toxic effect of α-synuclein depends 
on its expression levels. α-synuclein under physiological conditions would 
have a protective function, while its accumulation and its aggregation into 
oligomers or fibrils would have a detrimental effect for the cell (Irwin et al., 
2013; Vekrellis et al., 2004). It is known from the literature that α-synuclein is 
4.3 RELEASE OF ALPHA-SYNUCLEIN BY GLIAL 
CELL LINES IN PHYSIOPATHOLOGICAL 
CONDITIONS. 
104 
 
expressed and secreted by neurons, including cerebellar granule cells, but it is 
unknown whether it can also be released by microglia and astrocytes (Lee et 
al., 2010).  
A first aim of this study was to evaluate the gene expression of SNCA 
(encoding the α-synuclein protein in Rattus norvegicus) by Quantitative Real 
Time PCR (qRT-PCR) on primary cultures of cerebellar granule neurons, 
microglia and astrocytes. Cerebellum granules are known to contain high levels 
of α-synuclein. As shown in Table 2, SNCA mRNA levels are 50 times higher  
in cerebellar granules compared to astrocytes and 2500 times higher than 
microglia. 
 
α-syn 
media 
Ct 
GAPDH 
media Ct 
dCt α-syn – 
GAPDH 
ddCt  
dCt cell type – 
dCt granuli 
Valori assoluti rapporto α-
syn rispetto ai granuli   
Microglia 
42,77 ± 
0,76 
26,93 ± 
0,87 
15,83 ± 
1,05 11,67 ± 0,89 0,0004 
(0,0001-
0,0006) 
Astrociti 
36,52 ± 
0,24 
27,13 ± 
0,67 10,6 ± 0,30 6,43 ± 0,99 0,0188 
(0,005-
0,044) 
Granuli 
26,70 ± 
1,15 
26,55 ± 
0,63 4,16 ± 1,12 0 1   
 
Table 2. SCNA mRNA expression and qRT-PCR quantification 
Relative gene expression was calculated using the ΔΔCt method, where 
Ct represents the cycle threshold. ΔCt values were calculated as the difference 
between the target gene and the expression of the endogenous gene β-actin.  
Values are the mean ± SE of 3 independent experiments.  
 
Lee and colleagues have shown that α-synuclein is transmitted from 
neuron to neuron and from neuron to astrocyte through endocytosis and 
inclusion bodies (Rappold et al., 2010; Lee et al., 2010), but whether it may 
also be released by glial cells has not been yet clarified. Thus, we examined the 
expression and release of α-synuclein in primary rat cultures of microglia and 
astrocytes. Primary cultures of astrocytes and microglia were cultured in 
serum-free BME, cells were then lysed and media collected after 2, 24 and 48 
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hours. α-synuclein expression in cells and release in media were analyzed by 
Western blot. As shown in Figure 12 A, C, α-synuclein is expressed in both 
cell types, especially in microglia where it decreases over time (Fig. 14A). At 
the same time, α-synuclein is constitutively secreted by microglial cells and 
accumulates in the conditioned medium (Fig. 14C). In astrocytes, a peak of 
expression occurs at 24h (Fig. 14B), while the Western blot relative to 
conditioned media from astrocytes does not show secretion of α-synuclein over 
time (Fig.14D).  
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Fig. 14. α-synuclein expression in rat primary microglia, astrocyte and cerebellar 
granule neuron (CGNs) cultures.  
Western blot analysis and relative densitometry of α-syn expression in 
microglia (A), astrocytes (C) and the relative release in conditioned medium 
from microglia (B) and astrocytes (D). Each bar represents the mean ± SE of 3  
independent experiments as the ratio to β-actin. 500 µl of conditioned medium 
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were concentrated and loaded to assay α-synuclein release. Data are expressed 
as percentage to controls. * p < 0.05; ** p < 0.01 compared to controls. One-
way analysis of variance (ANOVA) followed by post-hoc Bonferroni test. 
Equal loading was confirmed by staining with Red Ponceaus S performed on 
transfered membranes. 
 
4.3.2 α-SYNUCLEIN EXPRESSION IN MURINE 
IMMORTALIZED CELL LINE OF MICROGLIA (N9) 
AND ASTROCYTES (IMA2.1) 
 
Since the aim of this study was to analize the expression and release of 
α-synuclein by glial cells, in order to limit the use of animals, we decided to 
assess whether the physiological expression and release of α-synuclein could 
take place in murine immortalized cell lines of astrocytes (IMA2.1) and 
microglia (N9).  
Both cell lines were cultured in serum free media, as done for primary 
cultures, in order to define a similar α-synuclein expression between primary 
and immortalized lines necessary to understand whether immortalized cells 
could be a reliable model for our studies. Western blot analysis of α-synuclein 
expression in both cell lines (Fig. 15 A and B), showed a progressive decrease 
over time, suggesting that α-synuclein may be mainly released.  
We also performed immunofluorescence staining to observe the 
intracellular localization of α-synuclein related to the lysosomal marker 
LAMP-1. Comparing the immunofluorescence staining on primary astrocytes 
to murine cell lines (Fig. 15 C), a cytoplasmic α-synuclein "spot" localization 
was observed, being more evident in primary astrocytes which may indicate a 
localization in secretory granules, probably of lysosomal nature, confirmed by 
partial co-localization with  the LAMP-1 marker. Partial co-localization with 
LAMP-1, could indicate that at least part of α-synuclein is exchanged between 
cells using vesicles (Takenouchi et al., 2009). 
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Fig. 15. α-synuclein expression in immortalized cell lines of microglia (N9) and 
astrocytes (IMA2.1).  
Western Blot analysis and relative densitometry of cell lysates from N9 
(A) and IMA 2.1 cells (B) show that α-synuclein expression gradually 
decreases over time in both cell lines. Each bar represents the ratio between α-
syn compared to β-actin. Each bar represents the mean ± SE from 3 experimets 
expressed as percentage to control. * p < 0.05; ** p < 0.01, compared to 
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control (α-synuclein at 2h). (C) Immunocytochemical analysis of α-synuclein 
(green) localization related to  LAMP-1 (red). 
 
4.3.3 α-SYNUCLEIN RELEASE IS MEDIATED BY 
LYSOSOMAL SECRETORY PATHWAY 
 
Since glial secretion through extracellular vesicles (EVs) is has become 
increasingly important in physiological glial-neuron communication, we 
assessed whether α-synuclein could be released from glial cells through this 
pathway. EVs were isolated from conditioned medium from IMA 2.1 and N9 
cells cultured for 2 hours in serum free medium. Western blot analysis revealed 
the presence of α-synuclein in conditioned media as shown in Fig. 14 A, B, 
where it accumulates over time.  α-synuclein was also present in the pellet 
fraction containing vesicles, positive to LAMP-1. These data demonstrate that 
microglia and astrocytes and the respective immortalized cell lines release α-
synuclein through both a classical and an EVs-mediated release, the latter 
occurring through the lysosomal secretory pathway.  
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Fig. 16. α-synuclein release via extracellular vesicles (EVs).  
Western blot analysis of conditioned medium shows constitutive 
secretion of α-synuclein by both N9 and IMA 2.1 cell lines (A,B). 
Ultracentrifugation of conditioned media from N9 microglia (C) and IMA 2.1 
astrocytes (D) shows α-synuclein release even through vesicles. Each bar 
represents the mean percentage ± SE of 3 samples from independent 
experiments; * p < 0.05; *** p < 0.001 compared to control (α-synuclein at 
2h). One-way analysis of variance (ANOVA) followed by post-hoc Bonferroni 
test.  
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4.3.4 EFFECT OF INFLAMMATORY STIMULI ON 
α-SYNUCLEIN RELEASE  
 
Previous results showed constitutive expression and secretion of α-
synuclein from microglia and astrocytes. We decided to investigate whether 
and how constitutive expression and secretion could be modulated in response 
to inflammatory stimuli able to activate IMA 2.1 and N9 cell lines. If on one 
hand the primary activation of microglia and astrocytes reflect a physiological 
mechanism leading to neuroprotection (Hu et al., 2015; Molofsky et al., 2012), 
on the other hand overactivation or the loss of glial cell functions may increase 
a pre-existing neuropathology (Streit et Xue, 2009).  
The first method used for microglial activation described in the 
literature was treatment with the bacterial endotoxin lipopolysaccharide (LPS) 
(Hetier et al., 1988).  IMA 2.1 and N9 cells were treated for 24 hours in 
DMEM medium without serum with increasing concentration of LPS [0, 10, 
100 and 1000 ng / ml]. As observed, the expression of α-synuclein in both cell 
types remained almost unchanged after treatment with different concentrations 
of LPS (Figure 17.1 A, B), while its secretion increased in proportion to the 
concentration of LPS (Fig. 17.1 C, D). Simultaneously to α-synuclein, the 
expression of  inducible nitric oxide synthase (iNOS) and nitrite release in the 
medium were studied as an indicator of activated glia. Treatment of N9 cells 
with increasing concentration of LPS increased the expression of iNOS in a 
dose dependent way (Fig. 17.2 E), while in IMA 2.1 cells only the 100 ng/ml 
LPS treatment increased the expression of iNOS, while the highest LPS 
concentration may be toxic for these cells (Fig. 15.2 F). In both cell types, LPS 
treatment promoted not only an increase in α-synuclein release but also an 
increase in nitrite release in the medium (Fig. 15.2 G, H). 
112 
 
 
 
Fig 17.1. Effect of lypopolyshaccharide (LPS) on α-synuclein release by microglia 
and astrocytes.  
Representative western blot analysis and densitometry of α-synuclein 
expression in N9 (A) and IMA2.1 cells (B) and release from N9 (C) and 
IMA2.1 cells (D) stimulated for 24 hours with increasing LPS concentrations 
[1; 10; 100; 1000 ng/ml]. Each bar represents the mean ± SE of 3 samples from 
independent experiments as the ratio to β-actin related to the control. * p < 
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0.05; ** p < 0.01, *** p < 0.001 compared to the control. One-way analysis of 
variance (ANOVA) followed by post-hoc Bonferroni test.  
 
 
 
Fig.17.2. Effect of inflammation on microglia and astrocyte activation. 
Western blot analysis and relative densitometry of N9 (E) and IMA 2.1 
cells (F) show increased activation (iNOS expression) depending on LPS 
doses. Each bar represents the ratio of iNOS compared to β-actin. Together 
with an iNOS increase, nitrite secretion in the medium from N9 (G) and IMA 
2.1 cells (H) was also increased. Each bar represents the mean percentage ± SE 
of 3 samples; * p < 0.05; ** p < 0.01; *** p < 0.001 compared to the control. 
One-way analysis of variance (ANOVA) followed by post-hoc Bonferroni test. 
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4.3.5 GLIAL ACTIVATION THROUGH ATP DOES 
NOT CHANGE α-SYNUCLEIN RELEASE  
 
To test the effect of physiological-like glial activation, we treated IMA 
2.1 and N9 cell lines for 4 hours with increasing concentrations of ATP [0, 100 
and 500 uM] in serum free DMEM medium. 
By increasing ATP concentrations, α-synuclein expression remains 
almost unchanged in the N9 microglia cell line (Fig.18.1A) and IMA 2.1 
astrocyte cell line (Fig.18.1B). ATP treatment seems to slightly increase, but 
not in statistically significant way, α-synuclein release from microglia 
(Fig.18.1C,) while it does not affect α-synuclein release by astrocytes 
(Fig.18.1D). Furthermore, the highest ATP concentration [500 uM] appears to 
activate N9 cells, as evidenced by the increased expression of iNOS (Fig. 18.2 
E) and nitrite secretion (Fig. 18.2 G), while IMA 2.1 cells do not seem to be 
affected by ATP treatment (Fig. 18.2 F,H). 
 
115 
 
 
 
Fig.18.1. Effect of ATP treatment on α-synuclein release by microglia and 
astrocytes.  
Western Blot analysis and relative densitometry of α-synuclein 
expression (A,B) and release in 4-hour conditioned media (C,D) from N9 
(A,C) and IMA 2.1 (B,D) cells treated with increasing ATP concentrations [0, 
0,5  or 1 mM]. Each bar represents the mean ± S.E of 3 independent samples as 
the ratio to β-actin. 500µl of conditioned medium from each sample were 
loaded. Each bar represents the mean ± SE of 3 samples from independent 
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experiments compared to the control. One-way analysis of variance (ANOVA) 
followed by post-hoc Bonferroni test. 
 
Fig.18.2. Effect of P2X7 receptor activation on microglia and astrocyte activation. 
Western blot analysis and relative densitometriy on lysates from N9 (E) 
and IMA 2.1 cells (F) shows the increased activation (iNOS expression) 
depending on ATP doses in microglial cells (E) but not in IMA2.1 cells (F). 
Each bar represents the ratio of iNOS compared to actin. Nitrite secretion in the 
medium shows the same trend as iNOS activation (G) (H). Each bar represents 
the mean percentage ± SE of 3 samples; ** p < 0.01; *** p < 0.001 compared 
to the control. One-way analysis of variance (ANOVA) followed by post-hoc 
Bonferroni test. 
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4.3.6 ACTIVATION OF NMDA RECEPTOR 
MEDIATED BY SERINE DOES NOT INTERFERE WITH 
PHYSIOLOGICAL GLIAL RELEASE OF α-SYNUCLEIN 
 
D-serine is a neuromodulator of N-methyl-D-aspartate receptors 
(NMDAR), able co-activate these receptors when they bind glutamate. The 
NMDA receptor has a binding site for glycine, however D-serine is an 
endogenous agonist which binds better than glycine itself to the NMDA 
receptor  (Panatier et al., 2006; Shleper et al., 2005). D-serine is synthetized by 
astrocytes from L-serine thanks to the enzyme serine racemase (SR), expressed 
mainly in glial cells and upregulated by glial activation (Wu and Barger, 2004). 
Overactivation of SR increases the production and the efflux of D-serine 
leading to a massive production of mitochondrial ROS and consequently 
overactivation of NMDA receptors. The increase in extracellular glutamate 
levels is considered one of the main causes of neuronal death (Van Damme et 
al., 2005; Bruijn et al., 2004). According to these evidences, we treated IMA 
2.1 and N9 cell lines with increasing concentrations of L-serine [0, 10, 50 and 
100 uM] in serum free DMEM for 24 hours. Equal volumes of medium (500µl) 
were collected and α-synuclein release was determined by western blot 
analysis. As shown in Figure 19 A, B the treatment with L- serine did not 
influence α-synuclein release in both the cell lines. 
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Fig.19. Effect of L-serine treatment on α-synuclein release. 
Representative western blot analysis and densitometry of α-synuclein 
release from N9 (A) and IMA2.1 cells (B) stimulated for 24 hours with 
increasing L-serine  concentrations [0; 10; 50; 100 µM]. Equal volumes (500 
µl) of 24h-conditioned medium from microglia (A) and astrocytes (B) were 
concentrated and loaded. Each bar is the mean ± SE of 3 independent 
experiments compared to control. One-way analysis of variance (ANOVA) 
followed by post-hoc Bonferroni test.  
 
4.3.7 INTRACELLULAR EXPRESSION AND 
EXTRACELLULAR RELEASE OF α-SYNUCLEIN FROM  
N9 AND IMA 2.1 CELL LINES OVEREXPRESSING WT 
AND MUTANT α-SYNUCLEIN 
 
Previous studies have shown that the A53T and A30P point mutations in 
the gene encoding for α-synuclein are related to the onset of an autosomal 
dominant juvenile form of Parkinson's disease (PD) (Singleton et al., 2013), while 
multiplication of the entire locus seems to lead to an earlier and more severe onset 
of the disease depending on the number of gene copies (Fuchs  et al., 2007; Farrer 
et al., 2004; Singleton et al ., 2003). According to the literature and to our data on 
the release of mutant SOD1 from primary glial cultures, it has been investigated 
whether overexpressed wild-type α-synuclein, or mutant A53T α-synuclein and 
A30P α-synuclein, could show the same secretion alterations observed for SOD1. 
We transiently overexpressed wild-type synuclein and familial PD-linked α-
synuclein mutants (A53T and A30P, kind gift from Dott. Nelson Cole, 
Department of Health & Human Services. National Institute of Health, Maryland) 
on N9 and IMA2.1 cell lines. Western blot analysis performed on lysed cells 24 
hours after transfection, showed no difference in the intracellular expression of α-
synuclein between the wild-type and mutant forms overexpressed in the N9 cell 
line (Fig.18A), though an evident intracellular accumulation of mutant α-
synuclein, with an even more evident accumulation of A53T α-synuclein, 
compared to wild-type α-synuclein was observed in IMA2.1 cells (Fig.20B). 
Western blot analysis performed on conditioned media 24 h after transfection with 
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A53T α-synuclein and A30P α-synuclein plasmids showed that cells 
overexpressing mutant α-synuclein release more protein than wild-type α-
synuclein overexpressing cells in the conditioned medium (Fog.20C, D) However, 
both cells lines seemed to respond in different ways to α-synuclein mutations; 
microglial cells expressed a similar amount of  A53T and A30P α-synuclein 
(Fig.20A), but showed an increase in mutant α-synuclein release, being more 
evident for A53T α-synuclein (Fig. 20C). IMA 2.1 cells showed an increased 
expression of both mutants of α-synuclein than wild-type α-synuclein, this 
increase was much more evident for A53T α-synuclein (Fig. 20B), yet IMA 2.1 
cells seem to balance the different mutant α-synuclein expression through 
secretion (Fig. 20D) since higher secretion levels of A30P  α-synuclein than A53T 
α-synuclein were observed. 
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Fig.20. Altered α-synuclein release in microglia and astrocytes overexpressing 
mutant α-synuclein. 
Western blot analysis and relative densitometry of α-synuclein 
expressed (A, B) and released (C, D) in 24h conditioned medium by microglia 
(A, C) and astrocytes (B, D) overexpressing wild-type α-synuclein, A53T and 
A30P α-synuclein. Each bar represents the mean ± SE of 3 different 
experiments normalized to β-actin. Equal volumes (500 µl) of 24h-conditioned 
media were concentrated and loaded in parallel. Each bar represents the mean 
± SE of 3 different experiments normalized to the control. ** p < 0.01; 
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***p<0.001 compared to the control; ### p < 0.001 compared to A53T α-
synuclein. One-way analysis of variance (ANOVA) followed by post-hoc 
Bonferroni test. 
 
4.3.8 EFFECT OF WILD-TYPE AND MUTANT α-
SYNUCLEIN OVEREXPRESSION ON MICROGLIA AND 
ASTROCYTE ACTIVATION 
 
Protein intracellular accumulation, observed in many proteinopathies, 
seems to be responsible for glial cell activation (Ferretti et al., 2012). Increase 
in the intracellular expression of iNOS and the consequent release of NO is 
considered a marker of glial activation (Yuste et al., 2015). In microglial cells, 
wild-type α-synuclein overexpression slightly increased iNOS expression, as 
shown by Western blot analysis (Fig.21A), while nitrite levels in the medium 
(Fig.21C) did not show significant differences between control and 
overexpression. Overexpression of mutant and wild-type α -synuclein in 
astrocytes did not cause any difference in iNOS expression (Fig.21B) and 
nitrite levels (Fig.21D), further underling that α-synuclein overexpression does 
not alter glial activation. 
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Fig.21. Effect of wild-type and mutant α-synuclein overexpression on microglia and 
astrocyte activation.  
Western blot and densitometry of N9 cells (A) and IMA 2.1 cells (B) 
show a partial activation of N9 cells due to wild-type α-synuclein 
overexpression (A) but no evident differencesin IMA 2.1 cell activation (B), 
while the A53T mutation induces the activation IMA 2.1 cells. In addition, 
there were no significant differences in nitrite release from N9 (C) and IMA2.1 
cells (D). Each bar represents the mean ± SE of 3 different experiments 
normalized to β-actin. * p < 0.05, compared to the control. One-way analysis of 
variance (ANOVA) followed by post-hoc Bonferroni test. 
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4.3.9 EFFECT OF WILD-TYPE AND MUTANT α-
SYNUCLEIN OVEREXPRESSION ON MICROGLIA AND 
ASTROCYTE VIABILITY 
 
Cells survival/death was evaluated by counting condensed nuclei, 
considered an index of apoptosis, and total nuclei, after Hoechst staining. 
N9 cells (Fig. 22A) and IMA2.1 cells (Fig.22B) overexpressing wild-
type α-synuclein, A53T type α-synuclein and A30P type α-synuclein were 
fixed in 4% PFA 24 hours after transfection and nuclei stained with Hoechst. 
As shown in Fig. 20C related to N9 cells and Fig.20D to IMA 2.1 cells, nuclei 
counting revealed an increase in apoptosis in both cell lines overexpressing 
wild-type and mutatnt α-synuclein. Microglia (Fig. 22C) seem to be more 
affected by A53T α-synuclein than by A30P type α-synuclein, however 
overexpression of wild-type α-synuclein also promoted apoptosis. Astrocytes 
(Fig. 22D) seem to be more affected by A53T α-synuclein than by A30P α-
synuclein, the same mutation previously showed to increase iNOS expression 
in IMA2.1 cells. 
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Fig.22. Effect α-synuclein overexpression on glial cell survival/death.  
Hoechst staining (A, B) and nuclei counting (C, D) of condensed/total 
nuclei from microglia (A) or astrocytes (B) overexpressing wild-type or mutant 
α-synuclein. Each bar is the mean ±S.E. of three independent experiments 
expressed as the ratio between condensed and total nuclei. * p < 0.05, *** p 
<0.001 relative to control; ### p < 0.001 relative to A53T α-synuclein. 
Bonferroni’s post-hoc test following one-way ANOVA. 
 
4.3.10 GLUTAMATE AND SERINE RELEASE BY 
MICROGLIA AND ASTOCYTES OVEREXPRESSING WT 
AND MUTANT α-SYNUCLEIN 
 
Concerning the role of glutamate in glutamate excitotoxicity (Van 
Damme et al., 2005; Bruijn et al., 2004) and the role of glial cells in the 
production of serine (Bezzi et al., 2004; Schell et al., 1995), we decided to 
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measure the levels of glutamate and serine through HPLC in 24 h conditioned 
media from microglia and astrocytes overexpressing wild-type α-synuclein, 
A53T α-synuclein and A30P α-synuclein. As shown in table 3, 24 h 
conditioned medium from N9 cells contains higher amounts of glutamate 
compared to serine. On the contrary, in 24 h conditioned medium from IMA 
2.1 cells, lower levels of glutamate and a greater amounts of serine were 
observed. However, in conditioned media from both glial cells, no significant 
differences were observed following wild-type α-synuclein, A53T α-synuclein 
and A30P α-synuclein overexpression, thus indicating that the presence of 
mutant α-synuclein did not interfere with the release of these two important 
aminoacids, at least in our experimental conditions. 
 
 
 
Table 3. HPLC measurement of glutamate and serine levels in 24 h conditioned 
media. 
HPLC measurement of glutamate and serine levels in 24h conditioned 
media from microglia and astrocytes overexpressing wild-type, A53T α-
synuclein and A30P α-synuclein.The table quantifies the µM concentration of 
each amino acid and each value is the average of three / four experiments ± SE. 
One-way analysis of variance (ANOVA) followed by post-hoc Bonferroni test. 
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5. DISCUSSION 
 
In this thesis, I presented data on the release of three different proteins; 
PNP, SOD1 and α-synuclein, by microglial cells. The main interest on these 
proteins derived from the fact that they are all involved in brain 
neuropathology, as mutations in the gene codifying for PNP induce PNP 
deficiency, a neurodevelopmental disorder characterized by immunodeficiency, 
while SOD1 and α-synuclein are both involved in neurodegenerative diseases, 
amyotrophic lateral sclerosis and Parkison’s disease respectively, both 
characterized by the presence of protein aggregates, neurodegeneration and 
neuroinflammation. Therefore, in all these neurological diseases there is a 
strong involvement of immune cells, however whether and how microglia, the 
brain immune cells, could be related has not been thoroughly studied. In 
particular, considering that previous results from our laboratory clearly 
demonstrated that microglial cells exert a neuroprotective role through the 
release of soluble factors (Polazzi et al., 2001, 2009, 2013, 2015; Polazzi & 
Monti, 2010) and that SOD1 is one of them, in this thesis we decided i) to 
check whether other proteins related to neurological diseases were released, ii) 
to study whether microglial cells could also release factors though exosomes 
and iii) to study the effect of different physiopathological stimuli on microglial 
protein release. We performed these studies by using two main in vitro models: 
i) primary cultures of glial cells and ii) glial cell lines. In vitro models allow 
using biochemical and molecular approaches in a “clean” cell system with no 
contamination by other brain cells, a crucial issue to clearly understand such 
complex biological processes. Primary cultures are widely considered the more 
physiological models to study glial cells, but they present bioethical issues 
related to the use of animals for experimental purposes. Therefore, for the last 
part of my thesis, we used glial cell lines, IMA2.1 astrocytes and N9 microglia, 
which are both immortalized mouse primary glial cells. 
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The study of PNP expression in the brain started in the early '90s, when 
it was demonstrated that in brain slices PNP co-localized with GFAP, an 
astrocytic marker, suggesting that PNP is primarily expressed by glial cells and 
not by neurons (Castellano et al., 1990). More recently, PNP expression has 
been reported mainly in microglial cells, astrocytes, blood vessels and in some 
nerve fibers, suggesting that glial cells are crucial for maintaining cerebral 
extracellular purine levels. Thus, the aim of this study was to demonstrate a 
cell-specific PNP expression in the CNS. Using rat primary in vitro neuronal, 
astrocyte and microglia cultures (Bilimoria, Bonni, 2008; Contestabile, 2002; 
De Vellis, Cole, 2012; Hertz et al., 1998), we confirmed that PNP is expressed 
by glial cells, both at the mRNA and protein levels, to a greater extent 
compared to neurons and that PNP is also constitutively released by these cells. 
The presence of considerable amounts of PNP in basal conditions allowed us to 
hypothesize that this enzyme is involved in physiological functions in the 
central nervous system (CNS). Indeed, it is known that glial cells cooperate 
with neurons in fundamental processes, such as neural plasticity and 
neurogenesis, as well as learning and memory, mainly through the release of 
soluble molecules, including purines (Bitzer-Quintero, González-Burgos, 
2012). The role played by microglial cells and astrocytes in the brain immune 
response is also well known. Actually, microglia and astrocytes exert their 
immune function mainly in the inflammatory process following acute and 
chronic neurodegenerative diseases, among which psychiatric disorders are 
included. In these pathological conditions, glial cells become activated 
(Eikelenboom et al., 2012) and exert their function by releasing several factors. 
For this reason, we decided to study whether PNP release from neural cells 
could be altered by glial cell activation after neuroinflammatory stimuli. We 
used bacterial LPS and IFN-γ, which are able to induce a wide range of 
inflammatory activities: increased phagocytosis, chemotaxis, cytokine 
secretion, activation of the respiratory burst and induction of nitric oxide 
synthase (Zielasek, Hartung, 1996). Additionally, we used ATP, which is 
released by injured and dying cells leading to activation of P2X7 receptors in 
5.1 PNP RELEASE BY PRIMARY GLIAL CELLS 
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glial cells (Franke et al., 2006). Neither LPS nor IFN-γ modified PNP release 
by any brain cell type, clearly indicating that these two inflammatory agents, 
usually able to activate glial cells in pathological conditions are not involved in 
the modulation of PNP release. On the contrary, we showed for the first time 
that ATP increases PNP release from both astrocytes and microglia through 
activation of the P2X7 receptor. Indeed, Bz-ATP, a P2X7 rceptor agonist, 
induced PNP release, while the release of PNP was blocked by the specific 
P2X7 receptor antagonist Ox-ATP (Michel et al., 2000) but not by the non-
specific P2Y receptor antagonist suramin, underling the central role of P2X7 
receptors in PNP release. Since ATP is released into the extracellular space 
either by exocytosis or by damaged and dying cells, this could be reasonably 
considered as one of the first signals used by neurons to activate glial cells in 
order to increase their neuroprotective potential stimulating the release of 
neuroprotective molecules from glial cells (Skaper et al., 2011).  
It is known that cell communication is mediated not only by molecules 
freely released in the extracellular space, but also through vesicular traffic and 
in most neurodegenerative diseases, protein release may be altered. Here, we 
showed that PNP release is mediated by vesicles secreted by glial cells 
especially following ATP stimulation. Interestingly, our data are also in 
agreement with findings indicating that this non-classical secretory pathway is 
modulated by ATP through P2X7 receptors in brain immune cells (Dubyak et 
al., 2012).  In fact, in presence of exogenous ATP, there was an increased co-
localization of PNP with the lysosomal protein LAMP-1 in microglia and 
astrocytes. Moreover, ATP also enhanced the amount of PNP and LAMP-1 
contained in secreted EVs, which potentially transport proteins, enzymes and 
RNAs from one cell to another and are key players in intercellular signaling 
with an emerging role of released vesicles in neuron-glia communication and 
as support to other glial cells and neurons (Frühbeis et al., 2013). PNP 
deficiency mainly affects the immune system, astrocytes and especially 
microglia, the immune cells of the brain, implicated in modulating this system. 
In fact, in pathological conditions, both cells show a continuous cross-talk with 
CNS-infiltrating T-cells and other components of the innate immune system, 
mainly by releasing several molecules (Ransohoff. et al., 2012). Thus, in this 
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framework, our study on PNP expression, sub-cellular localization, secretion 
and release regulation in glial cells opens the way to clarify the physiological 
role of this enzyme and casts light on the pathological mechanisms underlying 
PNP-deficiency.  
 
 
Following the previous results on PNP release from glial cells and 
previous studies from our laboratory on the neuroprotective role of microglial 
cells against neuronal damage (Polazzi et al., 2013), the second part of the 
project focused on the role that proteins secreted from glial cells may have in 
the onset and progression of some of the well-known neurodegenerative 
diseases. 
Polazzi et al., demonstrated a neuroprotective role of microglia exerted 
by low molecular weight secreted proteins. SOD1 was identified as one of 
these molecules, constitutively produced, released and accumulated in 
conditioned medium (MCM). On one hand, SOD1 seems to be a promising 
molecule, together with other low molecular weight secreted proteins, to 
restore injured neurons; on the other hand, misfolding, intracellular aggregation 
and mutations in SOD1 are some of the main hallmarks observed in patients 
affected by familial Amyotrophic Latera Sclerosis (ALS). Glial cells appeared 
to be crucial for the initiation and progression of the disease and a non-cell 
autonomous mechanism for ALS neurodegeneration has been postulated (Ilieva 
et al, 2009). Mutant SOD1 has been shown to cause a reduction in glial cell 
physiological function, activation of microglial cells characterized by an 
elevated production of cytotoxic molecules such as ROS, inflammatory 
molecules including iNOS, pro-inflammatory cytokines and failure of astrocyte 
glutamate uptake, thus suggesting that motor neuron degeneration could be 
triggered by glial cell dysfunction (Weydt et al., 2004; Hensley et al., 2006; 
Liao et al., 2012; Frakes et al., 2014). However, whether neurodegeneration is 
linked to a loss of physiological function or to a gain of toxic action by glial 
cells and whether astrocytes and microglial cells have the same behavior in 
5.2 SOD1 RELEASE BY PRIMARY GLIAL CELLS 
IN PHYSIOPATHOLOGICAL CONDITIONS 
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ALS is not known. Since 20% of familial ALS are caused by mutations in the 
SOD1 gene and SOD1 alterations are also involved in sporadic ALS (Rosen et 
al., 1993), here we studied the release of wild-type SOD1 and SOD1 mutations 
linked to ALS. To this aim, we overexpressed in rat primary cultures of 
microglia and astrocytes wild-type and mutant SOD1 (two most-common 
mutations linked to ALS, G93A and A4V), to compare the effect of different 
mutations and we observed a reduction in the release of mutant SOD1 
compared to wild-type SOD1 in both types of glial cells. It has been shown that 
SOD1 is released through exosomes by mouse motor neuron-like NSC-34 cells 
and astrocytes in ALS cell models (Gomes et al., 2007; Basso et al., 2013), 
leading to propose a prion-like mechanism for ALS pathology mediated by 
mutant SOD1. Here we showed that also microglial cells release SOD1 through 
vesicles.  
For the first time we showed a reduction in SOD1 release, 
independently from its release mechanisms with parallel intracellular 
accumulation in both microglia and astrocytes. On one hand, this could 
indicate a reduction in neuroprotection by glial cells, as released SOD1 has 
been demonstrated to exert a neuroprotective effect (Polazzi et al., 2013); on 
the other hand, the intracellular accumulation of non-released SOD1 could alter 
the properties of glial cells possibly leading to a physiological dysfunction or to 
the activation of these cells. In fact, neuroinflammation and glial cells 
activation have demonstrated to be a characteristic hallmark of most 
neurodegenerative diseases, including ALS (Robberecht, 2011). Furthermore, 
the intracellular co-localization of accumulated mutant SOD1 and LAMP-1 
seems to indicate a lysosomal dysfunction that could be the linked to decreased 
protein release by glial cells and to autophagy alterations. Growing evidence 
implicates autophagy defects as a potential cause of ALS pathology as well as 
in many other neurodegenerative diseases (Lee et al., 2015; Castillo et al., 
2013).  
Dysfunction in autophagic degradation pathways has been found in 
sALS and fALS patients, as well as in transgenic mouse models of SOD1-
fALS (Li et al., 2015), but all data focus on neurons. Here we showed that a 
notable reduction in microtubule-associated protein 1 light chain 3 (LC3 II) 
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expression in microglial cells overexpressing mutant SOD1 compared to wild-
type SOD1. LC3 is a cytosolic protein, which is lipidated to LC3II during the 
formation of autophagosomes, and localizes on autophagosomes and 
autolysosomes. LC3‑II levels are considered a good indicator of 
autophagosome formation and therefore autophagy (Tanida et al., 2004). We 
could assume that the intracellular accumulation of G93A SOD1 and A4V 
SOD1 in microglial cells may be linked to a blockade of autophagy, even if we 
cannot speculate whether the presence of mutant SOD1 causes the intracellular 
accumulation of these proteins and therefore the autophagy impairment or, on 
the contrary, whether mutant SOD1 blocks autophagy determining the 
consequent intracellular accumulation of SOD1. Interestingly, this happens in 
microglial cells only and not in astrocytes, while SOD1 accumulates in both 
types of glial cells. In particular, LC3II expression is undetectable in primary 
astrocytes, but we could consider that these cells have a very low metabolic 
rate. In parallel, we detected a decrease in the ratio between phosphorylated 
and total mTOR in microglial cells. This was apparently in contrasts with 
LC3II expression, but it may also indicate an mTOR-independent autophagy 
pathway, as in other neurodegenerative diseases, like Huntington and 
Parkinson’s disease (Sarkar et al., 2007), or microglial activation and 
neuroinflammation (Lisi et al., 2014). In agreement with the data on autophagic 
markers, here we demonstrate that overexpression of mutant SOD1 determines 
the activation of microglial cells, but not of astrocytes, as indicated by 
increased iNOS expression and nitrite production. Microglial cells are the 
resident immune cells of the CNS. In physiological conditions, “resting” 
microglia supervise and maintain homeostasis of the brain environment. In 
response to pathological insults, microglia become activated. The first 
microglial activation is beneficial for damage repair, but prolonged activation 
produces chronic inflammation, which leads to the release of reactive oxygen 
and nitrite species, pro-inflammarory cytokines and the loss of physiological 
neuronal support. Chronic activation of microglia is often accompanied by 
their phenotypic shift from the neuroprotective M2 (alternatively-activated) to 
the toxic M1 (classically-activated) state (Zhao et al., 2013). Here, we showed 
that microglial cells overexpressing mutant SOD1 are activated, but they 
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preserve their M2 state, as they continue to express two M2 markers, the 
Triggering Receptor Expressed on Myeloid Cell 2 (TREM2) and the Mannose 
Receptor C Type1 (MRC1). Indeed, the functional states of microglia during 
the progression of ALS have not been fully characterized, but in vivo studies on 
ALS SOD1 mice indicate that there is a transformation of microglia expressing 
mutant SOD1 from a neuroprotective M2 phenotype at disease onset to a 
cytotoxic M1 phenotype during disease progression (Liao et al., 2012). 
Actually, we cannot specify the stage of ALS disease we are representing by in 
vitro SOD1 overexpression on primary glial cell cultures, however, considering 
the results, we can speculate that our cellular model of ALS mimics an 
early/middle stage of the disease.  
Furthermore, the neuroprotective role of microglial conditioned 
medium against neuronal damage has been demonstrated (Polazzi et al., 2013) 
being SOD1 one of the neuroprotective molecules released by microglial cells 
(Eleuteri et al., 2008). Therefore, here we tested the neuroprotective effect of 
glial cells overexpressing wild-type or mutant SOD1 on cerebellar granule 
neurons, a widely-used and accepted model for 
neurodegeneration/neuroprotection studies, sensitive to glutamate 
excitotoxicity (Contestabile, 2002). We observed that microglia exert a 
neuroprotective effect independently from the type of SOD1 overexpressed, 
while overexpression of mutant SOD1 by microglial cells appears to be toxic 
for neurons in control conditions. On the other hand, astrocytes do not appear 
to be neuroprotective by themselves, but neither to increase neuronal damage 
due to glutamate excitotoxicity. However, astrocytes become slightly 
neuroprotective when they overexpress wild-type SOD1. Taken together, these 
data seem to indicate that microglia and astrocytes play different roles in 
neuroprotection/neurodegeneration, depending on the type of SOD1 expressed 
(wild-type vs. mutant) and on the physiopathological environment of neurons 
(control vs. neurotoxic conditions), while the literature tends to include both 
types of glial cells in the same molecular mechanisms (Puentes et al., 2016). 
Significant evidence links glutamate and serine release to motor neuron death 
in ALS non-cell autonomous neurodegeneration, as D-serine is a co-agonist of 
the N-methyl-D-Aspartate receptor, and serine racemase (SR) is mainly 
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expressed in glial cells and upregulated by glial activation, as well as in spinal 
cord of ALS patient and in SOD1 ALS mouse models (Paul, De Belleroche, 
2014). However, here we measured glutamate and serine in 24 h conditioned 
media from primary rat microglia and astrocytes overexpressing wild-type or 
mutant SOD1, but we did not observe any significant difference. Therefore the 
neurodegenerative/neuroprotective effect of glial cells in co-culture seems not 
to be related to changes in the release of these aminoacids.  
Trehalose has been proposed to promote the clearance of autophagy 
substrates such as mutant huntingtin protein or the A30P and A53T mutants of 
α-synuclein (Sarkar S. et al., 2007). Oral administration of trehalose in a 
transgenic mouse model of HD decreased polyglutamine aggregates in the 
brain and liver, improved motor function and extended lifespan (Tanaka M. et 
al., 2004). It has also been reported that trehalose treatment can ameliorate 
behavioral and pathological symptoms in a mouse model of tauopathy 
(Rodriguez-Navarro J.A. et al., 2010).  Additionally, a recent study on  the 
G93A SOD1 mouse model showed how daily administration of 2%  (w/v) 
trehalose significantly reduced the levels of mutant SOD1 and p62 and 
increased LC3-II levels in the spinal cord of 90-day-old G93A SOD1 
transgenic mice. Furthermore, independently of autophagy, trehalose 
consistently inhibited microgliosis and astrogliosis throughout the entire 
duration of the study (Li et al., 2015). 
In this study, we showed, for the first time, the role of trehalose in 
reducing intracellular accumulation of mutant SOD1 in glial cells and 
consequently the reduction of the activate state of microglia. Consistent with 
the previous data on the impairment of authophagy in microglial cells 
overexpressing mutant SOD1, trehalose treatment significantly reduced this 
pathological state allowing us to speculate on the promising use of this 
disaccharide in restoring the autophagic flux promoting the initiation of 
autophagy and increased lysosomal biogenesis to reduce microglial activation 
and neuroinflammation. We mentioned the neuroprotective role of microglia in 
case of neuronal damage (glutamate excitotoxicity), but, at the same time, 
overexpression of mutant SOD1 on microglial cells appeared to be toxic by 
themselves for neurons in control conditions. Co-treatment of co-culture with 
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trehalose and glutamate showed a great ability of trehalose not only to reduce 
glutamate excitotoxicity in neurons, but rather much more interesting, to 
reduce the toxicity of microglial cells overexpressing G93A SOD1 and A4V 
SOD1, restoring neuronal viability even in control conditions. Taken together, 
these data suggest an involvement of autophagy impairment in glial cells in the 
accumulation of proteins forming aggregates in proteinopathies such as ALS, 
and therefore in the onset and progression of neurodegenerative diseases, thus 
showing how restoring the physiological functions of glia through autophagy 
induction could be an innovative way to reduce neuronal death. 
 
 
Similarly to our studies on the role of SOD1 in glial cell 
pathophysiology in ALS, we carried on a parallel study on α-synuclein 
expression and release by glial cells as well as on the effect of wild-type or 
familiar PD-linked mutant α-synuclein overxpression. Although the 
physiological function of α-synuclein has not yet been clarified, its interaction 
with synaptic vesicles has been shown; α-synuclein is generally associated to 
the pre-synaptic membrane, is involved in the maintenance of membrane 
integrity during the release of neurotransmitters (Eliezer et al ., 2001) and in 
vesicle trafficking and fusion during signal transmission at the synaptic level 
(Auluck et al., 2010; Iwai. et al., 1995). It is also known that α-synuclein is 
transmitted from neuron to neuron and astrocyte through endocytosis and 
inclusion bodies (Lee et al., 2010; Rappold, Tieu, 2010), but whether it can 
also released by microglial cells has not been yet clarified. So far, most studies 
have mainly investigated the role of α-synuclein in neurons, excluding non-
neuronal cells such as glial cells. Parkinson’s disease (PD), however, involves 
the alteration of many other cell types in addition to neurons, modifying not 
only neuronal function, but also the cross-talk between different neurons and 
neighbouring cells (Appel et al., 2010). According to the “non-cell 
autonomous” hypothesis, which assesses the role of glial cells in 
5.3 ALPHA-SYNUCLEIN RELEASE BY GLIAL 
CELL LINES 
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neurodegenerative diseases, and considering the previous results on glial cell 
release of molecules even through vesicles, we started a preliminary study on 
the expression and release of α-synuclein in physiopathologycal conditions. α-
synuclein is transmitted from neuron to neuron and from neuron to astrocyte 
through endocytosis and inclusion bodies (Rappold et al., 2010; Lee et al., 
2010), but it is still unclear whether it is even released by microglial cells. We 
demonstrated for the first time that α-synuclein is expressed not only in 
neurons but also in microglial cells, both at the mRNA and protein levels. At 
the same time, we demonstrated α-synuclein release, through vesicles, not only 
by neurons as showed in the literature, but also by microglia and astrocytes in 
physiological conditions. The "spot" localization of α-synuclein and the partial 
co-localization with LAMP-1 allowed us to speculate on a localization in 
secretory granules, probably of lysosomal nature (Takenouchi et al., 2009).  
Neurodegenerative diseases, stroke, trauma and hypoxia, affect 
neuronal survival indirectly by triggering the state of neuroinflammation. In 
these conditions, microglia is activated in response to insults adopting a 
phagocytic phenotype and releasing pro-inflammatory mediators, cytokines 
and chemokines. The acute neuroinflammatory response seems to be beneficial 
to the CNS, as it tries to reduce the injury and restore damaged tissues (Wake. 
et al., 2013, Kiefer et al., 1995, Streit et al., 1999, Imai et al., 1997, Lalancette-
He´ bert et al., 2007, Yanagisawa et al., 2008, Madinier et al., 2009). On the 
other hand, chronic neurodegenerative diseases including amyotrophic lateral 
sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), 
tauopathies and multiple sclerosis (MS), are known to be associated with 
chronic neuroinflammation. Classically activated microglia, mimed in vitro  by 
LPS treatment,  have pro-inflammatory, neurotoxic properties, inhibiting the 
proliferation of lymphocytes; M1 activated macrophages secrete pro-
inflammatory cytokines such as interleukin IL-1α, IL-1β, tumor necrosis 
factors (TNF) and nitric oxide (NO). Activation of glial cells mediated by LPS 
treatment, was confirmed by the expression of inducible nitric oxide synthase 
(iNOS) and the release of nitrite in the medium. Classically activated microglia 
promote the release of α-synuclein. On one hand, this may be a defence 
mechanism necessary to preserve physiological functions because α-synuclein 
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accumulation and aggregation into oligomers or fibrils has a detrimental effect 
on cells (Irwin et al., 2013; Vekrellis et al., 2004). On the other hand, activation 
of glial cells may be a consequence and not the cause of neuronal damage; in 
this case, we could suppose that the increased release of α-synuclein occurs as 
a secondary event and could even increase damage also through vesicles, 
known to promote the trafficking of aggregated, damaged or misfolded 
proteins. On the contrary, ATP does not interfere with α-synuclein release in 
astrocytes and it partially increases the release by microglia. ATP activation of 
glial cells is less aggressive than LPS activation (Takato et al., 2009); the 
stimulus may be not strong enough to induce a significant inflammatory 
response in glial cells. Furthermore, to confirm this hypothesis, only the 
highest dose of ATP used was shown to activate microglial cells, while 
astrocytes seems to be more sensitive to this stimulus. Taken together, these 
results allowed us to speculate on the different role of glial cells in response to 
different stimuli.   
The role of D-serine in the modulation of N-methyl-D-aspartate 
receptors (NMDAR) is knwn; it is synthetized by astrocytes from L-serine 
thanks to the enzyme serine racemase (SR), expressed mainly in glial cells and 
upregulated by glial activation (Wu and Barger, 2004). Glial cell activation 
stimulates the release of cell death mediators, such as glutamate, cytokines and 
reactive oxygen species (ROS) and the super-activation of SR enzyme that 
increases the production and efflux of D-serine (Barger and Wu, 2004) leading 
to over activation of NMDA receptors. The increase in extracellular glutamate 
levels is considered to be one of the main causes of neuronal death (Van 
Damme et al., 2005; Bruijn et al., 2004). Here, we show that L-serine does not 
modify α-synuclein release from any cell type, clearly indicating that the 
glutamate receptor is not involved in the pathway mediating α-synuclein 
release. We have demonstrated constitutive α-synuclein production and release 
by glia and the consequent alteration of the release in case of strong activation. 
α-synuclein is also involved in neurodegenerative diseases; its 
pathogenicity is related to its propensity to aggregate as reported to be the main 
component of amyloid plaques in Alzheimer's patients (Campion et al. 1995). 
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α-synuclein fibrils are the main component of Lewy bodies in PD patients, but 
they are also found in other types of aggregates, Lewy neurites or 
oligodendroglial inclusions that characterize diseases indicated as 
"synucleinopathies" (Steiner et al., 2011; Kahle, 2008;). Missense mutations in 
the gene (A53T, A30P), or duplication or triplication of the wild-type form of 
α-synuclein are neurotoxic and responsible for familial forms of PD 
(Mosharov et al., 2006). Overexpression of human  wild-type, A53T and A30P 
α-synuclein pushes microglial cells towards the reactive phenotype 
characterized by  an increase in arachidonic acid metabolism, cytokine and 
interleukin secretion, reactive oxygen species, tumor necrosis factor α (TNF-α) 
and nitric oxide (NO) production (Rojanathammanee L. et al. 2011). According 
to the “non-cell autonomous” hypothesis and considering our previous results 
on α-synuclein release by glial cells, we decided to focus on the release of 
wild-type and mutant α-synuclein. To this aim, we overexpressed in 
immortalized cell lines of microglia and astrocytes wild-type and familial PD-
linked mutant α-synuclein (A53T and A30P), to compare the effect of different 
mutations. We observed an increase of mutant α-synuclein release compared to 
wild-type α-synuclein in both types of glial cells but with differences between 
both mutations and both cell types. This was not surprising, as it has been 
previously demonstrated that the amount of α-synuclein released after LPS 
treatment is increased, leading to propose a prion-like mechanism. We could 
also hypothesize that overexpression wild-type α-synuclein was able to 
determine the activation of microglial cells, but not of astrocytes, as indicated 
by increased iNOS expression. We cannot specify the disease stage we are 
representing by in vitro α-synuclein overexpression but considering the results, 
we can speculate that our cellular model mimics an early stage of the disease. 
Overexpression of α-synuclein, even only wild-type α-synuclein, promotes  
apoptosis in glial cells, being more evident following mutant α-synuclein 
overexpression. Taken together, these data may suggest that in case of strong 
damage, LPS treatment  in vitro or  Parkinson’s Disease mimed by 
overexpression of wild-type or mutant α-synuclein (A53T and A30P), 
activated glial cells release more α-synuclein. In accordance to the “non-cell 
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autonomous” mechanism and to the release of vesicles, α-synuclein released in 
these conditions may contribute to PD. 
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6. CONCLUSIONS 
 
In this thesis, we performed parallel studies on glial cell models 
regarding in vitro release of three different proteins, Purine Nucleoside 
Phosphorylase (PNP), Superoxide dismutase-1 (SOD1) and α-synuclein (α-
syn), which are all linked to neuropathological conditions. Our findings 
demonstrate that astrocytes and microglia, not only express but also release 
PNP, SOD1 and α-synuclein, even through vesicles, and that this release is 
modulated in different neuropathological conditions. 
PNP is a key enzyme in extracellular metabolism and the salvage 
pathway of adenine- and guanine-based purines. This enzyme is altered in 
PNP-deficiency, a neurological condition characterized by neurodevelopmental 
delay and immunodeficiency, where glial cells could play an important 
neuroprotective role, though this has never been studied. Here, we obtained 
data on PNP release by glial cells and we could speculate that, by releasing this 
enzyme, glial cells may support neuronal activity, by maintaining homeostasis 
of the purinergic system. In particular, since cerebellar neurons displayed low 
levels and reduced ability to release PNP, we hypothesized that glial PNP is 
particularly important for neuronal function.  
SOD1 is an enzyme crucial in both familial and sporadic ALS. Previous 
data from our laboratory and other groups have demonstrated that glial cells 
release SOD1, being involved in neuroprotection. Here, by using in vitro 
models of rat primary cultures of glial cells overexpressing wild-type or mutant 
SOD1, we observed that fALS-linked SOD1 mutants are less released than 
wild-type SOD1. In parallel, mutant SOD1 accumulates intracellularly and this 
can be linked to autophagy impairment, which in turn leads to glial activation. 
However, whether intracellular SOD1 accumulation is due to autophagy 
impairment or rather autophagy impairment could induce the intracellular 
accumulation of SOD1 remains unclear. Nonetheless, activation of microglial 
cells might be responsible for reduced neuroprotection against glutamate 
excitotoxicity in co-cultures with cerebellar granule neurons. Trehalose, which 
is able to induce autophagy, seems to restore the physiological expression and 
release of mutant SOD1, as well as the physiological neuroprotective role of 
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microglia. Astrocytes seem to be less susceptible to mutant SOD1 
overexpression and do not display neuroprotective functions against glutamate 
excitotoxicity, while even overexpression of wild-type SOD1 seems to provide 
neuroprotection.  
Finally, we focused on α-synuclein release by glial cells. While it is 
well-known that neurons and astrocytes release this protein, microglial cells 
have never been studied in this regard. By using immortalized mouse astrocyte 
and microglia cell lines, we observed that familial PD-linked α-synuclein 
mutants are more released than wild-type α-synuclein, in accordance to the 
increased release promoted by activated glial cells. The increased toxicity due 
to overexpression of mutant α-synuclein together with the increased release 
might be responsible for reduced neuroprotection and for the diffusion of 
potential toxic molecules which support the prion-like hypothesis for 
Parkinson’s Disease. 
Taken together, these data propose a crucial role of glial cells regarding 
protein release, at least in in vitro models, and suggest to deeply study this 
mechanism in order to find potential biomarkers for diagnosis and targets for 
the treatment of neurodegenerative diseases. 
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